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Abstract 
This research aimed to measure the effect on health outcomes of implementing 
selected recommendations of the Grampian Joint Drug Formulary in primary 
care. Antibiotics used in the treatment of uncomplicated lower urinary tract 
infections (UTIs), ulcer healing agents and peripheral vasodilators were selected 
for study, thereby reflecting both acute and chronic prescribing. 
For the UTI study, 12 randomly selected high and low prescribers of 
trimethoprim, the recommended agent, each agreed to distribute 20 patient 
questionnaires. Following a period of 18 months and despite repeated contact 
with the GPs, only 89/480 (19%) questionnaires had been distributed. Patient 
response was, however, very high with 80 (90%) questionnaires returned. Health 
outcome measures identified that trimethoprim resulted in no or mild symptoms 
in 40/45 (91 %) of patients. These findings must be interpreted with caution due to 
the low level of questionnaire distribution and thus cannot be extrapolated to the 
total population of patients. In addition, the poor questionnaire distribution did 
not permit comparison between trimethoprim and non-recommended therapy. 
One hundred and eighty four patients receiving repeat prescriptions for ulcer 
healing agents were identified from one general practice. Therapy in 95 patients 
did not adhere to formulary recommendations. Changes to therapy were 
considered inappropriate in 11 patients due to factors such as severe depression 
i,, 
and a further 8 were deemed unsuitable for participation for non-clinical reasons. 
The remaining 76 patients were contacted with 19 (25%) refusing to participate. 
Fifty seven patients were interviewed using the Glasgow Dyspepsia Severity 
Score and Short Form 36 (SF-36). Changes in health outcomes were measured for 
21 patients where a change in therapy had taken place. These results were 
difficult to interpret due to the diversity of changes recommended and the lack of 
data relating to those patients not participating. 
Work involving peripheral vasodilators aimed to determine the effect on health 
outcomes of cessation of therapy. Forty five patients receiving these agents in 2 
practices were identified, although 8 had not requested a prescription in the 
previous year. Two further patients were excluded from the study due to cancer 
and old age. The remaining 35 agreed to be interviewed using the Walking 
Impairment Questionnaire and SF-36. All patients were subsequently instructed 
to stop therapy for 2 months, although 6 (17%) refused to follow this instruction, 
one patient was seriously ill thus was excluded and 3 refused to be re- 
interviewed. Of the remaining 25 patients, no significant differences were 
observed in the domains studied. Seventeen patients (68%) expressed no desire to 
restart therapy, generating considerable savings. These results must be interpreted 
with caution since those not stopping therapy or refusing re-interview are likely 
to have responded differently to those completing the study. 
The measurement of health outcomes following formulary implementation 
deserves further work. 
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Chapter 1 
Prescribing in Primary Care 
1.1 Expenditure on prescribing in primary care 
Prescribing is a fundamental activity in primary care, with data showing that in 
the UK a prescription will be issued in 7 out of every 10 consultations with a 
general practitioner (GP) (Audit Commission 1994). Such acute and repeat 
prescribing is responsible for consuming vast NHS resources. In 1992/1993 10% 
of all NHS expenditure in England and Wales, £3.6 billion, was due solely to 
primary care prescribing (Audit Commission 1994). UK figures for 1992/1993 
showed a 14% increase over the previous year, with a further 11 % increase 
occurring in 1993/1994, both increases against a low rate of inflation 
(Department of Health 1994). An Audit Commission report of prescribing in 
primary care identified main areas to target in an attempt to optimise use of these 
resources, including: less overprescribing of certain drugs; reduced prescribing of 
drugs of limited clinical value; substitution of cheaper but comparable drugs; 
generic prescribing; and appropriate use of expensive preparations. 
Implementation of these recommendations would have reduced primary care drug 
expenditure by 11.8% in 1992/93 (Audit Commission 1994). 
1.2 Reviews of influences on prescribing 
Prescribing is, however, a complex process, influenced by the interaction of v-er}- 
many variables. Three reviews of the influences on prescribing have been 
published, identifying these variables. 
Hemminiki (1975) reviewed the literature on factors influencing prescribing in 
Western countries. Although detailing areas of advertising, prescriber education, 
influences of colleagues, control and regulatory measures, demands of patients, 
society, and prescriber characteristics, no large scale, controlled studies were 
cited, focusing solely on observational studies. The author concluded that the 
available literature was extremely scanty. 
A later review by Bradley (1991) cited studies of the variation in the quantity and 
quality of prescribing. Prescribing and the decision making process were dealt 
with in more detail, identifying the 3 main decisions to be made as: whether or 
not to prescribe at all; which medicine to prescribe; when to start using or stop 
using certain products. This review highlighted the lack of work in the UK. 
Denig and Haaijer-Ruskamp (1995), while reviewing the influence of cost on 
prescribing decisions, summarised studies involving groups of prescribers rating 
criteria for drug selection. To facilitate comparison, all studies were converted to 
the same 10 point rating scale. Results showed cost to be an important criterion, 
but less so than considerations of efficacy, adverse drug reactions, patient 
acceptability and prescribers' experience of particular drugs. However, only a 
limited number of studies were reviewed, none of which were carried out in the 
UK. 
1.3 Factors influencing whether or not to prescribe 
As identified by Bradley (1991), initially the prescriber must decide whether or 
not to issue a prescription. Although information relating to the UK is sparse, it 
has been shown that factors other than clinical need will influence this decision. 
Virji and Britten (1991) measured patients' attitudes towards the issue of a 
prescription and recorded whether or not a prescription was issued. Results 
indicated that the attitude of the patient influenced the outcome, with patient 
preference for treatment being associated with prescribing behaviour. 
Bradley (1992a) explored discomfort experienced by general practitioners 
surrounding decisions they had taken about whether or not to prescribe. 
Interviews were carried out with 69 general practice principals (51 %) in one 
English region. Drug groups for prescriptions which most often led to such 
feelings included antibiotics, tranquillisers and hypnotics, with reasons for 
discomfort including concerns about drug toxicity and appropriateness of 
treatment. Patient expectation was voiced as being the most common reason for 
such a decision. Further analysis of this work (Bradley 1992b) examined patient 
factors associated with this discomfort. These were found to include: knowledge 
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of the patient; the need to preserve the doctor-patient relationship; patient 
communication problems; social class and occupation. 
1.4 Factors influencing drug choice 
Having decided to issue a prescription, the prescriber must next choose from the 
available range of drugs. None of the early work researching this decision making 
process was carried out in the UK, and generally involved small groups of 
prescribers ranking criteria for drug selection based on hypothetical case 
descriptions. 
Harrell and Bennett (1974), proposed a model based on marketing theory which 
stated that prescribing of a specific drug was related to belief about the outcomes 
of that behaviour, the relative desirability of each outcome, the belief about what 
colleagues would advise in a similar situation and motivation to comply with that 
advice. They attempted to test this model using oral hypoglycaemics. A list of 
possible outcomes arising from such treatment was identified from group 
interviews with 31 prescribers. A questionnaire was subsequently developed and 
used during interview with 93 prescribers and mailed to 52 others. The 
questionnaire measured the following: beliefs about possible outcomes identified 
in relation to each oral hypoglycaemic, rated from extremely probable to 
extremely improbable; the relative desirability of each, either desirable or 
undesirable; beliefs about colleagues advice, rated from extremely improbable to 
extremely probable; motivation to comply, rated from don't care at all to care a 
J 
great deal. Actual prescribing data was collected from those who completed the 
questionnaire. Results identified that there were 6 main drug attributes for oral 
hypoglycaemics: efficacy; short duration of action; absence of serious adverse 
drug reactions; minimal hypoglycaemic effects; minimal cardiovascular effects; 
weight reducing effects. Overall a relatively weak link was demonstrated between 
prescribing behaviour and beliefs. 
Segal and Hepler (1982) similarly proposed that, according to cognitive theories 
of behaviour, a prescriber's drug choice resulted from the interaction of beliefs 
about the recognised outcome of drug choice and the values attached to those 
outcomes. Twelve physicians were interviewed to identify commonly occurring 
outcomes. Values were measured using one hypothetical clinical case, with 
prescribers rating each outcome from -10 (avoid at all costs) through 0 (no value) 
to +10 (most valued). Seventeen different outcomes were identified, the 6 most 
highly valued being: control of the disease state; patient compliance; minimal 
side effects; cost; patient demand; minimal colleague criticism. 
The same authors tested this relationship between prescriber's beliefs of possible 
outcomes and prescribing decisions under actual clinical conditions using case 
descriptions of 3 recent diabetic and 3 recent hypertensive presentations (Segal, 
Hepler 1985). A sample of 40 prescribers rated disease severity and resulting 
outcome values, using the same outcomes and rating scale as before (Segal, 
Hepler 1982). Each was also asked to outline the treatment plan for the patient. 
Results indicated that prescribers rated control of disease state highest, followed 
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by ease of compliance and lack of side effects for both clinical situations. Actual 
prescribing was found to relate highly to that predicted by the values attached to 
the treatment outcomes. 
Zelnio (1982) surveyed 250 randomly selected prescribers in Iowa, each rating 8 
prescribing criteria identified by previous work. Using a paired comparisons 
method, where all possible pairs of the criteria were presented in randomised 
order, with the prescriber selecting the most important from each pair, an order of 
importance was established. From a response rate of 69%, the most highly rated 
criteria were absence of potential side effects, probable efficacy and minimal 
contraindications. Less highly rated were dosage form, cost, source of drug 
information, frequency of administration and manufacturer's reputation. 
Lilja (1976) carried out similar work with Swedish prescribers. Using a mailed 
questionnaire detailing case histories of a non insulin diabetic and adult 
presentation of acute pneumonia, the following were determined: spontaneous 
drug choice; prescribers' attitudes towards 10 mentioned antidiabetics and 
antibiotics; judgements of the side effects for the 10 drugs; judgement as to the 
curing effects; judgements of costs. A response rate of 81% was obtained, with 
results showing that the curing effect was rated most important for both clinical 
situations. Absence of side effects was rated more important than cost when 
considering antidiabetics, but not antibiotics. The results for diabetes were similar 
to those of Harrell and Bennett (1985), but respondents could only rate the 3 
criteria listed. 
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The studies described above have several limitations: most involved small 
numbers of selected prescribers; few therapeutic areas were studied, mainly 
involving hypothetical cases where treatment decisions may vary greatly from 
real clinical situations. 
1.5 Factors influencing drug choice - the UK perspective 
As outlined earlier, there is a lack of research into factors influencing drug choice 
in the UK. In a study involving 75% of all general practitioners in one Scottish 
region, Taylor and Bond (1991) used duplicate prescription pads to collect data 
relating to 100 initial prescription situations. Each prescription was classified by 
the prescriber as being an established drug habitually selected, one newly adopted 
in the previous 12 months or superseded in the last 12 months but still being 
prescribed for an individual patient. Each prescriber was asked to indicate the 
major influence on the change leading to adoption or deletion. Individual GPs 
were found to prescribe from a relatively limited list of 100-200 different 
preparations, with the proportion of new drugs being low at 4.5% of all 
prescriptions and those deleted only 0.9%. Although only 2 influences could be 
cited for each change of prescription, major influences identified were 
government regulations, pharmaceutical representatives and hospital doctors. 
Several authors have studied GPs' attitudes towards the influence of cost on drug 
selection. The majority of GPs surveyed were found to agree that prescribing 
costs should be taken into account when prescribing and that costs could be 
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reduced without affecting patient care (Ryan et al 1990 Ryan et al 1992. Silcock 
et al 1997). 
Ryan et al (1996) investigated the actual relationship between cost and 
prescribing. Postal questionnaires measuring attitudes towards considering costs 
when prescribing were sent to all GP principals in one Scottish region. To ensure 
representativeness, the questionnaire was also sent to 94 GPs outwith the study 
region. To identify whether attitudes influenced prescribing, all prescriptions 
issued at consultations during 7 sample periods over a period of one year were 
recorded using duplicate prescription pads. A total response rate of 64% was 
achieved, with 76% agreeing that costs should be taken into account, a similar 
finding for GPs outwith the study region. For certain therapeutic groups (H2 
receptor antagonists and analgesics), prescribing was shown to be influenced by 
attitudes. 
Several workers have investigated the effects of the introduction of Government 
regulations on prescribing. The "limited list", which restricts prescribing of drugs 
in certain categories under the NHS, was introduced into the UK in April 1985. 
Following its introduction, questionnaires were sent to 1500 randomly selected 
GPs in the UK to determine the effect on prescribing (Anon 1987). A response 
rate of 48% was achieved, with only 8% stating that prescribing had changed 
considerably. 
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Other government initiatives have resulted in more marked changes in 
prescribing. 
The Indicative Prescribing Scheme (IPS) and general practice fundholding were 
both introduced into the UK in 1991 (Walley et al 1995). Under the IPS, an 
indicative prescribing amount is set to cover the costs of prescribing for the 
following year. Now termed "target budgets", these are set according to practice 
size, patient age and gender distribution. Originally these budgets were not linked 
to any penalty nor incentive to meet the defined target, however, certain regions 
have now introduced incentives schemes, allowing GPs to retain a proportion of 
the savings. Fundholding allows practices with list sizes over 5000 to hold a 
budget to pay for specific hospital care, drugs, staffing, community services, 
differing from the IPS in that any savings accrued in the drugs budget can be 
retained by the practice. 
Harris and Scrivener (1996) reviewed studies of the effect of fundholding on 
prescribing. By measuring costs and number of items, with non-fundholding 
practices as controls, they concluded that fundholding appeared to be having 
some success in reducing prescribing costs. The authors, however, commented 
that the control and active groups were not matched and that many of the control 
practices were also involved with regional incentive schemes. 
Bateman et al (1996) examined the effect of implementing an incentive scheme 
related to target budgets for prescribing in non-fundholding practices in one 
10 
region of England. Twenty three per cent of practices achieved the incentive 
target, saving between 1 and 3% on the target budget. Although no control group 
was involved in this study, the authors claimed that use of such an incentive 
could have a considerable effect on prescribing costs. 
Armstrong et al (1996) performed qualitative interviews with a selected sample 
of 18 general practitioners to identify reasons for recent changes in their 
prescribing behaviour. All identified two to five specific changes in the previous 
six months, mainly being antidepressants, angiotensin converting enzyme 
inhibitors and Helicobacter pylori eradication regimes. Several factors were 
identified for most changes including: an accumulation model of change, where 
new treatments were reinforced repeatedly from various sources including journal 
articles, talks, consultant letters; a challenge model of change, where the change 
was more immediate, for example, as a result of a specific clinical disaster; and a 
continuity model of change, based on a pre-existing willingness to change, for 
example, as a result of cost pressures. 
Weiss et al (1996) also reported on qualitative interviews with 23 general 
practitioners to explore whether a variety of pressures in primary care, including 
fundholding and the development of the Patient's Charter were actually felt as 
concerns and whether the perceptions of these pressures influenced prescribing 
decisions. These interviews resulted in the development of a questionnaire to 
address main themes of. GPs sense of burden; financial constraints and 
incentives; prescribing as a coping strategy; and patient demand. Questionnaires 
were distributed to 386 GPs in Southern England, with a response rate of 59%. 
Permission was also obtained to access prescribing data. Financial constraints and 
incentives were found to be related to the prescribing variables studied. Those 
most concerned about the adverse effects of financial pressure were found to 
prescribe less generically, had higher practice costs, issued more prescriptions 
and issued more antibiotics compared to the average FHSA practice. Many GPs 
also reported a sense of burden in meeting society and patient demands and using 
a prescription as a way of coping with increasingly demanding patients. 
1.6 Rational prescribing 
Decisions regarding drug choice may thus be influenced by the interaction of 
many, and often competing variables. To ensure optimal use of scarce NHS 
resources, prescribing should be responsible and rational. Parish (1973) originally 
defined responsible prescribing as being based on a clear clinical need and that 
the actions of the prescriber could be defended to both peers and patients. He 
defined rational prescribing as being appropriate for the patient, effective, safe 
and economical. This definition of rational prescribing was later refined by 
Barber (1995) who proposed that there were 4 aims a prescriber was trying to 
achieve: maximise effectiveness; minimise risk; minimise cost, taking account 
not solely of drug costs but also associated costs such as any necessary laboratory 
monitoring; respect the patient's choices. He acknowledged that trade offs may 
often need to be made between conflicting aims and that, depending on the 
situation, patient choice may be the most important consideration. 
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The Audit Commission report of prescribing in primary care (Audit Commission 
1994) compared national prescribing and expenditure with that of 50 selected 
practices, chosen on the basis of quality prescribing. It was estimated that poor 
prescribing in primary care in the UK had cost the NHS £425m in 1992/93. 
Although such an extrapolation may not be entirely valid, it does provide 
evidence for some degree of irrational prescribing. 
Hogerzeil (1995) described such irrational prescribing as a global problem. He 
identified many studies from both developed and developing countries showing 
evidence of polypharmacy, use of therapies not clinically indicated, use of 
unnecessarily expensive drugs, inappropriate use of antimicrobials. 
1.7 Drug formularies in primary care 
Rational prescribing can be promoted by the use of a drug formulary, defined as 
44 a selection of medicines, a preferred list voluntarily arrived at by prescribers" 
(Waine 1989). Medicines within such a formulary are selected on the criteria 
outlined by Parish (1973) and Barber (1995): efficacy; safety, cost-effectiveness; 
patient acceptability. Formularies have been widely recommended in primary 
care (Jolles 1981, Anon 1986a, Essex 1989, Drury 1990). The Greenfield Report 
of The Informal Working Group on Effective Prescribing (1982) strongly 
recommended the development of local formularies as a mechanism for 
improving prescribing. To facilitate this, the Royal College of General 
Practitioners produced practical advice for GPs, detailing tasks involved in 
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production, with sources of information and advice (Waine 1989). The 
recommendations were later reinforced by the Audit Commission report of 
prescribing in primary care (1994). 
There is, however, little published work detailing the development or use of 
practice formularies in the UK. Telling et al (1984) described how one practice 
used a computerised repeat prescribing system to produce reports of drugs 
prescribed as a starting point for the compilation of the practice formulary. The 
authors maintained that this process would allow production of a formulary not 
restricting drug choice. No data, however, was given on which to base this 
conclusion and, in particular, no patient experiences before and after 
implementation of the formulary recommendations were described. 
Grant et al (1985) provided a model for the development of a local formulary, 
describing the experience as being an enjoyable and dynamic educational 
exercise, leading to more rational and safer prescribing. They aimed to compile a 
formulary for use in primary care covering 90% of conditions, providing 
treatment for 90% of patients, compiled by and acceptable to GPs, taking cost 
into account. A select group of 19 GPs, responsible for undergraduate teaching at 
Newcastle University, agreed upon a list of drugs for inclusion in a practice 
formulary. Prescriptions were recorded by the participants for 2 short periods of 2 
weeks, with 10 further GPs acting as controls. Results indicated that involvement 
in formulary development was associated with higher levels of prescribing 
recommended agents. Formulary adherence was significantly higher for acute 
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rather than repeat prescribing, highlighting the additional difficulties associated 
with changing established therapies. This study did not, however. analyse 
prescribing trends over a longer period of time. 
Green (1985) described the creation, implementation and monitoring of such a 
formulary in one general practice. Using the prescribing data of each GP, the 
formulary was built up over a period of one year, covering 35 BNF categories, 
aiming to cover 80-90% of common conditions, providing treatment for 70-80% 
of cases. Drugs were selected on the basis of available evidence of efficacy, 
safety, cost and current prescribing levels, indicated by detailed analysis of 
prescribing data. Prescribing was monitored prior to and following the 
implementation of the formulary, focusing on antacids, laxatives, hypnotics and 
sedatives, cough preparations and analgesics. Results indicated that changes in 
line with the recommendations occurred in all therapeutic areas, with changes 
persisting for one year after formulary introduction, generating considerable 
savings. No data relating to patient experiences following formulary introduction 
were presented. 
Beardon et al (1987) reported on similar work. Prescribing data was again used to 
assess formulary success, with data indicating that use of formulary agents 
increased on introduction and was maintained in the following year. This study 
also involved regular feedback of performance to prescribers which may well 
have influenced prescribing behaviour. 
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Van Zwanenberg et al (1987) assessed the prescribing of a small group of 1 
young prescribers before and after educational intervention focusing on rational 
prescribing. Prescribing of 150 consecutive consultations was recorded by each 
before and after these sessions. None of the participants had been involved in the 
formulary described by Grant et al (1985). Data, however, indicated a significant 
increase in formulary prescribing following such intervention. Although no 
control group was included, these results indicated that the actual educational 
aspects of formulary development may themselves lead to improved prescribing. 
More recently, Eccles et al (1996), as part of a larger study of all non-fundholding 
practices in the Northern region of England, identified that of the 78% of 
respondents, 98% had a written or computerised formulary but that only 85% 
reported that the practice always or usually used it. 
Voss et al (1997), interviewed either the practice manager or a GP of 75% of 
practices in Southampton and south west Hampshire to identify their use of 
practice formularies. Only 48% of practices had a formulary, the majority of 
which (63%) only covered drug choice in certain therapeutic areas. Main criteria 
for drugs included were: efficacy; patient compliance; lack of side effects; 
prescriber familiarity; generic availability; cost. Neither of these studies provided 
any data relating to effectiveness of the formularies in achieving rational 
prescribing, nor patient acceptability. 
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It has been recognised that adherence to practice formularies may be reduced 
when patients are discharged from hospital on a non-formulary agent. (Turner 
1984, Anon 1986, Anon 1989). Indeed, Bond and Taylor (1991) identified that 
hospital prescribers were a major influence on primary care prescribing. As a 
result, the development and use of joint formularies between primary and 
secondary care has been widely advocated (Greenfield 1982, Anon 1989, Essex 
1989, Anon 1991). Work by Joshi et al (1994) showed that of all the hospital 
formularies in the UK in 1993, only 2 recommended agents for use in both 
primary and secondary care. NHS Circular MEL (The Scottish Office 1993) 12 
indicated that all health boards and NHS trusts in Scotland should have produced 
such a formulary by March 1994. 
Garvey et al (1990) described the development of a model for creating such a 
joint formulary. Stewart (1989) had previously shown considerable overlap 
between the hospital formulary in Grampian and repeat prescribing of selected 
therapeutic areas in primary care. A formulary development group consisting of 4 
GPs, 3 pharmacists and 2 clinical pharmacologists co-ordinated the development 
of the Grampian Joint Drug Formulary. Of fifty randomly selected GPs invited to 
receive a copy of the existing hospital formulary 49 responded positively. Based 
on this high level of interest, GPs were invited to comment on draft guidelines for 
each group of drugs to be included. Sixty GPs expressed an interest, resulting in 
the completion and distribution of the formulary in 1992. A further revision took 
place in 1995 (Grampian Medicines Committee 1995, Ferrow et al 1996). Drugs 
in the formulary are listed in therapeutic category, following BNF classification. 
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Within each section, first choice drugs are highlighted, along with brief 
information about the recommended drugs. A special indications category is used 
for those drugs not recommended as first line, fulfilling the following criteria: 
used in special situations; specialist supervision required; less favourable side 
effect profile; more expensive than first choice agents. Revision of the formulary 
is co-ordinated by the Grampian Medicines Committee Formulary Sub- 
Committee, a multi-disciplinary group comprising hospital consultants, GPs, 
hospital and community pharmacists. Wide consultation takes place between this 
group and practitioners with declared interests in particular therapeutic areas. 
Stewart et al (1996) measured adherence to Grampian Joint Formulary 
recommendations as patients were admitted to hospital, showing a high level of 
adherence (84%) to the recommended drugs. This study did, however, have 
several limitations in that the patients were elderly, being admitted to hospital and 
mainly receiving repeat prescriptions, hence represented neither patients nor 
prescribing in general. 
1.8 Clinical guidelines in primary care 
In addition to recommending particular drugs, the Grampian Joint Drug 
Formulary contains detailed prescribing policies for the use of antibiotics and 
hypnotics. Such guidelines have been defined as "systematically developed 
statements to assist practitioner and patient decisions about appropriate healthcare 
for specific clinical circumstances" (Field, Lohr 1990). Clinical guidelines aim to 
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"improve the effectiveness and efficiency of clinical care through the 
identification of clinical practice and desired clinical outcomes" (Scottish 
Intercollegiate Guidelines Network 1995). 
The development, dissemination and implementation of guidelines have been 
well described elsewhere (Grimshaw, Russell 1993a, Woolf 1993, Onion, Walley 
1995, Thomson et al 1995), identifying the need to: carefully choose the subject 
area; select the members of the development group; present, disseminate and 
implement the guideline; measure the impact of the guideline in terms of 
adherence and changes in health outcomes. 
Many terms have been used in the context of clinical guidelines, including 
policies, protocols, algorithms. There is currently much emphasis being placed on 
these developments in the NHS. A report by the Clinical Resource and Audit 
Group (Scotland) (1993) commended the development of national guidelines. 
Simultaneously, the Scottish Intercollegiate Guidelines Network (SIGN) was 
established by the Confederation of Royal Colleges in Scotland to sponsor and 
support the development of national guidelines on a multi-professional basis 
(Scottish Intercollegiate Guidelines Network 1995). It is anticipated that these 
guidelines will be reviewed and modified to produce local protocols, defined as 
"detailed developments of nationally derived guidelines for local application" 
(Clinical Resource and Audit Group 1993). 
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Siriwardena (1995) surveyed all GPs in Lincolnshire to determine attitudes to and 
behaviour surrounding clinical guidelines. Using a postal questionnaire with a 
response rate of 65%, he identified that 78% of GPs reported involvement in 
developing local guidelines. In general, response to the attitude statements 
indicated general support for such guidelines. The majority (69%) felt that 
guidelines were effective in improving patient care, although no data was 
presented to support this belief. 
Newton et al (1996), carried out similar work with a random selection of 1 in 7 
GPs in North Yorkshire. In addition, they measured knowledge and use of 3 
national guidelines: the British Thoracic Society guidelines for managing acute 
asthma; the Royal College of Radiologists guidelines for making the best use of 
radiology departments; the Royal College of General Practitioners guidelines for 
the care of patients with diabetes. From a response of 54%, they identified that 
GPs were most familiar with the BTS guidelines for acute asthma, although less 
had actually used or changed their practice as a result. As found previously 
(Siriwardena 1995), analysis of attitude statements indicated general support for 
clinical guidelines, with most agreeing that guidelines helped to improve the 
quality of care. Again, no data was given to support this belief. 
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1.9 The effect of formularies and guidelines on health outcomes 
Very little work has measured the effect of implementing either drug formularies 
or clinical guidelines on health outcomes such as symptom control or health 
related quality of life. 
Field (1989) determined whether the introduction of a formulary was acceptable 
to doctors and whether any changes implemented as a result would be acceptable 
to patients. A formulary was developed in one practice, aiming to cover 50% of 
prescribing, with 3 neighbouring practices acting as controls. Doctors attitudes 
towards formularies were measured prior to and following formulary 
introduction. Results indicated that those in the active practice were more in 
favour of the use of a formulary. Groups of 90-100 consecutive patients per year 
for 3 years receiving repeat prescriptions, without consultation, in all 4 practices 
were selected and interviewed to measure satisfaction with therapy. Those 
patients in whom therapy had changed (17.7%) were less satisfied than those 
where no change had occurred, however, the data presented did not demonstrate 
that those less satisfied belonged to the active practice, nor that the change was 
actually as a result of implementing formulary recommendations. 
More recently, Dowell et al (1995) measured patient satisfaction upon the 
introduction of a generic formulary in one practice. Questionnaires were sent to a 
random sample of 280 patients where therapy had been changed to the formulary 
recommendation, including substitution of a generic equivalent. A response rate 
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of 60% was obtained, with 46% being either slightly or very unhappy with the 
change, although this was thought to be associated with inadequate 
communication relating to the change. Semi-structured interviews conducted with 
16 patients 1 week and 6 months following the change showed that almost all 
patients were aware that reducing expenditure was at least part of the reason for 
the change, but that none felt that trial of a cheaper medicine to be unreasonable. 
Pearce and Begg (1992), while reviewing the literature relating to drug 
formularies in primary and secondary care, identified that no research focused on 
the area of change in health outcomes arising as a result of such developments. 
In a review on the effect of guidelines on medical practice, Grimshaw and Russell 
(1993b), identified 59 published evaluations of clinical guidelines that met 
defined criteria for scientific rigour. All but 4 detected significant changes 
relating to guideline adherence. Only 11 studies, however, measured changes in 
health outcomes as a result of such guidelines, the vast majority of which were in 
secondary care. Of those in primary care, the only area studied was smoking 
cessation. 
More recently, Conroy and Shannon (1995) reviewed the literature with regard to 
clinical guideline implementation in primary care, with particular emphasis on: 
potential conflict with clinical freedom; need for local ownership of guidelines; 
adherence to guidelines. No reference was made as to the effect of such 
guidelines on health outcomes. 
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Despite increasing emphasis being place on the development and use of 
formularies and clinical guidelines, there is a lack of research investigating the 
effect of such developments on health outcomes. The need for and importance of 
such research has been voiced by many workers (Pearce, Begg 1992, Woolf 
1993, Onion, Walley 1995, Voss 1997). 
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Chapter 2 
Patient Outcome Measures 
2.1 Health outcomes 
A health outcome was defined by Donabedian (1985) as being a "change in 
patients' current and future health status that can be attributed to antecedent 
health care. " McCallum (1993) more recently defined a health outcome as "a 
natural or artificially designated point in the care of an individual or population 
suitable for assessing the effect of an intervention, or the natural history of a 
condition". Shanks and Frater (1993) proposed a classification scheme for 
outcomes, acknowledging the problem of attributing change in health status to 
intervention. Four levels of outcome were identified: outcome; health outcome; 
health care outcome; and health outcome of health care. The latter was defined as 
being "a result evident in terms of health status which is attributable and 
responsive to health care", differing from health care outcome where the area of 
change could as equally be economic or social. A health outcome was defined as 
"an effect manifest as change in health status" but the cause of such a change 
could be unknown, whereas an outcome was simply a change in any sphere of 
life. This terminology does not appear to have been adopted enthusiastically and 
the most widely used term remains health outcome. 
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Increasing emphasis has been placed on the need to measure health outcomes, 
thereby providing an objective means of monitoring patients' progress. Shanks 
and Frater (1993) suggested that health service users, managers and clinicians 
would benefit from increased measurement of and importance being placed on 
health outcomes. 
Indicators of health outcome most frequently reported in the medical literature 
include: morbidity, mortality rates and changes in physical or physiological 
measurements. Further indicators reported include service use indicators, such as 
hospital admission and re-admission rates, adverse reactions and economic effects 
(Bowling 1995, Bowling 1997, McCallum 1993). 
Lohr (1988) classified health outcomes into the "five Ds": death; disease; 
disability; discomfort and dissatisfaction, with those of death, disease, disability, 
discomfort grouped into mortality indicators and disease, disability, discomfort 
into morbidity indicators. The author, however, provided little justification for 
classifying disease, disability and discomfort as mortality indicators. 
The most appropriate health outcome measure may be influenced by many 
variables including: the patient's environment; nature of disease state; type of 
health intervention. For patients in primary care, with an acute self-limiting 
disease state, the outcome indicator must be patient centred, primarily relief of 
symptoms. For many chronic disease states cure may not always be a realistic 
goal, and many have recommended that additional outcome measures should be 
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included and that the most important outcome measure may be health related 
quality of life, measured from the patient's perspective (Guyatt et al 1993, Tsev-at 
et al 1994, Ebbs et al 1989). 
2.2 Health related quality of life 
Quality of life has been defined as "an individual's perception of their position in 
life in the context of the culture and value systems in which they live in relation 
to their goals, expectations, standards and concerns" (WHOQOL Group 1993). It 
has been stated to be a broad ranging concept, affected in a complex way by not 
only physical health, but also psychological state, level of independence, social 
relationships, housing and occupation which are not directly linked with health. 
This has led to the adoption of the term health related quality of life, defined by 
Bowling (1995) as "the optimum level of mental, physical, role and social 
functioning, including relationships, perceptions of health, fitness, life 
satisfaction and well being. " This is in accordance with the World Health 
Organisation definition of health (1948) as a "state of complete physical, mental 
and social well-being, and not merely the absence of disease or infirmity". 
Several comprehensive reviews on the subject of health related quality of life 
have been published (McDowell and Newell 1996, Bowling 1995, Bowling 1997, 
Fitzpatrick et al 1992, Guyatt et al 1993, Tsevat et al 1994). 
Although the term health related quality of life is considered synonymous with 
health status and functional status (McDowell and Newell 1996), MacKeigan and 
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Pathak (1992) described a hierarchy of terminology, differentiating between these 
three concepts. Health related quality of life was described as representing 
functional status, physiological status, well being and life satisfaction; health 
status representing functional status and well being; and functional status 
representing physical, mental and social aspects. 
Many benefits derived from the measurement of health related quality of life have 
been described (McDowell and Newell 1996, Bowling 1995, Bowling 1997, 
Fitzpatrick et al 1993, MacKeigan, Pathak 1992, Guyatt et al 1993). These 
include broadening the scope of outcome measurements, obtaining the patients' 
view of aspects of their lives considered most important and providing a formal 
means whereby patients can judge the effectiveness of treatment. The impact of 
intervention on patients' emotions, physical functioning and lifestyle can be 
measured, focusing on any patient concerns. Research has shown that clinical 
indicators are not always good measures of outcome and that patients with 
identical clinical criteria may have widely differing views on the success of 
treatment (McDowell and Newell 1997, Bowling 1995, Bowling 1997, 
Fitzpatrick et al 1992, Guyatt et al 1993). Measures of health related quality of 
life are being increasingly included in population surveys of perceived 
health 
problems, medical audit, outcome measures in health services, evaluation 
research and clinical trials (Fitzpatrick et al 1992). 
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2.3 Health related quality of life instruments 
Health related quality of life instruments may be described as questionnaires 
comprising a number of questions or items, grouped together in a number of 
domains or dimensions. Each domain represents a distinct area of health status 
such as social functioning, emotional functioning or specific symptoms. 
Such instruments may be categorised as health profiles or health indices. Health 
profiles provide separate scores for each different domain being measured, 
thereby providing a degree of detail for both individual and investigator. Health 
indices, however, describe health related quality of life as a single score ranging 
from 0 (death) to 1 (perfect health), and are most often used in economic 
analyses. 
A further classification describes these instruments as either disease specific, 
domain specific or generic. A disease specific instrument includes questions and 
domains most appropriate for that particular disease state. Domain specific 
measures simply contain items referring to one particular domain, for example, 
physical functioning or symptom severity. Generic scales are much broader 
measures of health status, commonly measuring physical, mental and social 
health. Whereas disease and domain specific measures are often criticised for 
their narrow focus, generic measures may fail to identify small but important 
changes in health status. Many researchers in this field have recommended using 
an appropriate disease or domain specific instrument alongside a generic 
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measure, thereby ensuring both the ability to detect small alterations in health 
status while retaining the broader measures (McDowell and Newell 1996, 
Bowling 1995, Bowling 1997, Fitzpatrick et al 1992, MacKeigan, Pathak 1992, 
Malek 1997). 
2.4 Scientific review criteria for health related quality of life instruments 
Many instruments claiming to measure health related quality of life have been 
developed but prior to use, it is essential to ensure their appropriateness. To aid 
this task, defined scientific review criteria have been established. 
The Scientific Advisory Committee of the United States Medical Outcomes 
Trust, a world-wide distributor of health outcome measurement instruments 
(Perrin 1995), reviews instruments against a rigorous set of 8 attributes, with only 
those fulfilling these requirements being included in the Trust library. The 
necessary attributes are: conceptual and measurement model; reliability; validity; 
responsiveness; interpretability; respondent and administrative burden; alternative 
forms; cultural and language adaptations (Lohr 1996). Several others have 
recommended similar criteria (McDowell and Newell 1996, MacKeigan, Pathak 
1992, Fletcher et al 1992, Fitzpatrick et al 1992). 
The conceptual model describes the different domains which an instrument is 
claimed to measure and the relationship between these domains, with the 
measurement model being defined by the method of instrument scoring. Suitable 
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instruments should provide the rationale for combining items into domains. 
documented procedures for determining scores and evidence of distribution of 
scores. 
Measures of reliability and validity have been extensively described by others 
(McDowell and Newell 1996, Bowling 1995, Deyo et al 1991, Hays et al 1993). 
Reliability is the degree to which an instrument is free from random error, that is 
will produce consistent results on different occasions when there is no evidence 
of change. This is generally assessed in 2 ways: the test-retest; and internal 
consistency. Test-retest is the relationship between the scores obtained by the 
same person on two or more occasions. For continuous data, this may be 
established by determining the Pearson product-moment correlation coefficient or 
intraclass correlation coefficient (Deyo 1991). Internal consistency tests how well 
individual items on a scale are inter-correlated and the extent with which they 
correlate with overall scores, determined by calculation of Cronbach's alpha. For 
all tests of reliability, a minimum score of 0.7 is recommended for group 
comparisons (Nunally 1978). Intra and inter-rater reliability estimates are 
appropriate for instruments administered by interview and test the reliability 
when administered by the same interviewer on different occasions or different 
interviewers and are determined by calculation of kappa for categorical data. 
Validity, the extent to which an instrument measures what it is intended to 
measure, may be assessed in several ways: face validity, content validity. 
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criterion validity and construct validity. Face validity is a subjective measure of 
whether the instrument appears appropriate and unambiguous. Content validity is 
similarly subjective and refers to how well the questions reflect the aims of the 
instrument, generally determined by lay and expert panel judgements. Criterion 
validity tests how well the instrument correlates with the "gold standard" measure 
in a particular field. This is rarely carried out in health related quality of life 
research, due to the lack of a suitable "gold standard". In such circumstances, it 
then becomes necessary to establish construct validity. This is determined by 
assembling multiple indicators of validity. As many of the instrument domains as 
possible are correlated with other instruments or health outcome indicators. 
Convergent validity should be established, testing for high levels of correlation 
between related health outcome indicators and discriminant validity, testing for 
lack of correlation between unrelated indicators. 
Responsiveness is the least studied criterion, particularly when compared to the 
mass of literature relating to reliability and validity. Guyatt et al (1987) defined 
responsiveness as "the ability of an instrument to detect minimal clinically 
important differences. " One problem frequently encountered in this field of health 
outcomes is that the minimal clinically important difference may not be well 
defined. Additionally, many health related quality of life instruments do not yield 
a summary score, but provide scores for separate domains, with the minimal 
clinically important difference very possibly differing among these domains. 
Jaeschke et al (1989) defined the minimal clinically important difference as "the 
smallest difference in score in the domain of interest which patients perceive as 
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beneficial". Determination of such a difference has important implications for 
sample size calculations in clinical studies. Deyo et al (1991) recommended 
comparing scores before and after an intervention of known efficacy, with any 
improvement in score representing the minimal clinically important difference. 
Jaeschke et al (1989) used this approach with a small number of patients 
suffering from chronic heart or chronic lung disease. They identified that the 
minimal clinically important difference was represented by a change of 0.5 on a7 
point Likert scale. This approach has not been shown to be appropriate with 
larger patient numbers, nor a range of disease states. Drummond and O'Brien 
(1993) acknowledged problems in determining such a difference and concluded 
that often value judgements were necessary. Fletcher (1995) also stated that 
instruments which yielded high levels of floor or ceiling effects (very high or 
very low scores) were less likely to be responsive. 
Other less well documented criteria of the Scientific Review Committee include: 
interpretability, the degree to which clinical meaning can be assigned to 
instrument scores; instruments should require minimal respondent and 
administrative time and cost; instruments should ideally be available 
for different 
modes of administration and should be translated widely. 
The Scientific Advisory Committee also stressed that such properties are context 
specific in terms of setting, population and disease states and that 
it cannot be 
assumed that an instrument which works well in one situation will necessarily 
be 
appropriate for another. 
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2.5 Generic measures 
Several instruments have been developed specifically as generic measures of 
health related quality of life. Of these, the more commonly used include: the 
COOP charts for primary care, which provide a rapid assessment of health for 
patients in primary care (Nelson et al 1987); DUKE health profile, similarly 
developed to measure outcomes in a primary care setting (Parkerson et al 1990); 
McMaster health index questionnaire, developed primarily as a research tool 
(Chambers 1984); Sickness impact profile, recommended for use in a variety of 
settings (Gilson et al 1975); Nottingham health profile, originally developed for 
use in primary care, but subsequently included in clinical trial evaluations (Hunt 
et al 1985). These measures have been superseded by the recently introduced 
Short Form 36 (SF-36) which has been claimed to be the generic measure of 
choice, measuring health status from the patient's point of view (Ware 1993). 
2.6 Short Form 36 Health Survey (SF-36) 
SF-36 was developed from the Rand Corporation Health Insurance Experiment 
(Lohr et al 1986) in the United States, which used a 245 item questionnaire to 
compare the impact of alternative health insurance systems on health status. 
While this outcome measure fulfilled its original purpose, its length prohibited its 
subsequent use in both practice and research. The original 245 questions were 
refined to 20 producing SF-20 (Ware et al 1992), but this was criticised for 
failing to retain the broad measures of health outcomes compared to the original 
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(McDowell and Newell 1996), resulting in the development of SF-36 (Ware et al 
1993). This instrument measures each of 8 health domains: physical functioning 
(10 items); role limitation because of physical health problems (4 items); bodily 
pain (2 items); social functioning (2 items); general mental health (5 items); role 
limitation because of emotional problems (3 items); vitality (4 items); general 
health perceptions (5 items); and one item relating to transition in health status 
over the last year. SF-36 can be administered as a self completion questionnaire, 
telephone interview or face to face interview. It is presented as a health profile, 
with each domain scored from 0 to 100, a higher score indicating a better health 
status (Ware, Sherbourne 1992). 
SF-36 has been tested for validity and reliability and indeed these studies have 
been described as "exemplary" (Newell and McDowell 1996). SF-36 was 
constructed to measure those domains most frequently included in health surveys 
(physical, role and social functioning, mental health and general health 
perceptions) as well as 2 additional measures (bodily pain, vitality), providing 
evidence of both face and content validity. More objective data relating to 
construct validity was provided by McHorney et al (1993) in a study conducted in 
the United States. Patients aged over 18 years presenting to a clinician were asked 
to complete questionnaires centring around chronic disease, depressive 
symptoms, sociodemographic characteristics and general health status, with 
clinicians providing information relating to diagnosis and disease severity for all 
21564 patients. Those with hypertension, diabetes, congestive cardiac failure, 
recent myocardial infarction and depression were identified and completed a 
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further questionnaire containing SF-36. Patients with serious medical conditions 
were found to score significantly lower on all 8 scales, compared to those with 
minor conditions, indicating poorer health related quality of life. The physical 
functioning, role limitation due to physical functioning and vitality scales were 
most valid in detecting differences between patients with minor and serious 
medical conditions whereas the mental health, role limitation due to emotional 
problem and social functioning scales were most valid in distinguishing between 
severity of psychiatric conditions. The authors claimed that the observed 
differences in scores could be of value in predicting sample sizes for comparative 
studies. Additionally, these differences in scores obtained with differing severity 
of clinical conditions could be useful for interpreting scores. Further evidence of 
validity was provided by Ware et al (1993), with data showing high levels of 
correlation between SF-36 and 15 other health outcome measures. 
Reliability was also tested by McHorney et al (1994), using data from the same 
population as previously described (McHorney et al 1993). Internal consistency 
reliability coefficients (Cronbach's alpha) were calculated for each of the 8 
domains, yielding values ranging from 0.78 to 0.93, in excess of the 
recommended values of 0.5-0.7 (Nunally 1978). Ware et al (1993) combined 
results of 14 studies, giving a median alpha score exceeding 0.8 for all scales, 
except social functioning, which scored 0.76. 
The responsiveness of SF-36 is the least studied of the criteria applied by the 
United States Medical Outcomes Trust. However, it has been stated that measures 
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which discriminate between groups of patients at one time are likely to be 
responsive (Ware 1993). Indeed, SF-36 has been included in the Trust library. 
2.7 SF-36 - the UK perspective 
Several workers have confirmed the usefulness of SF-36 in primary care settings 
in the UK. Brazier et al (1992) tested the validity, reliability and acceptability of 
SF-36 and compared it to the Nottingham Health Profile. Face to face interviews 
using the original US version of SF-36, were conducted with healthcare 
professionals in one general practice, resulting in slight alterations to the wording 
of 6 questions. This anglicised version of SF-36 and the Nottingham Health 
profile were sent to a large sample of 1980 randomly selected patients aged 16 to 
74 years from 2 general practices in Sheffield, with a high response rate of 83%. 
This new version of SF-36 was found to be internally consistent, with Cronbach's 
alpha exceeding 0.85 for all domains. Although none of the US studies had 
evaluated test-retest reliability of SF-36, this was assessed by mailing a further 
copy to 250 randomly selected respondents after 2 weeks. The test-retest scores 
were found to be highly correlated with those from the main survey. Further 
results demonstrated evidence of construct validity in that health related quality 
of life scores decreased with social class for all dimensions; those consulting a 
GP in the previous 2 weeks had poorer health status, as did those for whom the 
GP had diagnosed one or more chronic problems. Each item on the Nottingham 
Health Profile is simply answered yes or no, compared to SF-36 where responses 
are rated yes or no for only 2 domains, the remaining 6 being rated on 3 to 6 point 
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scales. On comparing the results obtained with these 2 instruments, SF-36 was 
shown to have greater discriminatory powers, producing less skewed frequency 
distributions than the Nottingham Health Profile. Using the latter, many 
respondents scored the best possible health, the questionnaire failing to 
discriminate between groups of patients. 
In a further large study based in primary care, Jenkinson et al (1993) provided 
population norms for SF-36 and provided further evidence of reliability and 
validity in such a setting. SF-36 was mailed to 13042 randomly selected adults 
from 4 English health authorities, with a response rate of 73%. This instrument 
was again shown to be internally consistent, with Cronbach's alpha greater than 
0.8 for all dimensions except social functioning (0.76). Evidence of construct 
validity was provided in that patients with long standing illnesses were found to 
score significantly lower on all domains, as did those consulting a GP in the 
previous 2 weeks. The authors concluded that SF-36 was a particularly suitable 
measure for clinical research in primary care, but would require supplementation 
with a disease or domain specific measure. 
Further analysis of this work (Jenkinson et al 1994) showed that scores for the 7 
domains measuring functioning and well-being were strongly associated with 
patient responses to the single item asking patients to rate overall health on a 
scale of poor to excellent. 
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Garratt et al (1993) similarly tested the validity, reliability and acceptability of 
SF-36 in primary care using 4 clinical conditions: low back pain; menorrhagia; 
suspected peptic ulcer; varicose veins. A total of 1700 patients in Grampian were 
recruited, identified in 1 of 2 ways: those referred to outpatient departments and 
those identified by their GPs. A random sample of 900 members of the general 
public acted as controls. All those included were mailed a copy of SF-36. 
Response rates of 76% of patients and 60% of controls were achieved. Again, 
internal consistency was high, with Cronbach's alpha exceeding 0.8 for all 
domains. Construct validity was shown in several ways: scores for the patient 
population were significantly lower than those of the control group, thus 
indicating lower health related quality of life; referred patients had lower scores 
than non-referred; high levels of agreement were obtained for SF-36 scores and 
GP's perceptions of disease severity. Not only did this study confirm the 
usefulness of SF-36 in primary care, its design included common clinical 
conditions, several of which were minor. 
While most studies of SF-36 have included patients aged 18-64 years, Lyons et al 
(1994) administered SF-36 by interview to 1201 randomly selected individuals in 
West Glamorgan aged 20-89 years of age. Of the 827 patients (69%) agreeing to 
participate, 216 (26%) were aged between 65 and 89 years. Analysis of data from 
this elderly subgroup again identified SF-36 as being internally consistent with 
Cronbach's alpha values greater than 0.8 for all domains. Again, patients with 
long standing disability, those admitted to hospital or attending outpatients 
departments in the previous year scored significantly lower on almost all 
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domains. Despite the smaller sample size, this study provided further information 
on the usefulness of SF-36. 
A manual containing this anglicised version of SF-36 is now available (Ware et al 
1993), which recommends its use either by self completion, telephone or face to 
face interview, in subjects aged 14 years and over. 
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Chapter 3 
Therapeutic Areas, Including Health Outcome Measures 
3.1 Urinary Tract Infections 
3.1.1 Clinical presentation 
Urinary tract infections (UTIs) are associated with multiplication of micro- 
organisms in any part of the urinary tract. These infections may be classified 
anatomically as either upper, occurring in the kidneys and/or ureters, or lower, the 
site of infection being the bladder and/or urethra. A further classification indicates 
likely response to therapy, describing UTIs as either uncomplicated or 
complicated. With complicated UTIs, the presence of certain risk factors may 
result in less favourable response to therapy. These risk factors have been defined 
as: anatomical abnormalities of the urinary tract, presence of an indwelling 
catheter, recent urinary tract instrumentation, diabetes mellitus, other 
immunosuppressed conditions, immunosuppressant drugs, recent antibiotic use, 
hospital acquired infections, symptoms lasting more than 7 days at presentation, 
male sex, age (children, elderly), pregnancy (Johnson, Stamm 1989, Hooton, 
Stamm 1991, Ronald et al 1992, Wilkie et al 1992). Lower uncomplicated UTIs 
are the most prevalent, with data showing that the annual GP consultation rate for 
females is 6.25/100 (Royal College of General Practitioners 1986). These patients 
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present with symptoms of urinary frequency and dysuria which will often remit 
spontaneously. Indeed, the goal of antibiotic therapy is simply to provide 
resolution of symptoms in the shortest possible time with the minimum of 
adverse effects as economically as possible (Nicolle 1990, Ronald et al 1992). 
3.1.2 Ideal antibiotic therapy 
Neu (1992) outlined the optimal characteristics of antibiotic therapy for 
uncomplicated lower UTI as being: active against the major pathogens, shown to 
be primarily Escherichia coli (Wilkie et al 1992); adequate urinary 
concentrations for sufficiently long periods to eliminate these pathogens; low 
potential for the development of resistance; lack of major alteration of intestinal 
flora; does not lead to perianal fungal colonisation; minimal adverse effects. 
Rubin et al (1992) stated that almost every antibiotic with high levels of activity 
against Gram negative organisms such as E. coli would fulfil these criteria, 
providing success rates in excess of 80%. 
3.1.3 Comparative clinical trials 
Many poorly designed clinical trials of uncomplicated lower UTI have been 
conducted, each claiming evidence of the superiority of one form of therapy over 
another. Fihn and Stamm (1985) critically reviewed all published studies from 
1981-1983 against a set of 12 criteria, derived from published methodological 
standards for conducting clinical trials, adapted for studies of lower UTI. Those 
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studies reviewed fulfilled an average of only 56% of criteria. Particular areas of 
concern were: the lack of adequate power to detect clinically important 
differences; no clear definitions for diagnosing either cure or failure; no 
stratification of patients with previously defined risk factors. As a result, the 
authors defined standards to be incorporated into the design of future studies. The 
main recommendation was that studies should have adequate power to detect 
clinically important differences. Other recommendations were: excluding patients 
with risk factors for complicated infections or at least stratifying these patients 
within the study design; criteria for diagnosing UTI should be clearly defined; 
study duration should be at least 4 to 6 weeks following completion of therapy, to 
allow for any relapses; adverse drug reactions should be monitored. Similar 
standards have been described by others (Working Party of the British Society of 
Antimicrobial Chemotherapy 1989, Rubin et al 1992). Norrby ((1992) and 
(1994)) further recommended that these studies should have at least an 80% 
power to detect a clinically important difference of not greater than 10% at a 
significance level of 5% (2 tailed test). The results of well designed, prospective, 
randomised, controlled clinical trials form the basis of evidence for inclusion of 
drugs into local antibiotic policies. 
3.1.4 Antibiotic policies in primary care 
Antibiotic policies have been widely adopted in secondary care, aiming to 
provide a unified approach to the treatment of infections, taking 
into account 
local resistance patterns (Gould 1988). Remington and Hepburn 
(1990) described 
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a similar approach to policy development in primary care. Despite the mass of 
literature relating to the development and implementation of antibiotic policies in 
secondary care, little has been published relating to primary care. 
Wyatt et al (1990) aimed to determine the need for a primary care based 
antibiotic policy in Northern Ireland. Prescribing data was surveyed over a5 year 
period to determine those antibiotics most frequently prescribed, changes in 
prescribing patterns and resulting cost implications. While results indicated no 
great changes in terms of numbers of prescriptions, the use of certain newer 
entities (minocycline, co-amoxiclav, ciprofloxacin) and resultant costs had 
increased substantially. The authors concluded that an antibiotic policy would 
help rationalise prescribing of these newer agents. 
Further work by the same authors (Wyatt et al 1992) attempted to monitor the 
effect of introducing an antibiotic policy into primary care in Northern Ireland. 
Prescribing data from one small general practice was collected over two 6 month 
periods, before and 1 year following policy introduction. Consistent antibiotic 
prescribing within the practice during the first period reduced the likelihood of 
demonstrating any positive impact of the policy. Accordingly, an increase in non- 
policy prescribing was achieved during the second period of data collection. 
Swann and Clark (1994) similarly described policy development in two areas of 
England. Data from questionnaires completed by GPs in Leicester relating to 
choice of antibiotic therapy identified the lack of a consistent approach. This was 
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communicated to those involved as part of a newsletter containing additional 
educational material. The eventual result was the production of a local antibiotic 
policy. The stimulus for policy development in Derbyshire came from analysis of 
prescribing data which identified the diversity of antibiotics being prescribed. No 
attempt was made to measure the impact of either of these policies on prescribing 
patterns or health outcomes. 
Needham et al (1988) reported on an audit of antibiotic prescribing in one general 
practice prior to and following the introduction of an antibiotic policy devised by 
the GPs, local pharmacists and a consultant microbiologist. Details of antibiotics 
prescribed over a1 month period prior to and 12 months following completion of 
the policy were analysed. Results indicated that prescribing of several non- 
recommended agents reduced and that prescribing costs overall fell by 25%. The 
authors made some attempt to measure outcomes, with no increase in hospital 
admissions, patient consultations or home visits occurring during the study 
period. No measures of patients' perceptions of symptom resolution were 
included. 
3.1.5 Antibiotic policy recommendations 
The Grampian Joint Drug Formulary (Grampian Medicines Committee 1995) 
contains antibiotic policies specifically developed for both primary and secondary 
care. The primary care section recommends trimethoprim as first line therapy in 
patients presenting with an uncomplicated lower UTI. Cephalexin should 
be used 
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in patients having experienced treatment failure with trimethoprim or with a 
history of allergy to this agent. 
3.2 Ulcer Healing Agents 
3.2.1 Dyspepsia, clinical presentation 
Dyspepsia has been defined as any "upper abdominal or retrosternal pain, 
discomfort, heartburn, nausea, vomiting or other symptoms considered to be 
referable to the proximal alimentary tract" (Colin-Jones et al 1988). Community 
based research identified that approximately 40% of the adult population 
experienced dyspepsia during a6 month period, with 25% consulting their GP 
due to such symptoms (Jones, Lydeard 1989). Common causes include gastro- 
oesophageal reflux and oesophagitis, duodenal and gastric ulceration, non-ulcer 
dyspepsia, non-steroidal anti-inflammatory drugs (NSAID), over-indulgence in 
alcohol (Crean 1992). 
It has been estimated that approximately 10% of the adult population of Western 
countries will suffer from either duodenal or gastric ulceration at some point in 
their lives, with 80% of ulcers recurring in 1 year (Kurata, Haile 1984). Reflux of 
acidic stomach contents may lead to oesophagitis, which is classified according to 
endoscopic findings of mucosal damage (Skoutakis et al 1995). Up to 25% of 
patients consulting their GP due to dyspepsia have non-ulcer dyspepsia, defined 
by an international working party as "upper abdominal or epigastric pain, 
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discomfort, heartburn, nausea, vomiting or other symptoms considered to be 
referable to the upper gastrointestinal tract, and lasting for more than 4 weeks. 
unrelated to exercise and for which no focal lesion or systemic disease can be 
found responsible" (Patchett et al 1991). 
3.2.2 Role of Helicobacter pylori 
The isolation of Helicobacter pylori (H pylori), a small curved or spiral Gram 
negative, flagellated bacterium, from gastric samples (Warren, Marshall 1983) 
and demonstration of an association with gastritis was the stimulus for much 
further research. The microbiology, epidemiology, clinical manifestations and 
particularly therapeutics relating to H. pylori have been extensively reviewed 
(Axon 1991, Anon 1993, Marshall 1994, Tytgat 1994, Lee 1994, Owen 1995, 
Rauws and Tytgat 1995). H pylori is found principally in the gastric antrum, 
surviving the acid environment by the action of the enzyme urease, converting 
urea to ammonia, thereby increasing the intragastric pH. In Western countries, 
approximately 20% of adults under 40 years and 50% over 60 years are thought 
to be infected with H. pylori. Colonisation of the stomach leads to gastritis in 
nearly all those infected, but is without symptoms in the vast majority. It has been 
shown to be associated with 60-70% of gastric ulcers and 95% of duodenal 
ulcers, due to gastric metaplasia of the duodenal mucosa. Accumulated evidence 
now indicates that H. pylori infection is the main causative factor associated with 
ulcer development, since eradication of infection results in very low levels of 
ulcer recurrence. The role of H. pylori in oesophagitis is less well established, 
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with the frequency of occurrence being similar in both infected and non-infected 
individuals. There is also a lack of data relating to the role in non-ulcer dyspepsia 
and NSAID induced ulceration. 
3.2.3 Therapeutic Strategies 
Histamine2 receptor antagonists (H2RAs) are well established drugs for the 
treatment of both duodenal and gastric ulcers, with healing of the vast majority of 
duodenal ulcers being obtained in 4 weeks, although gastric ulcers may take 
longer to heal. There appears to be little difference in efficacy between H2RAs, 
the main differences being in terms of drug costs and potential for interaction 
with other drugs. Cimetidine, although cheaper than ranitidine, inhibits 
microsomal cytochrome P450, leading to elevation of plasma levels of drugs 
metabolised by this system. Proton pump inhibitors (PPIs) have been shown to 
provide slightly faster healing rates, but whichever agent is used for initial 
therapy, 70-80% of ulcers relapse within 1 year. This may be reduced by 
continuous low dose maintenance therapy but his does not alter the tendency for 
ulcer recurrence on withdrawal of therapy (Feldman, Burton 1990a, Feldman, 
Burton 1990b, Brooks 1992, Pentson, Wormsley 1992). 
More recently, the role of H. pylori has led to the development of regimes to 
eradicate this organism, with studies identifying that successful eradication 
results in very low recurrence rates. The choice of eradication therapy has been 
the subject of much debate. A meta-analysis (Chiba et al 1992) identified much 
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poor quality research in this area. Of 150 studies, only 20 met standard criteria for 
the conduct of clinical trials and warranted inclusion in the systematic overview. 
Triple therapy with an ulcer healing agent and 2 antibiotics was shown to be the 
most effective but interpretation of results was complicated by the use of different 
doses and durations of therapy in those studies reviewed. Similar conclusions 
were reached by Tytgat (1994) and Pentson (1994). Harris and Misiewicz (1995), 
however, stated that it was not possible to recommend the most appropriate 
therapy until well designed, randomised, controlled trials had been reported. 
Less research has been published in relation to the treatment of oesophagitis and 
the choice of agent for NSAID prophylaxis. For oesophagitis, a step-wise 
aproach to treatment is most commonly recommended, initially with an anti- .r 
motility agent initially before progressing to H2RAs and finally PPIs. H2RAs 
typically relieve symptoms in 50% of patients after 4 weeks and heal oesophagitis 
after 8 weeks therapy. PPIs have been shown to be superior in terms of both 
symptom relief and healing but at higher drug cost. Accordingly, these agents are 
recommended for use in cases of therapeutic failure or in patients with severe 
erosive oesophagitis (Medicines Resource Centre 1993, Wilde, McTavish 1994, 
Skoutakis 1995, Anon 1996b). Few large clinical studies comparing agents for 
NSAID prophylaxis have been reported. In particular, no study compares 
different H2RAs. Misoprostol, a prostaglandin analogue, has been shown to be 
more effective than H2RAs in preventing gastric ulceration, and as effective for 
duodenal ulceration, but at an increased risk of adverse effects (Nash et al 1994). 
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3.2.4 Ulcer healing agents, drug utilization in primary care 
Ulcer healing agents are commonly prescribed drugs. UK prescribing data for 
1992 identified that H2RAs and PPIs accounted for 10% of the drugs bill, over 
£250 million, and 2% of all dispensed prescriptions (Medicines Resource Centre 
1993). Scottish data for 1994/95 showed that expenditure on these agents had 
increased 12% on the previous year, being responsible for 19% of the drugs bill 
and 10% of dispensed prescriptions in primary care (Anon 1995). There are also 
substantial differences in costs between these agents, with one months treatment 
with ranitidine 150mg twice daily being £27.89, compared to cimetidine 400mg 
twice daily £6.94 and omeprazole 20mg once daily £35.45. It is of extreme 
importance to ensure that drug utilization studies are carried out to establish that 
these agents are being used appropriately. 
Ryder et al (1994) reported on such a study involving seven general practices 
(60148 patients), which identified the need for further guidelines to ensure 
appropriate use. Patients prescribed ulcer healing agents for longer than 6 months 
were identified from computerised repeat prescribing systems. Results showed 
that 493 patients (0.82%) were receiving long term therapy, with 75% of patients 
exceeding 5 years treatment. The most common indication was duodenal ulcer 
(37%), followed by oesophageal disease (24%), with gastric ulcer relatively 
uncommon at 5%. No diagnosis was documented in the medical notes of 
15% of 
patients. The most commonly prescribed agent was ranitidine (80%), with many 
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patients still receiving treatment doses of 150mg twice daily, as opposed to 
maintenance doses of 150mg at night. 
3.2.5 Treatment guidelines 
Several guidelines relating to the appropriate use of eradication therapy have now 
been published. The first of these recommended reserving therapy for H pylori 
positive patients with a diagnosed duodenal ulcer associated with management 
problems resulting in frequent recurrences requiring either maintenance therapy 
or possible surgery (Anon 1993). A similar approach was recommended by 
Neeman and Kadish (1994). Several have, however, recommended treating all H. 
pylori positive patients with a history of duodenal ulceration (Anon 1994, Rauws, 
van der Hulst 1995). Delaney (1995) reviewed the evidence relating to primary 
care and recommended treating all H. pylori positive patients with either 
duodenal or gastric ulceration. National guidelines have now been developed and 
distributed throughout Scotland for implementation (Scottish Intercollegiate 
Guidelines Network 1996), recommending eradication therapy in all patients 
with either duodenal or gastric ulceration. Unlike previous publications, this 
guideline recommends specific therapy using one weeks treatment with a PPI 
plus 2 antibiotics and provides advice on the need to determine the presence of 
H 
pylori. 
Such guidelines do not, however, exist for the treatment of oesophagitis, nor the 
choice of agent for NSAID prophylaxis. National publications 
have, however, 
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recommended increased use of cimetidine relative to other H2RAs, notably 
ranitidine. The Audit Commission report of prescribing in primary care identified 
that due to the low incidence of interactions of cimetidine with other drugs and 
the lower cost of cimetidine, that such substitution would produce annual savings 
of £45 million for the UK (Audit Commission 1994). 
3.2.6 Grampian Joint Drug Formulary Recommendations 
The Grampian Joint Drug Formulary generally follows this recommendation, 
listing cimetidine as the first choice H2RA for use in gastric and duodenal 
ulceration as well as oesophagitis. Ranitidine is recommended in situations where 
cimetidine would be unsuitable, namely in combination with warfarin, phenytoin, 
theophylline and aminophylline. Omeprazole is recommended for use in patients 
who are unresponsive to H2RAs or in severe oesophagitis. For use in NSAID 
prophylaxis, concurrent administration of either an H2RA or misoprostol is 
recommended. Little reference is made to eradication therapy, other than stating 
that several regimes have been proposed and that there may be a role for patients 
with duodenal ulceration (Grampian Medicines Committee 1995). 
3.2.7 Implementing recommendations 
Relatively little UK work in primary care has examined the effect of 
implementing recommendations regarding H pylori eradication therapy. 
51 
Cotrill (1994) used computerised repeat prescribing systems to identify 206 
patients (2.4% of the practice population) receiving repeat prescriptions for either 
ranitidine or cimetidine. Those patients with either a duodenal or gastric ulcer 
were identified from their medical notes and those patients consenting tested for 
the presence of H pylori. Positive patients were randomised to receive either 
triple or dual therapy. Use of H2RAs in these patients reduced substantially in the 
year following eradication, generating considerable economic savings. A similar 
study was reported more recently. Rosengren and Poison (1996) identified 277 
patients (3.9%) receiving long term ulcer healing therapy, 45 of whom had 
duodenal ulceration. Only 29 patients were willing to undergo testing, 20 of 
whom were found to be positive and 18 expressed an interest in eradication 
therapy. H. pylori was successfully eradicated in all patients. Although these 2 
studies followed patients for periods of 4 months (Rosengren and Poison) and 12 
months (Cotrill), little measures of health outcomes were included in the study 
designs, with only confirmation of eradication and use of H2RAs being reported. 
No attempt was made to quantify patients' experiences of symptoms nor health 
related quality of life. 
Much of the work relating to cimetidine substitution was performed in the United 
States, with several researchers focusing solely on intravenous therapy (Foulke 
and Sieper 1990, Fudge et al 1993). Of those relating to oral therapy, the only 
outcome reported following the change was the use of antacids. 
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Falbe et al (1992) only reported pharmacy issues of H2RAs following a hospital 
based initiative to increase cimetidine use. 
DeZearn et al (1996) promoted cimetidine in a study centred around managed 
care organisations. Individual patient summaries were sent to prescribers, 
detailing current therapy, indication, dose, requesting a switch to generic 
cimetidine, with results compared to those of a control group. Although an 
increase in cimetidine was observed, no attempt was made to ensure that the 
control group was appropriate, nor that the changes were as a direct result of the 
information supplied. 
Keith et al (1994) aimed to limit excessive use of treatment doses of H2RAs in a 
state correctional system. Continued use of treatment doses beyond the 
recommended 8 weeks required the completion of an authorisation form by the 
prescriber. Results indicated a reduction in mean daily dose and total duration of 
therapy, generating considerable cost savings. Similar results in both long term 
and ambulatory care were obtained by Zimmerman et al (1994). Neither of these 
studies incorporated any health outcome measures. 
In the UK, McKenzie et al (1996) aimed to evaluate the effect on primary care 
prescribing of a series of interventions. Guidelines were launched at educational 
sessions with prescribers throughout Glasgow, aiming to increase cimetidine use 
relative to other H2RAs, limit omeprazole to use in moderate to severe 
oesophagitis and to increase the use of eradication therapy in duodenal ulceration. 
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These points were later reinforced in a series of bulletins. Prescribing data was 
used to monitor guideline impact, with Lothian acting as a control. A non- 
significant rise in the ratio of cimetidine to ranitidine was observed in the target 
area compared to control. No real effect was observed in relation to omeprazole 
use nor the use of eradication therapy. 
Similarly disappointing results were described by Roberts et al (1997), who 
issued reports on methods of altering prescribing with no detriment to patient care 
to all practices in the Northern Regional Health Authority. One such 
recommendation involved increasing the use of cimetidine relative to related 
agents. Results failed to demonstrate any subsequent increase in cimetidine use. 
3.2.8 Health outcome measures 
If studies aim to investigate the effect of implementing guidelines or changing 
established therapy, consideration must be given to the effect on health outcomes, 
using measures meeting approved scientific criteria previously described. In 
disease states such as duodenal and gastric ulceration and oesophagitis, this 
should ideally consist of both disease specific and generic measures of health 
related quality of life. 
Hallerback (1993), Korman (1993) and Wilhelmsen and Berstad (1994) 
constructed or used existing measures in patients with various upper 
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gastointestinal diseases but failed to provide any data relating to validity, 
reliability or responsiveness. 
Glise (1993) used the Psychological General Well Being Index (PGWB), a 
measure of feelings of well being and distress, as a generic measure in duodenal 
ulcer patients pre-endoscopy and at a further 4 stages during a1 year follow up 
period. Of those questionnaires distributed, 392 (95%) were returned, with results 
showing pre-endoscopy scores lower than population values, indicating 
discriminatory validity. The measure was shown to possibly be responsive, with 
scores increasing during treatment with ulcer healing agents, although no tests of 
statistical significance were included. No data was provided relating to scale 
reliability and no disease specific measure was included. 
Svedlund et al (1988) described the construction of a disease specific measure, 
Gastrointestinal Symptom Rating Scale (GSRS), for use in patients with irritable 
bowel syndrome and peptic ulcer disease. Items were selected from the literature 
and on the basis of clinical experience. Inter-rater reliability was evaluated with a 
small sample of 20 patients, interviewed by 2 psychiatrists on different occasions, 
with high levels of agreement. No attempt was, however, made to measure 
construct validity, internal consistency nor responsiveness. 
Further data relating to GSRS and PGWB was provided by Dimenas et al (1993) 
in a study of 146 patients before and 4 weeks following endoscopy. Patients 
completed 3 questionnaires, PGWB, GSRS and Ulcus Esophageal Subjective 
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Symptom Scale (LIESS), a new scale developed to quantify symptoms frequently 
experienced and to extend the range of GSRS to areas other than peptic ulcer 
disease and irritable bowel syndrome. Sixty eight patients provided initial data 
leading to slight modification of UESS, following which a further 78 completed 
questionnaires pre-endoscopy, 57 of whom completed a follow up questionnaire 4 
weeks later. Internal consistency for 3 dimensions of UESS was acceptable but 
was poor for the fourth dimension. Similarly, only 3 dimensions were responsive 
to treatment. Construct validity was established by comparing GSRS and UESS 
with PGWB and each other showing high degrees of correlation. This work was 
limited by the small sample size and the failure to include data relating to test- 
retest reliability. Further evaluation would be required prior to use in a clinical 
setting. 
Martin et al (1994) developed a further measure for use in peptic ulcer disease, 
the Quality of Life in Duodenal Ulcer Patients (QLDUP). This was derived from 
the full version of SF-36, with a further anxiety dimension added and 5 
dimensions specifically relating to gastrointestinal symptoms. Data was collected 
from 3 groups of patients: 80 with acute duodenal ulcer; 69 with history of 
duodenal ulcer but in remission; 82 non-ulcer controls. Results of the SF-36 
components revealed acceptable internal consistency, test-retest reliability and 
discriminatory validity. Further work in the UK also tested SF-36 in patients 
with peptic ulcer disease, as described in chapter 2. PGWB described by Glise 
(1992) and Dimenas et al (1993) was included in the Rand Corporation Health 
Insurance Experiment from which SF-36 was developed. Stacey et al (1996) 
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extended the use of SF-36 in patients with gastro-oesophageal reflux disease. 
Results were provided for 354 patients suffering from reflux for 1 month and 
receiving no medication. Initial SF-36 scores were lower than population values, 
providing evidence of discriminatory validity. Significant increases in scores in 
all 8 dimensions were obtained following 2 weeks treatment with ranitidine. SF- 
36 would appear to be an appropriate generic measure of health related quality of 
life in patients with symptoms of dyspepsia. 
Two further UK studies focused on the development of disease specific measures. 
Garratt et al (1996) developed a measure for patients with dyspepsia and ulcer 
related symptoms, which was tested in 135 patients referred to an outpatient 
gastroenterology department and 152 further patients not referred but identified 
by their GPs. Internal consistency proved acceptable and dyspepsia scores were 
found to correlate well with the GP's perception of symptom severity. Further 
evidence of validity was provided by comparing dyspepsia scores with those 
obtained from completion of SF-36, with high correlations being observed in 5 
domains, pain, social functioning, energy and fatigue, mental health and role 
limitation attributable to physical problems. Test-retest in a sample of 114 
patients was shown to be acceptable. Limitations of this measure 
include the lack 
of data relating to responsiveness and the fact that all questions relate to 
experiences in just the previous 2 weeks. 
El-Omar et al (1996), developed the Glasgow Dyspepsia Severity 
Score for any 
symptom or combination of symptoms related to the upper gastro-intestinal 
tract. 
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Acceptable levels of inter and intra-reliability were obtained with samples of 50 
and 30 patients respectively. Discriminant validity was shown in 3 groups of 
patients: 80 healthy controls; 80 with non-ulcer dyspepsia; 70 with duodenal 
ulcer. No difference was identified between the duodenal ulcer and non-ulcer 
dyspepsia groups, but scores for the control group were significantly lower. 
Responsiveness was tested for by comparing scores before and 1 year following 
eradication therapy in 48 patients, with a significant reduction in scores. No data 
was, however, provided to allow evaluation of responsiveness in other disease 
states and data relating to internal consistency was lacking. This measure does, 
however, measure dyspepsia scores over a longer period and, in combination with 
SF-36, may be the best available measure of health related quality of life in 
patients with dyspepsia. 
3.3 Peripheral Vasodilators 
3.3.1 Peripheral vascular disease, clinical presentation 
Peripheral vascular disease occurs as a result of slowly progressing 
arteriosclerosis of the major arteries of the lower limbs, rarely affecting those of 
the upper limbs (Balkau et al 1994). Intermittent claudication, defined as 
"cramping discomfort in the calf clearly provoked by exercise and relieved by 
some minutes rest" is the commonest presenting symptom (Kannel, McGee 
1985). Peripheral vascular disease is more common in males and usually presents 
after the age of 50 years, with peak presentation rates occurring between the ages 
58 
of 65 and 74 years. Predisposing risk factors include cigarette smoking, diabetes 
mellitus, elevated blood pressure and obesity (Kannel, McGee 1985). 
Approximately 20% of patients with intermittent claudication require surgical 
treatment with the remainder either improving or remaining unchanged over time. 
Hiatt et al (1995) defined the major goals of therapy in intermittent claudication 
as relief of symptoms and improvement of health related quality of life. The 
mortality rate of patients with intermittent claudication, however, approaches that 
of a population aged 10 years older with the majority of patients dying from 
arteriosclerotic cardiac complications (Balkau et al 1994). 
3.3.2 Standards for clinical trials of peripheral vasodilators 
Several agents, including naftidrofuryl, oxerutins and oxpentifylline, are 
marketed for the treatment of intermittent claudication. Heidrich et al (1992) 
proposed standards for the conduct of clinical trials of such agents. Optimal study 
design should be double-blind with random allocation of treatments. A placebo 
control must be included with a run in period of at least 2 weeks. A parallel group 
study is recommended with a treatment period of at least 2 to 6 months. The main 
method of assessment of response centres around the measurement of both pain 
free walking distance and absolute walking distance. These measures should be 
performed using standardised treadmill gradients and speeds and should be 
carried out at least twice during the run in phase and at monthly intervals during 
the trial. Additional forms of assessment include the use of self-assessment 
questionnaires to provide an estimate of the patients' evaluation of any effects of 
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treatment. Other workers have proposed guidelines for interpreting results of such 
trials. Due to the large placebo response often obtained, a difference of less than 
40% improvement between drug and placebo may be unimportant (Cameron et al 
1988). Rudofsky and van Laak (1994) further recommended that successful 
treatment must increase pain free walking distance by 50-60%. 
3.3.3 Reviews of clinical trials involving peripheral vasodilators 
Verstraete (1982) reviewed the evidence for the use of peripheral vasodilators, 
identifying that, while these agents may increase resting blood flow in normal 
subjects, clinical experience had proved disappointing. A more critical review 
was undertaken by Cameron et al (1988). All trials in patients with intermittent 
claudication published between 1965 and 1985 were reviewed. Many of the 75 
trials identified were of very poor quality with very few meeting standards 
previously described. In particular, 33% included no control group and those with 
a placebo control often had no run-in period. No trial documented the method of 
estimating sample size with some trials reporting data from only 7 patients 
(median 35). The method of assessing the effects of treatment was also poorly 
reported. Of those describing treadmill testing, no consistent gradients nor speeds 
were used. Although 39 trials had claimed a positive benefit from the use of 
peripheral vasodilators, the outcome was shown to be related to design, with 
uncontrolled trials being three times more likely to show benefit. The authors 
concluded that no trial with adequate methods had produced positive results 
which others had been able to confirm. 
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Lehert et al (1990) reported on a meta-analysis of 4 clinical trials of naftidrofuryl 
versus placebo involving a total of 776 patients. Data was provided for 449 
patients, the remainder being excluded for reasons not fully documented in the 
meta-analysis. These trials adhered to several of the standards previously 
described, being double blind, randomised, parallel group comparisons but the 
method of treadmill testing varied between the trials. At 3 months naftidrofuryl 
increased pain free walking distance by 55% compared to 25% for placebo. Of 
the 3 trials continuing for 6 months, painfree walking distance on naftidrofuryl 
increased by 76% and 41% for placebo. Although statistically significant, these 
differences are unlikely to be clinically important, according to criteria proposed 
by Cameron et al (1988). 
Data from these 4 studies were included with one later trial in a further meta- 
analysis by Lehert et al (1994). Comparison of results obtained for naftidrofuryl 
and placebo showed that although naftidrofuryl increased pain free walking 
distance, this increase was only 22m greater than that obtained by placebo, a 
difference of doubtful clinical importance (Cameron et al 1988). Lehert et al 
(1994), however, claimed that treatment with naftidrofuryl consistently increased 
walking distance. More recent meta-analyses of the same trials have reached 
similar conclusions (Barradell, Brogden 1996, Anon 1996a). 
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3.3.4 Use of peripheral vasodilators in primary care 
Given the lack of evidence to support widespread prescribing of these agents, 
many have recommended restricting their use to those patients with severe 
disabling symptoms. Treatment should initially be for a limited trial of 2 to 3 
months followed by withdrawal to ascertain any need for continued use (Ruckley 
1986, Lowe 1990, Waller, Chant 1995). Excessive use of these agents has been 
identified as a marker of poor prescribing (Avorn, Soumerai 1983). The Audit 
Commission report of prescribing in primary care recommended a general 
reduction in the use of agents of limited clinical efficacy and estimated that 
restricted use of peripheral vasodilators would generate savings amounting to 
£8.8 million per annum in England and Wales (Audit Commission 1994). 
Accordingly, peripheral vasodilators are not recommended in the Grampian Joint 
Drug Formulary. 
3.3.5 Health outcome measures 
Outcome measures used in studies of patients with intermittent claudication have 
traditionally centred around treadmill testing. This measure may be limited by the 
lack of practicality in the primary care setting and failure to evaluate the patients' 
perceived ability to walk. As previously stated, the aims in the treatment of 
intermittent claudication are to relieve symptoms and improve health related 
quality of life, increasing the need to incorporate such measures in the evaluation 
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of any treatment effects. Joyce (1994) described the lack of and need for suitable 
measures. 
Several health outcome measures have been described in patients with severe 
disease undergoing vascular surgery. Hunt et al (1982) used the Nottingham 
Health Profile as a generic measure, showing reduced health status compared to a 
control group. Humphreys et al (1994) used the Rosser system, a limited generic 
measure of health related quality of life focusing only on mobility and pain, and 
Euroqol, a more recently introduced generic measure. Euroqol was developed to 
provide a generic measure in areas of mobility, self-care, role activity, family and 
leisure activities, pain and mood in a single index score (Euroqol Group 1990). 
Results using these 2 measures showed a high level of correlation, with the 
authors concluding that Euroqol may be the more superior measure but that 
further evaluation would be required prior to more widespread use. 
SF-36 was used as a generic measure to assess the effects of exercise in 202 
patients referred for vascular out-patient investigation (Currie et al 1995). 
Patients were treated either surgically or commenced on an exercise programme. 
Results showed that exercise produced statistically significant changes in the 
domain of bodily pain, whereas surgery affected areas of physical functioning, 
role limitation due to physical functioning, bodily pain and vitality. No disease 
specific measure was included in this evaluation. 
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The Walking Impairment Questionnaire was developed by Regensteiner et al 
(1990), to characterise speed and distance of walking reflecting treadmill testing. 
This questionnaire quantifies self-reported severity of claudication pain and 
ability to walk defined distances and speeds. Results are scored on a scale of 0% 
(unable to perform due to severe claudication) to 100% (no impairment). This 
was administered to a small sample of 19 patients (10 active, 9 control) as part of 
a study to evaluate the effects of a structured exercise programme. Seven further 
patients completed questionnaires before and after vascular surgery. Results 
showed the questionnaire to be internally valid in that walking ability decreased 
with increasing distances and speeds. Further evidence of validity was provided 
from high levels of correlation between questionnaire scores and treadmill test 
results. Control patients completed questionnaires on 2 separate occasions, with 
results providing evidence of the measure's reliability. The questionnaire was 
also shown to be responsive to the effects of surgery and exercise. 
The Walking Impairment Questionnaire and SF-20, an earlier version of SF-36, 
were used in a further study to evaluate the effects of a structured exercise 
programme in patients with intermittent claudication (Regensteiner et al 1996). 
Twenty nine patients completed questionnaires prior to and following periods of 
either supervised treadmill training, strength training or no intervention. Results 
showed significant increases in SF-20 scores in the domain of physical 
functioning following 12 weeks of treadmill training and significant increases in 
walking impairment scores at 24 weeks. Strength training increased walking 
impairment scores at 12 weeks. 
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Hiatt et al (1995) concluded that the use of a disease specific and generic measure 
should be included in the assessment of interventions in patients with intermittent 
claudication and recommended combining the Walking Impairment 
Questionnaire with SF-36. 
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Chapter 4 
Methodology 
4.1 Introduction 
4.1.1 Aim 
The aim of this research was to evaluate the effect on health outcomes of 
implementing selected recommendations of the Grampian Joint Drug Formulary 
in primary care. 
4.1.2 Areas of study 
Drug groups were selected to reflect both acute and chronic prescribing as 
follows: 
1. antibiotics used in the treatment of uncomplicated lower urinary tract 
infections, representing acute prescribing. 
2. ulcer healing agents, which may be prescribed in acute courses but, in selected 
patients, may be continued over longer periods of time. 
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3. peripheral vasodilators, representing chronic prescribing. 
4.1.3 General methodology 
Prescribing Information System for Scotland (PRISMS), a software system 
capable of performing rapid analysis of prescribing data, was developed by a 
team of computer programmers and medical prescribing advisers in 1991. This 
system allows analysis of all prescribing data collected by the Pharmacy Practice 
Division of the Common Services Agency, down to the level of root drug and 
individual prescriber. Data is now sent to all health boards in Scotland within 8 
weeks of prescriptions being dispensed (Donald 1995). PRISMS data was used as 
a means of identifying both general practices and individual GPs within 
Grampian for possible inclusion in the study. Prior to accessing this data, it was 
necessary to obtain permission from all general practices in Grampian. This was 
requested in writing from all 93 practices, with only one practice (1.1 %) 
unwilling to participate. 
4.1.4 Study approval 
The study was approved by the Joint Ethical Committee of Grampian 
Health 
Board and The University of Aberdeen. Approval was also obtained 
from the 
Area General Practice Sub-committee. 
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4.1.5 Statistical analysis 
Statistical analysis was performed and graphics produced using SPSS for 
Windows Release 6.0. Sample size calculations were performed using nQuery 
Advisor Release 2.0. 
4.1.6 Systematic Review of Literature 
Medline and International Pharmaceutical Abstracts were used as databases 
employing the following search terms: prescribing, prescribe, drug formulary, 
policy, protocol, guideline, outcome, health outcome, quality of life, health 
related quality of life, antibiotic policy, urinary tract infection, dyspepsia, 
Helicobacter pylori, ulcer healing agent, arterial occlusive disease, peripheral 
vascular disease, peripheral vasodilator, research methods and primary care, 
research methods and general practice. The UK Clearing House for Information 
on the Assessment of Health Outcomes at the Nuffield Institute for Health 
provided database searches for outcome measures used in dyspepsia and 
peripheral vascular disease. 
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4.2 Urinary Tract Infections 
4.2.1 Objectives 
The objectives of this part of the research were to: 
1. identify the antibiotic therapy prescribed to females aged 18-60 years 
presenting in primary care with symptoms of lower uncomplicated urinary tract 
infections. 
2. identify any patient factors influencing drug selection. 
3. measure health outcomes resulting from such treatment. 
4. compare the outcomes of those patients receiving therapy in line with the 
recommendations of the Grampian Joint Drug Formulary to those receiving non- 
recommended therapy. 
4.2.2 Method 
4.2.2.1 Questionnaire validation 
This study was carried out over an 18 month period from March 
1995 until 
September 1996. Information relating to antibiotic prescribing and health 
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outcomes were obtained from 2 sources. The GP provided drug utilization 
information, detailing drug prescribed, dose, duration of therapy, any patient 
factors which influenced drug choice and the use of microbiological sensitivity 
testing. Measures of health outcome centred around the patient's perception of 
symptoms experienced, severity, symptoms on completion of treatment and 
adverse drug reactions. Further information was obtained from the patient relating 
to compliance with therapy and the need for further GP consultation. Draft 
questions were prepared and tested for face and content validity by a panel 
consisting of a consultant microbiologist, general practitioner, medical 
prescribing advisor, community pharmacist, hospital pharmacist and several lay 
persons, resulting in slight alteration to the wording of some of the questions. 
4.2.2.2 Selection of patients 
The study was designed to include only female patients, aged 18 to 60 years 
presenting to their GP with symptoms of uncomplicated lower UTI. Those with 
risk factors predisposing to complicated infections and therefore likely to 
adversely affect outcomes were excluded from the study as follows: anatomical 
abnormalities of the urinary tract; presence of an indwelling catheter; recent 
urinary tract instrumentation; diabetes mellitus; other immunosuppressed 
conditions; immunosuppressant drugs; antibiotic use in the previous 2 weeks; 
symptoms of acute pyelonephritis; pregnancy, breast feeding. Patients with a UTI 
in the previous 3 months were also excluded as response to therapy and results of 
any microbiological sensitivity test may have altered drug selection. 
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4.2.2.3 Calculation of Sample Size 
To enable comparison of health outcomes between patients receiving formulary 
and non-formulary therapy, adequate sample sizes were necessary. This 
calculation required an estimate of the likelihood of treatment success with the 
formulary recommendation and the clinically important difference to be detected 
at a particular level of significance. Due to the lack of data relating to the efficacy 
of trimethoprim in Grampian, other indicators of the likelihood of success were 
used. Local sensitivity data identified that approximately 80% of all urinary 
isolates in Grampian were sensitive to trimethoprim (Gould 1993). Furthermore, 
Rubin et al (1992) had stated that all marketed antibiotics should provide cure in 
at least 80% of patients. It was therefore estimated that trimethoprim, the first line 
formulary recommendation, would provide favourable outcome in 80% of 
patients. In trials of lower uncomplicated UTIs, the clinically important 
difference should not be greater than 10%, with a power of 80% at a significance 
level of 5% (2-tailed test) (Norrby 1992, Norrby 1994). This resulted in 199 
patients being required for both the formulary and non-formulary groups. The 
study therefore initially aimed to recruit 240 patients to each of these groups, 
assuming that 80% of patients would return the questionnaire. 
4.2.2.4 Selection of prescribers 
This study required 2 populations of prescribers: those adhering to the 
formulary 
recommendations prescribing trimethoprim first line; and those prescribing 
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alternative agents. The main indication for trimethoprim is in the treatment of 
uncomplicated lower UTI (Joint Formulary Committee 1997). To enable 
identification of these 2 populations, it was assumed that those GPs with higher 
prescribing frequencies of trimethoprim were adhering to the recommendations, 
those with lower prescribing frequencies were not. Analysis of PRISMS data for 
Grampian was used to determine the median prescribing frequency of 
trimethoprim over a3 month period. Using this data, prescribers were stratified 
into those prescribing more or less than the median amount. Given the common 
presentation of females with lower uncomplicated UTI in primary care (6.25/100 
consultations), it was estimated that 12 prescribers in both groups, each 
distributing 20 questionnaires, would result in a study duration of approximately 
10 to 20 weeks, with minimal demands being made of any of the participating 
GPs. This short duration also allowed for the recruitment of further GPs, if 
necessary, to provide the required patient numbers in both groups. 
4.2.2.5 Data collection 
To enable identification and correction of any potential problems with study 
design, the method was piloted with one randomly selected GP. Further randomly 
selected GPs were contacted and permission sought for a meeting during which 
the study aims were explained. During these meetings, care was taken not to 
inform the GPs that prescribing of different individuals would be compared as 
such information itself may have altered prescribing habits. Particular emphasis 
was, however, placed on the anticipated extent of GP and patient 
involvement. 
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Access to patients' medical notes was also requested during this meeting. 
Sufficient GPs were contacted until agreement to distribute 20 questionnaires was 
obtained from 12 high and low prescribers of trimethoprim. Each participant was 
provided with a desk top organiser, clearly displaying the inclusion and exclusion 
criteria. This system served 2 purposes: acting as a constant reminder of the 
study; and providing easy storage for the patient questionnaires and reply paid 
envelopes. In addition, the questionnaires were coloured yellow to facilitate easy 
recall by both GP and patient. The top sheet of the questionnaire (Appendix 1) 
was completed by the GP at the time of the consultation, during which informed 
consent for participation was also obtained from the patient. These top sheets 
were detached from the remainder of the questionnaire and stored at the practice 
reception for collection each week by the researcher. The patient completed the 
remainder of the questionnaire outwith the surgery. This was organised in 2 parts: 
section 1 was completed prior to the commencement of the prescribed antibiotic; 
section 2 following completion of the course of medication (Appendix 2). The 
patients were instructed to return the questionnaires in the reply paid envelopes. 
Those patients not returning the questionnaire within 2 weeks of collecting the 
top sheets from the practice received reminder letters and a maximum of 3 further 
questionnaires at weekly intervals (Appendix 3). All patients in agreement were 
contacted either by letter or telephone 4-6 weeks following completion of 
antibiotic to identify any return of symptoms and subsequent action (Appendices 
4,5). Further data was collected from the medical notes of all patients who either 
consulted their GP at a later stage or had urine samples cultured using a standard 
data collection form (Appendices 6,7). 
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4.2.2.6 GP follow up 
All participating GPs were contacted a few weeks into the study to determine any 
difficulties being experienced with carrying out the study. Further contact was 
made in writing at a later stage to determine any problems and to provide 
information relating to their own rate of questionnaire distribution and those of all 
other participating GPs (Appendix 8). Following a period of 18 months of data 
collection, all GPs were informed in writing that no further questionnaires should 
be distributed (Appendix 9). 
4.2.2.7 GP Feedback 
Results of questionnaire distribution, drugs prescribed, use of microbiological 
sensitivity testing and resultant health outcomes were communicated to all 
GPs in 
Grampian via a newsletter distributed by the Communicable Disease Team of 
Grampian Health Board (Appendix 10). 
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4.3 Ulcer Healing Agents 
4.3.1 Objectives 
The objectives of this part of the research were to: 
1. identify patients in primary care receiving repeat prescriptions for ulcer healing 
agents. 
2. identify for each patient the ulcer healing agent prescribed, dose, duration of 
therapy, indication and results of any investigations. 
3. identify patients receiving therapy not in accordance with the recommendations 
of the Grampian Joint Drug Formulary. 
4. measure the effect on health outcomes of changing therapy in line with the 
recommendations of the Grampian Joint Drug Formulary. 
4.3.2 Method 
4.3.2.1 Selection of practice 
Potential practices for inclusion in the study had to fulfil 2 criteria: relatively low 
use of cimetidine, identified as a low ratio of cimetidine to ranitidine 
from 
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PRISMS data; no current initiative to identify suitable patients for H. pylori 
eradication therapy, identified from discussions with the medical prescribing 
adviser and the general medical practice facilitator of Grampian Health Board. A 
meeting was arranged with one such practice, during which the study aim and 
objectives were discussed, with particular emphasis being placed on the 
anticipated demands on both prescribers and patients. The practice, which was 
fund-holding, with 3.5 whole time equivalent GPs and a practice list size of 6551 
patients, was both supportive of the study aims and objectives and fully agreed to 
participate. Selection of a practice in this way allowed a cluster sample of patients 
to be obtained for the study. Data was collected over a 20 month period, from 
December 1995 to August 1997. 
4.3.2.2 Selection of patients 
The practice computer system (EMIS, Egton Medical Information Systems) was 
used to identify those patients receiving ulcer healing agents on repeat 
prescription. A data collection form (Appendix 11) was devised and piloted to 
record the following information from these patients' medical notes: age, current 
ulcer healing agent prescribed, dose, duration of therapy, indication, 
investigations, previous ulcer healing agent use, other current therapy and 
medical problems. This form was subsequently used to collect this information 
for all patients. An interim drug utilization report was prepared and distributed to 
the GPs involved. 
76 
4.3.2.3 Guidelines 
A guideline for appropriate ulcer healing agent use in these patients was devised, 
based on the recommendations of the Grampian Joint Drug Formulary, and 
agreed by all GPs within the practice. In general, this recommended eradication 
therapy in patients with a history of duodenal or gastric ulcer unless shown 
previously to be H. pylori negative, or where there were valid reasons for 
continuous prescription of an ulcer healing agent, for example, NSAID 
prophylaxis, severe oesophagitis. Cimetidine was recommended for all 
indications, except in those patients receiving concurrent warfarin, phenytoin, 
theophylline or aminophylline. Omeprazole was to be restricted for use in severe 
oesophagitis or where poor response had been demonstrated with H2RAs. 
Maintenance doses of cimetidine 400mg at night, ranitidine 150mg at night and 
omeprazole 10mg daily were recommended. Cimetidine was to be used for 
NSAID prophylaxis as the GPs were reluctant to use misoprostol due to past 
experience indicating a high frequency of adverse effects. Patients suitable for 
having their therapy changed were identified and possible savings arising from 
guideline implementation estimated. 
4.3.2.4 Health outcome measurements 
A list of potential patients for interview was prepared and circulated to all GPs 
for comment as regards suitability for domiciliary interview. Those suitable were 
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contacted in writing, explaining the method of patient selection for inclusion in 
the study, nature and likely duration of interview (Appendix 12). These patients 
were further contacted by telephone a few days later to seek permission for this 
interview and to arrange a convenient time. Informed patient consent (Appendix 
13) was obtained prior to commencement of each interview, which was 
undertaken in 3 stages. During stage 1, information relating to the ulcer healing 
agent prescribed, dose, duration of therapy and indication were obtained, along 
with data relating to smoking, analgesic use and the effect of the medical 
condition on diet. The Glasgow Dyspepsia Severity Score (El-Omar et al 1996) 
was used as a specific disease state measure in stage 2 and SF-36 (Ware et al 
1993) as a generic measure in stage 3 (Appendix 14). Permission to use these 2 
measures had previously been obtained. Each interview was carried out in the 
patient's home and lasted approximately 45 minutes. In those patients previously 
identified as being suitable candidates for H pylori eradication therapy, further 
discussion took place regarding the nature and possible benefits, following which 
these patients were asked to indicate their willingness to receive such therapy. 
Results of each interview were fed back to the GP responsible for each patient 
using a form devised for this purpose (Appendix 15), outlining possible options 
for therapy based on the guideline. Space was included for the GP to indicate 
agreement with the recommendation and to specify the actions taken. For each 
candidate likely to receive H pylori eradication therapy, a patient information 
leaflet (Appendix 16) was included in the information given to the GP, to be 
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given to the patient along with any prescription for eradication therapy. The GPs 
retained the responsibility for explaining any changes to the patients. 
The practice was visited regularly to collect completed feedback forms. In those 
patients where a change in therapy had been indicated by the GP, further 
information was obtained from the medical notes and practice computer to 
identify if the agreed change had been implemented, and to record any further GP 
or hospital visits, new diagnoses or changes in therapy likely to influence 
measurement of health outcomes (Appendix 17) Each patient was contacted six 
months following a change in treatment and permission requested to repeat the 
interview, using a slightly modified interview schedule (Appendix 18). 
Glasgow Dyspepsia Severity Scores were calculated by summing the responses 
for each item, giving a maximum score of 20, a higher score indicating poorer 
control of symptoms (El-Omar et al 1996). SF-36 scores were calculated as 
recommended (Ware et al 1993) with a score being obtained for each domain on 
a scale of 0-100%, a higher score indicating a better health status. 
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4.4 Peripheral Vasodilators 
4.4.1 Objectives 
The objectives of this part of the research were to: 
1. identify patients in primary care receiving repeat prescriptions for peripheral 
vasodilators. 
2. identify for each patient the peripheral vasodilator prescribed, dose, duration of 
therapy, indication and original prescriber. 
3. measure the effect on health outcomes of withdrawing therapy in line with the 
recommendations of the Grampian Joint Drug Formulary. 
4.4.2 Method 
4.4.2.1 Selection of practices 
Potential practices for inclusion in the study had to fulfil 2 criteria: relatively high 
use of peripheral vasodilators, identified from PRISMS data; no current initiative 
to reduce prescribing of these agents, identified from information supplied by the 
Grampian General Practice Audit Committee. Meetings were arranged with 2 
practices, during which study aim and objectives were discussed, with particular 
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emphasis being placed on the anticipated demands on both prescribers and 
patients. Selection of these practices allowed cluster samples of patients to be 
obtained for the study. The practices, both fund-holding with practice list sizes of 
5579 and 5343 patients respectively, were both supportive of the study aim and 
objectives and fully agreed to participate. Data was collected over a 14 month 
period, from July 1996 to September 1997. 
4.4.2.2 Selection of patients 
The practice computer systems (EMIS, Egton Medical Information Systems and 
G-PASS, General Practice Administration System for Scotland) were used to 
identify those patients receiving repeat prescriptions for peripheral vasodilators. 
A data collection form (Appendix 19) was devised and piloted to record the 
following information from these patients' medical notes: age, peripheral 
vasodilator prescribed, dose, duration of therapy, indication, original prescriber, 
vascular investigations, concurrent therapy and medical problems. This form was 
subsequently used to collect this information for all patients. An interim drug 
utilization report was prepared and distributed to the GPs involved. 
4.4.2.3 Health outcome measurements 
A list of those patients receiving continuous therapy was prepared and circulated 
to all GPs for comment as regards suitability for domiciliary interview. Suitable 
patients were contacted in writing by the GPs, explaining the method of patient 
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selection for inclusion in the study, nature and likely duration of interview 
(Appendix 20). These patients were further contacted by telephone a few days 
later to seek permission for this interview and to arrange a convenient time. 
Informed patient consent (Appendix 21) was obtained prior to commencement of 
each interview, with each patient receiving a patient information leaflet 
(Appendix 22). During stage 1 of the interview information relating to the 
peripheral vasodilator prescribed, dose, duration of therapy and indication were 
obtained, along with any history of smoking. The Walking Impairment 
Questionnaire (Regensteiner et al 1990) was used as a disease specific measure in 
stage 2 and SF-36 (Ware et al 1993) as a generic measure in stage 3 (Appendix 
23). Permission to use these 2 measures had previously been obtained. Each 
interview was carried out in the patients' homes and lasted approximately 45 
minutes. 
Results of each interview were fed back to the GP responsible for each patient 
using a form devised for this purpose (Appendix 24). Letters signed by the GPs 
were sent to these patients instructing them to stop taking their peripheral 
vasodilator (Appendix 25). Patients were informed that they would be reviewed 
after a period of 2 months and to contact the surgery with any queries. 
Following this 2 month period, the practices were visited and further information 
obtained from the patients' medical notes regarding any further GP or hospital 
visits, new diagnoses or changes in therapy likely to influence measurement of 
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health outcomes (Appendix 26). Each patient was subsequently contacted by 
telephone and permission requested to repeat the interview. 
Walking Impairment Questionnaire scores were calculated as recommended 
(Regensteiner et al 1990), providing separate scores for walking distance, 
walking speed and claudication pain on a scale of 0 (unable to perform due to 
severe claudication) to 100% (no impairment). SF-36 scores were calculated as 
before. 
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Chapter 5 
Urinary Tract Infections: Results and Discussion 
5.1 Results 
5.1.1 GP response 
Telephone contact with 27 randomly selected GPs resulted in meetings being 
arranged with 24, during which all agreed to participate in the study. Initial rates 
of questionnaire distribution were much lower than had been anticipated. On 
contacting all GPs, several admitted having forgotten about the study, but no 
particular problems were voiced by the remainder and all wished to continue their 
involvement. This contact resulted in only a modest increase in questionnaire 
distribution, thus it became necessary to contact all GPs in writing to inform them 
of rates of distribution and further identify any contributing factors. Again, no 
such problems were identified by the GPs and this contact had very little effect on 
the rate of questionnaire distribution. Due to this poor response, the study was 
brought to a close after 18 months of data collection, with only 89 of the planned 
480 questionnaires (19%) having been given out during this period. Figure 5.1 
illustrates the distribution rates of all the GPs involved. 
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Figure 5.1: Questionnaire distribution rates over an 18 month period. 
The majority of questionnaires 59 (66%) were distributed by 3 GPs, all of whom 
had been previously identified as prescribing below the median frequency of 
trimethoprim. Of the 89 questionnaires distributed, 17 (19%) were from those 
GPs identified as prescribing higher than the median and 72 (81 %) lower than the 
median frequency. There was no association between previously identified 
prescribing frequency for trimethoprim and whether or not any questionnaires had 
been distributed (x2 = 0.17, p=0.68,1 d f). 
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5.1.2 Drug utilization data 
Figure 5.2 illustrates the antibiotics prescribed for lower uncomplicated UTIs. 
Others 
Ciprofloxacin 6% 
Nitrofurantoin 
16% 
Co-amoxiclav 
11% 
Cephalexin 
2% 
Trimethoprim 
61% 
Figure 5.2: Antibiotics prescribed to patients presenting with symptoms of 
a lower uncomplicated UTI. 
The "other" category comprised 1 prescription for each of the following: 
amoxycillin, cephradine, cefaclor, fosfomycin, nalidixic acid. 
Trimethoprim was the most commonly prescribed agent (54 patients), 
representing a level of adherence to the antibiotic policy of 61% (95% confidence 
intervals 51 - 71). There was no association between those prescribing above and 
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below the median frequency of trimethoprim and the observed prescribing rate of 
policy and non-policy therapy (x = 0.87, p=0.35 1 df). 2 
A variety of patient factors influencing selection of therapy were identified in 22 
further patients as shown in table 5.1. 
Factor Identified Number of patients 
Previous adverse drug reaction to co- 
trimoxazole 
5 
Previous infection unresponsive to 
trimethoprim 
4 
Possible pregnancy 3 
Severity of symptoms 2 
Penicillin allergy 2 
Recurrent infection 1 
Receiving carbamazepine 1 
Concurrent chest infection 1 
Concurrent skin infection 1 
Prescribed therapy effective in past 1 
Patient prone to thrush 1 
Table 5.1: Patient factors influencing selection of therapy identified by 
GPs. 
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Only 1 patient with a history of previous adverse drug reaction on exposure to co- 
trimoxazole was prescribed cephalexin as recommended in the policy, the 
remaining patients receiving a variety of agents. Several of the above identified 
factors such as possible pregnancy and concurrent infections would render 
trimethoprim less appropriate, hence adherence to the policy may be potentially 
higher. 
All patients prescribed trimethoprim received a dose of 200mg twice daily, with 
the median duration being 5 days (range 3-7 days) as shown in table 5.2. 
Duration (days) Number of patients (%) 
3 21(39) 
5 24 (44) 
7 9(17) 
Table 5.2: Duration of trimethoprim therapy. 
5.1.3 Measures of health outcome 
The fate of patients in terms of this study is summarised in figure 5.3. 
88 
480 planned questionnaires 
89 distributed in total 
35 patients prescribed 54 patients prescribed 
non-formulary agents trimethoprim 
45 returned 
40 no or mild symptoms 
on completion of treatment 
22 symptom free 
questionnaire 
31 patients followed 
up after 4-6 weeks 
9 symptomatic 
7 returned to GP 
Figure 5.3: Flow chart indicating fate of patients during study. 
89 
Questionnaires were returned by 80/89 patients (90%), with the majority being 
returned without need of further reminders as shown in table 5.3. 
Number of Reminders Number of Patients (%) 
0 60 (75) 
1 11(14) 
2 7(9) 
3 2(2) 
Table 5.3: Questionnaire return rates. 
Samples sizes of 199 patients receiving both formulary and non-formulary agents 
had been calculated to allow detection of a clinical difference of 10% with a 
power of 80%. Given the small sample sizes obtained, comparisons of health 
outcomes between these groups were not made and only health outcomes 
resulting from trimethoprim, the recommended agent, are reported. 
Of the 54 patients prescribed trimethoprim, 45 (83%) returned the questionnaire, 
of which forty patients (91 %) reported no or only mild symptoms on completion 
of treatment as shown in table 5.4. 
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Symptom Description Number of Patients (%) 
Gone away 33 (73) 
Mild 7(16) 
Moderate 4 (9) 
Severe 1 (2) 
Table 5.4: Symptoms reported on completion of trimethoprim therapy. 
The median time for symptoms to resolve completely was 3-4 days. Two of the 
patients reporting mild and all with moderate or severe symptoms on treatment 
completion returned to their GP. 
Of the 80 patients returning the questionnaire, 60 (75%) agreed to be contacted by 
letter or telephone 4-6 weeks later. Of those prescribed trimethoprim initially, 31 
(69%) agreed to be contacted. Of these, 22 (71 %) were symptom free, while 9 
(29%) had experienced either symptoms on completion of treatment or within this 
follow up period, 7 of whom returned to their GP. One patient was referred for 
gynaecological opinion, the remainder being treated with further courses of 
antibiotics. 
Two patients prescribed trimethoprim (4%) reported possible side effects 
sufficiently serious to warrant discontinuing treatment and consulting their GP 
(itch 1 patient, nausea 1 patient). Four further patients reported less troublesome 
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adverse events (tiredness 2 patients, nausea 1 patient, thrush 1 patient). All others 
completed the prescribed courses. 
5.1.4 Microbiological testing 
Microbiological sensitivity testing was performed at the time of initial 
presentation for 37 of the 89 patients (42%). The results of these were obtained 
from the patients' medical notes, but were unavailable for 9 patients, 8 of whom 
had moved outwith the practice boundary and had been misplaced for 1 patient. 
Data obtained for 28 patients indicated that no growth was present in the urine 
samples of 11 (39%). E. coli was found to be the most common infecting 
organism, being the sole pathogen in 9 patients and along with E. faecalis in 1 
patient. Other infecting organisms were Coliform (5 patients) and S. 
saprophyticus (2 patients). Resistance to trimethoprim was observed in 6/18 
(33%) instances. Sensitivity reports indicated that 10 of these 17 patients were 
receiving an antibiotic with the appropriate spectrum of activity. Two further 
patients were sent prescriptions for agents with appropriate spectra, but in both 
cases cheaper agents would have been more appropriate. Of the 6 patients who 
were initially prescribed trimethoprim and received further courses of antibiotic 
for symptom recurrence, 4 had not had a urine sample cultured on initial 
presentation. Three of these received further courses of empirical therapy. 
The 
urine samples of the remainder, who had also received further treatment, 
demonstrated no microbial growth on either initial or follow up culture. 
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5.2 Discussion 
No previous research in primary care has measured patient centred health 
outcomes resulting from implementing antibiotic policy recommendations. The 
outcome measure in this study was primarily the patient's perspective of the 
speed and extent of symptom resolution experienced. In acute self limiting 
infections such as uncomplicated lower UTIs, this is of much more relevance to 
the patient than measures such as microbiological cure (Nicolle 1990, Ronald et 
al 1992). This general approach to health outcome measurement for acute and 
self limiting disease states has been recommended by several authors (Guyatt et 
al 1993, Tsevat et al 1994, Ebbs et al 1989). 
5.2.1 Interpretation of Findings 
Health outcomes results obtained in this study are limited and should be 
interpreted with caution, principally due to the small sample sizes of both 
prescribers and patients. Of particular note, it was not possible to compare health 
outcomes resulting from formulary and non-formulary treatment, one of the main 
objectives at the outset of the study. Instead, the majority of health outcomes are 
simply presented in terms of trimethoprim, the first line recommendation, and 
indeed the majority of these prescriptions came from 3 GPs. Treatment with this 
agent was found to provide favourable results in 91 % of patients at the point of 
treatment completion, with few patients discontinuing treatment because of 
possible adverse events and similarly low numbers returning to the prescriber at 
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this point. Previous standards for the design and conduct of studies in this area 
(Working party of the British Society of Antimicrobial Chemotherapy 1989, 
Rubin et al 1992) recommended following patients for a period of no less than 4 
weeks as shorter periods had been shown to miss the return of symptoms in many 
patients. Data from the present study supports this recommendation, with 29% of 
patients experiencing symptoms on follow up. Although this represents a marked 
deterioration of health outcomes when compared to the initial resolution of 
symptoms, not all patients felt that these symptoms warranted a further visit to 
their GP. As stated above, the majority of these patients were recruited by 3 GPs 
and thus are unlikely to be representative of the majority of patients in primary 
care. Accordingly, these results must be interpreted with great caution. 
The drug utilization data yielded 61 % adherence to the recommendation of the 
policy, in terms of selecting trimethoprim as a first line agent. This result cannot 
be compared to earlier studies since previous work simply determined whether 
antibiotics prescribed were included in a list of recommended drugs, with no 
information provided relating to indication of therapy. Kelsey et al (1996) 
recommended that 85% of all prescribed antibiotics should be 
included in such a 
list. Such an approach is, however, limited since information relating to the 
indication for therapy is essential in order to determine the appropriateness of 
prescribing. Although the level of adherence obtained 
in this study was 
considerably lower than 85%, clinical factors affecting 
drug selection were 
identified in many instances, and although several of these, such as penicillin 
allergy, concurrent carbamazepine therapy would not alter 
the appropriateness of 
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trimethoprim, others such as the presence of simultaneous chest and skin 
infections render trimethoprim less suitable. The most common factor identified 
was past adverse drug reactions experienced with co-trimoxazole. Although these 
are most likely to be associated with the sulphamethoxazole component (Anon 
1986b), it may also be appropriate to avoid trimethoprim, particularly in primary 
care, where the patient will be monitored less closely than in secondary care. 
5.2.2 Limitations of antibiotic policy 
The antibiotic policy recommendations for primary care simply list the selected 
drugs to be used for each indication, with no guidance provided on the need for 
microbiological sensitivity testing, nor the appropriate duration of therapy. The 
results of this study would appear to identify that such guidance is necessary. 
with considerable variation being observed in both of these areas. The median 
duration of trimethoprim was found to be 5 days, with a range of 3 to 7 days. The 
optimal duration of therapy in uncomplicated lower UTIs has been greatly 
debated in the medical literature. Bailey (1990), while reviewing studies of single 
dose therapy, cited studies demonstrating that for several agents, including co- 
trimoxazole, trimethoprim, nitrofurantoin, 4-quinolones, single dose was as 
effective as longer courses, but with lower incidence of adverse effects and 
reduced drug costs. Failure of single dose therapy was identified as being an 
indication for further urinary investigations. On the basis of this evidence an 
algorithm for the management of uncomplicated lower UTIs was produced, 
recommending single dose therapy first line (Bailey 
1993). The author, however, 
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failed to critically review those studies cited. Leibovici and Wysenbeek (1991) 
and Stamm (1992) demonstrated that most of the studies cited were not of 
sufficient size to allow detection of a clinical difference with a power of 80%. 
Meta-analysis of studies fulfilling minimal inclusion criteria (Norrby 1990, 
Leibovici, Wysenbeek 1991) identified that 3 days therapy with many agents was 
the optimal duration, being more effective than single dose and as effective as 
longer courses. No major differences in the frequencies of adverse effects were 
identified between single dose and 3 days treatment. Studies of ß-lactams 
produced lower cure rates than observed with other agents, regardless of 
treatment duration. Many have now recommended that such uncomplicated lower 
UTIs are treated initially with a3 day course of antibiotics other than ß-lactams 
(Johnson, Stamm 1989, Norrby 1990, Leibovici, Wysenbeek 1991, Wilkie et al 
1992). 
E. coli was found to be the most common infecting organism, a finding consistent 
common with that of previous work (Wilkie et al 1992). Of greater interest was 
the high frequency with which no growth was identified in urine samples. An 
inconsistent approach was demonstrated in the use of microbiological sensitivity 
testing with such tests being performed in less than half of patients and, in many 
cases, no action was taken on receipt of these results even on recurrence of 
symptoms. These findings highlight the need for guidance to be provided within 
the antibiotic policy. Many have recommended that such testing is unnecessary 
in 
females presenting with symptoms of uncomplicated lower UTI, with initial 
treatment simply directed towards E. coli (Johnson, Stamm 1989, Brooks 1990, 
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Hooton, Stamm 1991, Stamm, Hooton 1993). Olesen and Oestergaard (1995). 
however, identified differences in treatment strategies between Danish GPs, 
urologists and microbiologists, with GPs being more likely to include sensitivity 
testing as part of the overall management in younger patients. 
The need to include guidance on the role of microbiological sensitivity testing is 
of particular importance since, for all antibiotics used in the treatment of 
uncomplicated lower UTIs, the cost of such testing greatly outweighs drug costs. 
Previous work has shown that drug costs comprise only 13% of the overall cost 
of treatment if microbiological sensitivity testing is performed both initially and 
on completion of treatment (Schultz et al 1984). This highlights the need for well 
designed pharmacoeconomic evaluation of different strategies for treating these 
infections. Such an evaluation was described by Carlson and Mulley (1985) who 
developed a decision analysis model to compare effects and costs of single and 
multiple doses of amoxycillin and co-trimoxazole in the management of 
uncomplicated lower UTIs. Using cure rates identified from previous studies, 
single dose therapy was shown to be most effective at reducing symptoms, at a 
lower cost, with initial microbiological sensitivity testing increasing speed of 
symptom resolution by 10%, but at an increase in cost of 40%. These findings 
must, however, be interpreted cautiously since much of the data was derived 
from 
poorly designed studies with limited patient numbers. In addition, only 
direct 
costs of drugs and microbiological sensitivity testing were considered. 
More 
recently, several authors have described additional costs which should 
be 
incorporated into such analyses, including further direct costs of GPs' time, 
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treatment of adverse effects and symptom recurrence, and indirect costs 
associated with loss of work, pain and suffering by the patient. (Patton et al 1991. 
MacDonald 1994, MacDonald et al 1995, Plumridge, Colledge 1996) These 
studies may indeed identify that initial therapy with a more expensive agent may 
provide improved patient outcomes at lower overall costs, but at a higher drug 
cost. Despite these recommendations, pharmacoeconomic studies relating to the 
treatment of uncomplicated lower UTI in primary care have not been described. 
5.2.3 Critical Appraisal of Method 
As stated earlier, results of health outcomes reported in this study are limited, 
primarily due to the poor response from those GPs involved and thus the lack of 
representativeness of the patients involved. Jones (1993) described the problems 
for researchers trying to become integrated into a non-research culture in primary 
care medicine, where little enthusiasm from GPs is not uncommon. In this present 
study, considerable time and effort were expended to ensure that the GPs were 
fully informed of the study aims and requirements and indeed 89% of GPs 
contacted were keen to be involved. The study was deliberately designed to place 
minimal burdens on the GPs and many steps were taken to ensure continued 
awareness of the study by the GPs. For example, desk top organisers were 
provided for displaying the questionnaires, which were brightly coloured. Each 
practice was visited weekly to collect the informed consent sheets, 
simultaneously acting as further prompts to all reception staff and 
GPs. Contact 
with the GPs was made on several occasions to determine any problems 
being 
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experienced. Informing GPs of their individual distribution rates and those of 
others, some of whom had distributed all questionnaires in a short period of time 
similarly had little effect on questionnaire distribution, resulting in the study 
being halted with only 19% of questionnaires given out. A duration of 10-20 
weeks had originally been estimated for this data collection period. Following 
analysis of results, it had been planned that the results would be communicated to 
the GPs, with a later period of data collection to measure any resulting changes in 
prescribing and health outcomes. Those GPs adhering to the policy, prescribing 
trimethoprim, may have been keener to record their prescribing and distribute 
questionnaires, but no association was identified between distributing any 
questionnaires and whether the GP had been identified previously as prescribing 
above or below the median frequency for trimethoprim. 
There is a need to study drug utilization evaluation of acutely prescribed 
medicines in primary care, particularly comparing recommended and non- 
recommended therapies. Although the GP is in the prime position to identify 
suitable patients for these studies, perhaps alternative methods of patient 
recruitment or encouraging GP participation are necessary. It has 
been suggested 
that financial incentives could alter GP response rates for mailed questionnaires 
(Deehan et al 1997) and perhaps such an approach could have 
been used in this 
study in order to aid patient recruitment. 
Despite the disappointing performance of the GPs, patient response rate was 
extremely high, with 89% of questionnaires 
being returned. This may have been 
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due to the questionnaire being short, brightly coloured and including a reply paid 
envelope, methods shown previously to increase response (Childers, Ferrell 1979, 
Nedrhof 1978). A further contributing factor may have been due to the patients 
being recruited by their GP, a further reason for identifying methods of increasing 
GPs involvement in research. 
This study was designed with dual purposes of collecting drug utilization data 
and comparing health outcomes derived from recommended and non- 
recommended therapies. Although it was not designed to be a clinical trial, all 
recommended standards for conducting such a trial were incorporated into the 
design. Sample sizes were calculated to provide a power of 80% to identify a 
clinical difference of 10% at a significance level of 5%. Only patients with 
symptoms of uncomplicated lower UTIs were included, excluding those with risk 
factors known to predispose to complicated infections, therefore potentially 
altering health outcomes. Patients were followed for the recommended period of 
4-6 weeks after completion of antibiotic therapy to identify symptom persistence 
or recurrence. 
Despite these measures, the method was limited in several respects. The 
estimation of trimethoprim success rate at 80% was based on sensitivity data and 
a recommendation by Rubin et al (1992). The link between sensitivity data of all 
urinary isolates and cure rate for uncomplicated lower UTI has not been 
established and Rubin et al provided no objective data relating to their claims. 
Despite these deficiencies, sample size was calculated based on estimated success 
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rate with a plan to repeat this calculation using actual data from those patients 
receiving trimethoprim. The planned comparison of policy and non-policy as 
described may not have been appropriate, since the non-policy agents may not 
have been a homogenous group, particularly in terms of efficacy. Research has 
shown that ß-lactam antibiotics have been associated with poorer health 
outcomes in comparison to other agents. The method of stratifying GPs into 2 
groups of higher and lower prescribers of trimethoprim may not have produced 
the diverse groups anticipated. Strickland-Hodge and Jepson (1981) 
recommended a method of stratifying into 3 groups of high, medium and low 
prescribers, with high prescribers being more than 1 standard deviation above and 
low 1 standard deviation below the median. Analysis of prescribing data for 
Grampian identified less than 20% of GPs being outwith 1 standard deviation unit 
on either side of the median frequency of trimethoprim, with many of these 
located in very rural areas. Using the method of Strickland-Hodge and Jepson 
(1981) would have produced a study with great practical limitations. As a result, 
prescribers were simply stratified into those above and below the median, with a 
plan to recruit further GPs at a later stage until the necessary 199 patients in each 
group were obtained. Most of the prescribers in both groups were probably better 
described as medium prescribers and indeed no difference was observed in 
trimethoprim prescribing during the study between those classed initially as high 
and low prescribers. Alternatively, there may have been a Hawthorne type effect 
(Roethlisberger, Dickson 1939) on those previously prescribing lower amounts of 
trimethoprim. 
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5.2.4 Conclusion 
Little conclusion can be drawn from these results relating to the efficacy of 
trimethoprim as recommended in the Grampian Joint Drug Formulary. This 
research provides more data relating to the difficulties of collecting data relating 
to acute prescribing in primary care, an area which deserves more attention. 
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Chapter 6 
Ulcer Healing Agents: Results and Discussion 
6.1 Results 
6.1.1 Drug utilization 
A total of 184 patients (3% of the practice list) were identified from the practice 
computer system as receiving repeat prescriptions for ulcer healing agents. Ninety 
seven patients (53%) were female and 87 (47%) male with a median age of 63 
years (range 13 - 87). Fourteen patients (8%) had not received a prescription 
during the previous 6 months, 51 (28%) had received prescriptions on an 
intermittent basis. The remaining 119 patients (65%, 2% of the practice list) had 
received continuous prescriptions for at least the previous 6 months. 
The fate of these patients in this study is summarised in figure 6.1 
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184 patients 
receiving repeat prescriptions 
14 51 119 
no prescription in intermittent continuous 
previous 6 months prescriptions prescriptions 
6 30 11 78 
eradication 
therapy 
treatment in 
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change inappropriate potential 
due to patient changes 
84 
potential 
changes 
8 
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for interview due to 
non-clinical reasons 
76 
deemed suitable 
57 
patients 
agreed 
19 
patients 
refused 
5 13 39 
changes no changes changes 
implemented recommended recommended 
prior to 
interview 
21 
implemented 
11 
ranitidine altered 
to cimetidine 
Figure 6.1: Flow chart indicating fate of patients during study. 
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Duration of continuous therapy is shown in figure 6.2. 
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Figure 6.2: Duration of continuous ulcer healing agent use. 
The median duration was found to be 1-2 years, with only 7 patients (6%) having 
received therapy for greater than 5 years. 
Diagnosed indications for therapy in these 119 patients are illustrated in figure 
6.3. 
6-12 1-2 2-3 3-4 4-5 >5 
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Figure 6.3: Indications for continuous ulcer healing agent therapy. 
The most common indications were gastro-oesophageal reflux disease (38 
patients) followed by duodenal ulcer (23 patients). The "other" category 
comprised 6 cases of gastritis, 4 with duodenitis and 1 case of gastric carcinoma. 
Multiple indications were identified in several patients. For example, 14 patients 
had a history of duodenal ulceration and gastro-oesophageal reflux disease; 
twelve patients with a history of duodenal ulceration were receiving concomitant 
NSAID therapy. 
In some patients, the investigation on which the diagnosis was based had been 
carried out many years earlier, as shown in table 6.1. 
9% Duodenal ulcer 
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Diagnosis Median time since diagnosis (years) Range (years) 
Duodenal ulcer 9 1-40 
Gastric ulcer 2 0.5 - 17 
Gastro-oesophageal 
reflux disease 
2 1-23 
Table 6.1: Median time since investigations. 
Fifteen patients were identified where no investigations had been carried out, as 
described in table 6.2. 
Reason for therapy Number of patients 
Dyspepsia 7 
Chemotherapy induced dyspepsia 1 
Dyspepsia associated with severe depression 2 
Dyspepsia associated with pancreatitis 1 
Dyspepsia associated with personality disorder 1 
Dyspepsia associated with surgery 1 
No indication, commenced by secondary care 1 
No indication, commenced by GP 1 
Table 6.2: Indications for therapy in patients not investigated. 
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The following ulcer healing agents were prescribed to the 119 patients receiving 
continuous therapy. 
Cimetidine 
10% 
Omeprazole 
24% 
c 
,ý 
Ranitidine 
66% 
Figure 6.4: Ulcer healing agents prescribed, continuous therapy. 
This represents 100% adherence to the Grampian Joint Drug Formulary in terms 
of drug choice. Thirty patients were receiving therapy in accordance with the 
guideline previously described. In a further 11 patients, changing therapy would 
have been unsuitable for a variety of reasons including poor prognosis, severe 
depression. In the remaining 78 patients, potential changes were identified as 
shown in table 6.3. 
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Potential Change Number of patients 
Eradication therapy 13 
Change to cimetidine 47 
Change to generic cimetidine 4 
Reduce omperazole dose 9 
Reduce ranitidine dose 1 
Reduce cimetidine dose 1 
Increase cimetidine dose 1 
Increase ranitidine dose 1 
Discontinue ranitidine 1 
Total 78 
Table 6.3: Potential changes to therapy. 
The most common change was to alter ulcer healing agent to cimetidine. Only 13 
potential candidates for H. pylori eradication therapy were identified. Of the 9 
patients with a history of gastric ulceration, only 1 patient was deemed a suitable 
candidate, with 2 patients previously testing negative for H. pylori, 3 were 
receiving continuous NSAID therapy requiring continued prophylaxis, the 
causative agent had previously been identified as an NSAID in 2 patients, and 1 
patient suffered from severe oesophagitis, requiring continuous treatment. Of the 
32 patients with duodenal ulceration, only 12 (38%) were potential candidates for 
H. pylori eradication therapy. In the remaining patients, either continuous therapy 
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with an ulcer healing agent was required (10 were taking NSAIDs, 2 had Barrett's 
oesophagus and 1 an oesophageal stricture) or H. pylori was not the causative 
agent (3 patients had previous negative H pylori tests and NSAID use was 
responsible for the ulcer in a further 3 patients), hence eradication therapy would 
not have been appropriate. A possible increase to a treatment dose of H2RA was 
identified in 2 patients, both with a history of duodenal ulceration, receiving 
concurrent NSAIDs. One further patient was identified as receiving both 
ranitidine and misoprostol as prophylaxis. Only 2/119 patients (2%) were 
receiving other therapy with which cimetidine would interact in a clinically 
important manner (1 theophylline, 1 warfarin). 
Of the 51 patients receiving intermittent ulcer healing agents during the previous 
6 months, 36 (71 %) had received greater than 2 months therapy. Eleven patients 
were identified with a history of either gastric or duodenal ulceration. In these 
patients, 3 had recently received eradication therapy, 1 was receiving NSAID 
therapy intermittently and 1 patient had been shown to be H. pylori negative. The 
remaining 6 patients were identified as further suitable candidates for H pylori 
eradication therapy. 
Estimated cost savings arising from implementation of these changes exceeded 
£ 14,000 in the first year, including the cost of eradication therapy. 
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6.1.2 Patient interviews 
The GPs indicated that 8 of the 84 patients identified as potential candidates for 
altering therapy would be unsuitable for interview for non-clinical reasons, 
primarily patients known to be aggressive or demanding. Letters were sent to the 
remaining 76 patients, of whom 57 (75%) agreed to participate. 
On interview, only one of these patients was completely unaware of the 
indication for therapy, the remainder describing either the correct term such as 
"duodenal ulcer" or symptoms such as "indigestion". Five patients with no 
indication for therapy documented in their medical notes listed indications of 
indigestion (3 patients), hiatus hernia (1 patient), nausea (1 patient). Sixteen 
patients (28%) continued to smoke, despite repeated advice to stop and few 
patients described any major alterations to diet other than general healthy eating. 
Five patients reported experience of possible adverse effects with ulcer healing 
agents. Four of these were as a result of ranitidine therapy, mild diarrhoea in all 
cases. One patient receiving Tagamet described breast swelling. 
On interview, it was identified that changes in line with the recommendations of 
the interim report had already been implemented in 5 patients, with 1 receiving 
eradication therapy, 3 being changed to cimetidine and ranitidine discontinued in 
the remaining patient. None of these 5 patients expressed concern regarding this 
change and all were satisfied with their current therapy. Cost savings due to these 
changes were calculated at £930 in the first year following the change. 
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In 13 patients, no changes were recommended, due to a variety of reasons. Four 
patients previously identified as suitable candidates for H pylori eradication 
therapy were reluctant to alter existing treatment, which they viewed as very 
effective. Treatment in a further 4 patients had recently been altered by secondary 
care making it inappropriate to further alter treatment. Ulcer healing agent 
therapy had been discontinued completely in 3 patients and altered recently by 
the GP in 1 patient. One further patient expressed concerns regarding the efficacy 
and toxicity of Tagamet. 
As a result of the information obtained from interview and the medical notes, 
changes were recommended as shown in table 6.4. 
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Change Recommended Number of Patients 
Eradication therapy 6 
Change to cimetidine 23 
Reduce omeprazole dose 2 
Change ranitidine to omeprazole 2 
Change omeprazole to ranitidine 1 
Change omeprazole to Tagamet 1 
Reduce ranitidine dose 1 
Increase ranitidine dose 1 
Increase cimetidine dose 1 
Change Tagamet to ranitidine 1 
Total 39 
Table 6.4: Recommended changes to therapy. 
Several recommendations were different from those previously identified. 
Changing Tagamet to ranitidine rather than cimetidine was recommended for a 
patient with possible cimetidine induced gynaecomastia. A patient previously 
receiving Tagamet had been recently altered to omeprazole by secondary care, for 
no apparent reason. Information from the patient indicated a past problem of itch 
with generic cimetidine, thus the most appropriate recommendation appeared to 
be to revert to the prescription for Tagamet. In 2 instances a change 
from 
ranitidine to omeprazole rather than cimetidine was recommended 
due to poor 
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symptom control. In particular, one of these patients was taking ranitidine 150mg 
five times daily. 
Information documented on the feedback forms indicated that the GPs were in 
agreement with all recommendations. However, after a period of 12 months, only 
21 changes (54%) had actually been implemented, despite repeated reminders. In 
many cases, the GP had made an entry in the patient's medical notes indicating 
such change to be made at the next patient appointment, but had failed to do so. 
In those patients where a change in therapy had been implemented, no further GP 
or hospital visits, new diagnoses nor further changes in therapy had occurred 
which were likely to influence health outcomes. 
6.1.3 Health outcomes 
Differences in scores for the Glasgow Dyspepsia Severity Score and the 8 
domains of SF-36 were tested for Normality as shown in table 6.5. 
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Domain Shapiro-Wilk W statistic Level of Significance 
Dyspepsia Score 0.94 0.43 
General health 0.97 0.76 
Mental health 0.92 0.078 
Bodily pain 0.93 0.18 
Physical functioning 0.96 0.52 
Social functioning 0.96 0.46 
Vitality 0.96 0.46 
Role limitation due to 
physical functioning 
0.86 < 0.01* 
Role limitation due to 
emotional functioning 
0.86 < 0.01* 
Table 6.5: Tests for normal distribution of data (n = 21, df = 21). 
Two of the above domains gave significance levels less than 0.05 (*) therefore 
indicating deviation from a normal distribution, and were thus analysed using 
non-parametric methods. 
115 
For those domains following a normal distribution, the following differences in 
scores were observed following implementation of recommendations: 
Domain Mean 
difference in 
score 
95% 
confidence 
intervals 
Paired t-test 
statistic 
Level of 
significance 
Dyspepsia 
Score 
0.5 -0.8 to 1.8 0.84 0.41 
General health 1.7 -5.0 to 8.5 0.53 0.60 
Mental health 0.6 -6.2 to 7.4 0.17 0.86 
Bodily pain 8.9 -4.0 to 21.8 1.43 0.17 
Physical 
functioning 
5.2 -0.4 to 10.9 1.94 0.67 
Social 
functioning 
11.4 -1.5 to 24.2 1.85 0.079 
Vitality 0 -9.2 to -9.2 0.00 1.00 
Table 6.6: Changes in health outcomes following implementation of 
recommendations (n = 21, df = 20). 
As can be seen from the above table, implementation had no significant effect on 
the health outcomes studied. 
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For the 2 domains not following a normal distribution, no significant difference 
in the domain of role limitation due to emotional functioning was observed. 
(Wilcoxon matched pairs signed-ranks test, z= -0.59, p=0.55, n= 21, df = 20). 
A difference was, however, observed in the data for role limitation due to 
physical functioning (z = -2.12, p=0.034, n= 21, df = 20) with higher scores. 
and thus improved health outcome, being obtained following the change. 
The sample size of 21 patients was calculated to be sufficient to detect a 
difference of 2 points on the Glasgow Dyspepsia Severity Score (range 0-20) 
from a mean score of 7.4 prior to change in therapy (standard deviation = 2.9), 
with a power of 80% at a significance level of 5% (2-tailed test). 
Changes in these 21 patients consisted of changing ranitidine to cimetidine (11 
patients), eradication therapy (4), reducing omeprazole dose (2), changing 
omeprazole to Tagamet (1), changing omeprazole to ranitidine (1), reducing 
ranitidine dose (1), changing omeprazole to ranitidine (1). Analysis of data solely 
relating to change of ranitidine to cimetidine is given in table 6.7. 
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Domain Mean 
difference in 
scores 
95% 
confidence 
intervals 
Paired t-test 
statistic 
Level of 
significance 
Dyspepsia 
Score 
1.1 -0.0 to 2.2 2.21 0.052 
General health -1.1 -10.0 to 7.8 -0.27 0.79 
Mental health 2.5 -6.5 to 11.6 0.62 0.55 
Bodily pain 18.4 -2.1 to 38.8 2.00 0.073 
Physical 
functioning 
7.3 0.5 to 14.1 2.39 0.038* 
Social 
functioning 
14.7 -3.5 to 33.0 1.80 0.10 
Vitality 4.1 -9.7 to 17.9 0.66 0.53 
Table 6.7: Changes in health outcomes following substitution of ranitidine 
with cimetidine (n = 11, df = 10). 
A significant increase in the score for physical functioning was observed, 
indicating an improvement in health status. 
On analysing the data resulting from replacing ranitidine with cimetidine, no 
differences were observed in role limitation due to emotional functioning 
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z= -1.28, p=0.20, n= 11, df = 10; or role limitation due to physical functioning 
z=-1.94, p=0.052, n= 11, df= 10. 
The above sample size was calculated to be sufficient to detect a difference of 1.5 
points on the Glasgow Dyspepsia Severity Score (range 0-20) from a mean score 
of 8.0 prior to change in therapy (standard deviation = 1.6), with a power of 80% 
at a significance level of 5% (2-tailed test). 
No correlations were identified between the changes in the Glasgow Dyspepsia 
Severity Score and the changes observed in any of the 8 domains of SF-36 as 
illustrated in table 6.8. 
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Domain Correlation 
coefficient 
Level of 
significance 
General health 0.018 0.94 
Mental health -0.13 0.58 
Bodily pain -0.006 0.98 
Physical functioning 
Social functioning 
0.046 
0.13 
0.84 
0.58 
Vitality -0.10 0.66 
Role limitation due to emotional 
functioning 
0.032 0.89 
Role limitation due to physical 
functioning 
-0.22 0.34 
Table 6.8: correlation between differences in dyspepsia score and SF-36 
domains (n = 21). 
Pearsons correlation coefficient was used for normally distributed data, 
Spearmans correlation coefficient used for data not shown to be normally 
distributed (role limitation due to emotional and physical functioning). 
During the course of the study, six of the 21 patients had their treatment altered 
back to the original prescription. In 4 of the patients, the original change had been 
from ranitidine to cimetidine, 1 further patient had received eradication therapy 
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and subsequently restarted cimetidine 400mg bd, the remaining patient had tried a 
reduced dose of omeprazole. One diabetic patient was changed back to ranitidine 
from cimetidine due to worsening of blood glucose control, which continued to 
be elevated on reinstating ranitidine. Results for these patients are presented 
relating to the time prior to reverting to the original therapy. The small patient 
numbers involved, however, do not permit comparison of health outcomes 
between patients remaining on therapy and those reverting back. 
Overall cost savings arising from the changes in therapy in these 21 patients were 
estimated at £3717 in the first year, including the cost of eradication therapy. 
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6.2 Discussion 
The main aim of this research was to implement selected formulary 
recommendations and measure the subsequent effect on health outcomes. All 
patients studied had previously been receiving repeat prescriptions for ulcer 
healing agents. Two measures of outcome were used, the Glasgow Dyspepsia 
Severity Score, a disease specific measure and SF-36, a generic measure of health 
related quality of life. Despite repeated general guidance to prescribe eradication 
therapy for appropriate patients and to increase the ratio of cimetidine relative to 
other H2RAs, no previous work has focused on the resultant effect on health 
outcomes such as these. 
An initial drug utilization review of ulcer healing agent use in one general 
practice in Aberdeen indicated that 2% of the practice were receiving continuous 
therapy. Similar work by others had produced figures of 0.8% (Ryder et al 1994), 
2.2% (Cotrill 1994), 3.9% (Rosengren, Poison 1996). These figures would 
confirm that these agents are widely prescribed and thus should be high priority 
agents for regular review. Unlike the study of Ryder et al (1994), where the 
majority of patients (75%) had been prescribed these agents for more than 5 
years, only 6% of patients in this study had been receiving these agents for such a 
period. The 2 most common indications for therapy were identified as gastro- 
oesophageal reflux and duodenal ulcer, a similar finding to that of Ryder et al 
(1994). Although 9% of patients receiving continuous therapy had not undergone 
any diagnostic investigations, in many cases patient 
factors such as severe 
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depression or undergoing chemotherapy rendered such investigations 
inappropriate. In those patients previously having undergone investigation, many 
were identified as still receiving therapy years later without further investigation. 
For example, the median time since diagnosis of duodenal ulcer was found to be 
9 years. Several sources have recommended eradication therapy in patients with a 
diagnosis of duodenal or gastric ulceration (Delaney 1995, Scottish 
Intercollegiate Guidelines Network 1996), however, this may not alleviate 
symptoms if patients have developed further causes of dyspepsia, such as gastro- 
oesophageal reflux, in the interim period. Indeed, Rosengren and Poison (1996) 
proposed that patients receiving long term therapy may no longer have active 
duodenal ulcer disease but they provided little evidence to substantiate this 
statement. 
Ranitidine was found to be the most commonly prescribed agent, with only 10% 
receiving cimetidine. A commonly cited reason for avoiding the use of cimetidine 
is the potential for drug interactions due to inhibition of microsomal cytochrome 
P450 (Sabesin 1993). Relatively few patients (1.68%) were, however, identified 
where the use of cimetidine would have been problematic as a result of 
interacting therapy. Nevertheless, it is important that prescribers are aware of 
those agents whose serum levels are altered to a clinically important degree 
by 
cimetidine. 
This study illustrated the difference between formulary adherence and adherence 
to a prescribing guideline. Only ranitidine, omeprazole and cimetidine were 
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issued on repeat prescriptions, all of which are recommended in the Grampian 
Joint Drug Formulary. In many patients, however, prescribing was not in line 
with the guideline produced based on the recommendations of the formulary. 
The initial patient interview was conducted for 2 reasons: to confirm the ulcer 
healing agent therapy actually being taken; and to provide baseline data on health 
outcomes prior to any change in therapy. The importance of obtaining this 
information prior to any such change was demonstrated in several patients. 
Instances of previous adverse drug reactions and changes in ulcer healing agents 
were identified which had not been documented in the patients' medical notes. 
6.2.1 Interpretation of Findings 
Results of changes in health outcomes following the implementation of a 
recommendation were obtained for 21 patients. The distributions of changes were 
found to approximate to a normal distribution for all domains studied except 
those of role limitation due to emotional and social functioning. This is in 
contrast to advice provided by the developers of SF-36 who recommend using 
parametric statistics in any analysis (Ware et al 1993). The absence of a normal 
distribution in these 2 domains is most likely due to the relatively small sample 
size of 21 patients. 
Results obtained for differences in health outcome measures before and 
following 
a change in therapy indicated no significant 
difference in any of the areas studied 
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except for role limitation due to physical functioning, which appeared to improve 
following the change. In particular no change was observed in the Glasgow 
Dyspepsia Severity Score. In measuring health outcomes, a disease specific 
measure is included to ensure responsiveness to small changes in outcome 
unlikely to be detected by a more generic measure (Bowling 1995, McDowell and 
Newell 1996, Bowling 1997). Prospective calculation of sample size necessary to 
detect a clinically important difference was not possible since this required an 
estimate of the mean baseline score and variance of the differences. Research 
centring around the use of the Glasgow Dyspepsia Severity Score is limited. In 
particular, no work has estimated clinically important differences. Determination 
of a clinically important difference in the field of health outcomes may be 
problematic. Deyo et al (1991) recommended measuring the difference obtained 
by administering an intervention of known efficacy. The present study did not 
aim to identify this difference, since all patients were receiving therapy with 
efficacious agents prior to any change. The sample size of 21 was, however, 
calculated to be sufficient to detect a difference of 2 points, on a scale ranging 
from 0-20, with a power of 80%. Drummond and O'Brien (1993) stated that 
value judgements may be required to determine the minimal clinically important 
difference. Contact with one of the developers of the Glasgow Dyspepsia Severity 
Score provided information that clinical experience indicated that a difference in 
2 units would be clinically important. Calculation of sample size required to 
demonstrate a difference in the domains represented by SF-36 is similarly 
complicated since results are presented as 8 separate domains, rather than 
being 
summed to produce one summary statistic. Calculation of sample size 
for each of 
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these domains requires knowledge of a clinically important difference for each 
and is likely to produce different results for each domain. It has therefore been 
recommended that focus is placed on the domain of greatest interest (Jaeschke et 
al 1989). This approach was employed in this study and the difference which 
could be identified calculated for the disease specific measure. 
Further analysis of data obtained from these 21 patients, however, identified that 
this was not a homogenous group, containing patients where different types of 
changes had been implemented including those: attempting to improve 
symptoms; reducing dose of ulcer healing agent; increasing dose; prescribing 
eradication therapy; altering ulcer healing agent prescribed. Health outcomes 
arising from such a diversity of changes are likely to be different and, in some 
cases, actually oppose each other. For example, changing from ranitidine to 
omeprazole may reduce dyspepsia score whereas reduction in omeprazole dose 
will not reduce score and may indeed actually increase score. Including such data 
in an overall analysis is less likely to identify any real changes. 
Changing therapy from ranitidine to cimetidine formed the largest group. Further 
analysis of the data relating solely to these patients identified that the only 
difference observed was in the domain of physical functioning with scores 
actually increasing following this change, indicating an improvement in health 
outcomes in this domain. Caution must, however, be exercised in interpretation of 
the data since the probability value for the Glasgow Dyspepsia Severity Scale 
was very close to 0.05 and thus there is a high likelihood that changing 
from 
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ranitidine to cimetidine may worsen dyspepsia. However, it is also possible that 
non-identified factors occurring in the interim period other than the change in 
drug choice may have influenced this outcome. Although no such information 
relating to hospital or general practice attendances, new diagnoses were identified 
from the patients' medical notes, changes important to the patients may not have 
been recorded in this way. Indeed, as stated earlier, the drug utilization data 
ontained from the patients' medical notes often contrasted with that obtained 
from the patient. 
The data relating to changes in health outcomes obtained in this study must be 
interpreted with caution primarily due to the lack of information available to 
establish representativeness of the final group of 21 patients relative to the overall 
population of patients. There were several points at which patients were "lost" 
For example, change to therapy was considered inappropriate in 11 patients due 
to clinical factors such as severe depression. A further 8 patients were deemed 
unsuitable for interview by the GPs and 19 patients refused to be interviewed. 
The results of any changes in health outcomes in these patients may have been 
different from those of the 21 patients completing the study. 
6.2.3 Critical Appraisal of Method 
Patients in this study were not randomly selected from practices throughout 
Grampian. Instead, cluster sampling was used as a method of obtaining a sample 
of patients in a geographical area. The assumption was made that 
these patients 
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would only differ from the population of patients in terms of their GP, which 
would be unlikely to have an effect of changes in health outcomes. 
Following the initial drug utilization study, patients were identified in whom 
there was the potential for a change in therapy due to non-adherence to the agreed 
guideline. The GPs agreed with all recommendations for changing therapy. In 
several patients, the recommendations had been implemented prior to interview, 
resulting in health outcome scores not being included in any further analysis. 
None of these patients expressed any dissatisfaction with the change in therapy, 
which generated considerable savings. Only 54% of recommendations were 
actually implemented, despite several meetings at which GPs were reminded of 
those patients where no change had occurred. Perhaps the study protocol should 
have identified the pharmacist as being responsible for implementing 
recommendations once agreement from the GPs had been obtained. A pharmacist 
run clinic aiming to identify appropriate patients for eradication therapy has been 
described (Moorhouse et al 1996). Results indicated improved symptoms, 
measured subjectively by patients, and reduced use of ulcer healing agents. In the 
present study, several further patients were reluctant to receive H pylori 
eradication therapy, despite explanation of possible benefits. Similar reluctance 
was observed by Rosengren and Poison (1996) in a study involving 40 duodenal 
ulcer patients receiving continuous ulcer healing agent therapy. 
An appropriate health outcome measure must be valid, reliable and responsive. 
Previous validity data for the Glasgow Dyspepsia Severity 
Score showed its 
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ability to discriminate between both duodenal ulcer, non-ulcer dyspepsia and 
control patients with no complaints of dyspepsia. Responsiveness was shown in a 
sample of patients receiving eradication therapy (El-Omar et al 1996). The 
present study involved many types of recommendations other than eradicating H. 
pylori in patients with duodenal or gastric ulcer. There is a lack of data relating to 
the ability of the Glasgow Dyspepsia Severity Score to be responsive in these 
areas, despite the claim by the authors that it is suitable for any symptoms related 
to the upper gastro-intestinal tract. For example, when altering from one H2RA to 
another, the likely change in dyspepsia score would be expected to be minimal 
and this measure may fail to detect such a change. Similarly, this measure has not 
been used in patients receiving an ulcer healing agent for NSAID prophylaxis, 
where many of the patients may not actually experience any symptoms of 
dyspepsia and indeed dyspepsia itself is a poor indicator of outcome. 
SF-36 has been evaluated in patients with duodenal ulcer (Garratt et al 1993) and 
gastro-oesophageal reflux disease (Stacey et al 1996). These studies identified 
that SF-36 scores were lower in patients with these disease states than control 
groups and indicated that scores increased following treatment, particularly the 
domain of bodily pain in patients with gastro-oesophageal reflux 
disease. 
However, these patients had not previously received any treatment which 
increased the likelihood of responsiveness following treatment with an ulcer 
healing agent. The possibility of being responsive to the types of changes 
involved in this study may be much lower. Similarly, SF-36 
has not been 
evaluated in areas of NSAID prophylaxis. 
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Previous work with SF-36 has shown that the domains of physical functioning, 
role limitation due to physical functioning and vitality are those most likely to 
identify differences between minor and serious medical conditions (McHorney et 
al 1993). Garratt et al (1993) proposed a relationship between the crude measure 
of GP's perception of symptom severity and SF-36 scores. Results of correlation 
tests between the more objective Glasgow Dyspepsia Severity Scores and the 
domains of SF-36, however, failed to identify any correlation. However, 
correlation may be difficult to demonstrate between measures scored in such 
different ways, the Glasgow Dyspepsia Severity Score ranging from 0 to 20 in 
increments of 1 unit, SF-36 from 0 to 100, and for some domains the incremental 
unit being 33. 
6.2.3 Conclusions 
Despite the above limitations, this study measured health outcomes following 
changes in ulcer healing agent in line with the recommendations of the Grampian 
Joint Drug Formulary. While considerable cost savings were generated, results of 
health outcomes are more difficult to interpret due to the lack of data relating to 
representativeness of the patient group, the diversity of the changes made and the 
possible lack of suitable outcome measures. The measurement of 
health outcomes 
is extremely important but may require the development or testing of more 
appropriate measures. 
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Chapter 7 
Peripheral Vasodilators: Results and Discussion 
7.1 Results 
7.1.1 Drug utilization 
A total of 45 patients from both practices (0.4% of the combined practice lists) 
were identified from the computer systems as receiving repeat prescriptions for 
peripheral vasodilators. Thirty three patients (73%) were female and 12 (27%) 
male with a median age of 74 years (range 36-88). Eight patients (18%) had not 
received a prescription in the previous year. 
The fate of these patients in this study is summarised in figure 7.1 
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45 patients 
receiving repeat prescriptions 
8 
no prescriptions in previous year 
2 deemed unsuitable for interview 
37 
continuous prescriptions 
35 deemed suitable 
35 requested to stop 
therapy for 2 months 
following interview 
6 refused 1 excluded 28 contacted 
3 refused 25 agreed 
ter. 
8 expressed desire to 
recommence therapy 
17 successfully 
stopped 
Figure 7.1: Flow chart indicating fate of patients during study. 
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The range of peripheral vasodilators prescribed continuously to the remaining 37 
patients (82%) is shown in figure 7.2. 
Oxerutins 
Oxpentifylline 
3% 
Naftidrofuryl 
71% 
Figure 7.2: Peripheral vasodilators prescribed on repeat prescriptions. 
The most commonly prescribed agent was naftidrofuryl (27 patients) followed by 
oxerutins (8 patients). One patient was receiving both of these drugs 
simultaneously. 
Indications for therapy documented in these patients' medical notes are illustrated 
5% 
in figure 7.3. 
11 11 
Other 
8% 
Not recorded 
11% 
Varicose veins 
5% 
Chilblains 
5% 
Intermittent 
claudication 
71% 
Figure 7.3: Indications for peripheral vasodilators. 
The most common indication for therapy was intermittent claudication (26 
patients). The "other" category comprised 1 case of each of the following: 
gangrenous toes; cold hands and feet; and leg cramps. Four patients were 
identified with no documented indication. One of these patients had herself 
requested a trial of naftidrofuryl which had then continued, without review, for 13 
years. 
Therapy had been initiated in primary care in 32 patients (87%), compared to 5 
patients (13%) in secondary care. 
Duration of continuous therapy is shown in figure 7.4. 
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Figure 7.4: Duration of continuous peripheral vasodilator use. 
The median duration was 3.5 years (range 0.5-17), with seven patients continuing 
therapy for greater than 5 years. Review of the continued need for therapy was 
documented in the medical notes of only 1 patient (2%) where discontinuation 
had resulted in symptom recurrence. No details of such reviews were documented 
in the medical notes of the remaining 36 patients. 
The total annual cost of peripheral vasodilators in both practices amounted to 
£6105. 
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7.1.2 Patient interviews 
Two patients were identified by the GPs as being unsuitable for interview. One of 
these patients was undergoing chemotherapy, the other was an elderly gentleman 
residing in a nursing home. Letters were sent to the remaining 35 patients, all of 
whom agreed to participate in the study. 
Patients were generally aware of the indication for therapy as illustrated in table 
7.1. 
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Cited Indication Number of patients 
Poor circulation 15 
Leg pains 8 
Blood disorders 2 
Blood clots 1 
Hardening of arteries 1 
Blocked arteries 1 
Cold feet 1 
Worn muscles 1 
Varicose veins 1 
Chilblains 1 
Intermittent claudication 1 
Not aware of indication 2 
Table 7.1: Indications cited by patients. 
Three of the 4 patients where no indication had been recorded in their medical 
notes described circulation problems (2 patients), leg pains (1 patient). The 
remaining patient with no documented indication was unaware of the reason for 
therapy. 
Eleven patients (31 %) continued to smoke despite repeated advice to stop. 
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Following interview and feedback of results to the GPs, all patients were sent 
letters instructing them to stop therapy for a period of 2 months. Information from 
the medical notes identified that 6 patients (17%) had not stopped their peripheral 
vasodilator with no reason documented in 4 of these 6 patients. Of the remaining 
2 patients, 1 had recently undergone surgery for gastric cancer and the other had 
previously suffered return of symptoms on discontinuation of therapy. One 
patient who had stopped therapy had been severely ill in hospital suffering from 
peritonitis, duodenal ulceration and stroke and therefore took no further part in 
the study. The remaining 28 patients were contacted by telephone. Three patients 
were not keen to be re-interviewed as they had suffered return of symptoms on 
cessation of therapy. Twenty five patients agreed to be re-interviewed to 
determine the effect of stopping therapy. 
7.1.3 Health outcome measures 
Differences in scores between the 2 interviews for the Walking Impairment 
Questionnaire and the 8 domains of SF-36 were tested for Normality as shown 
in 
table 7.2. 
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Domain Shapiro-Wilk W statistic Level of Significance 
Walking impairment 0.82 <0.01 * 
Walking distance 0.86 <0.01* 
Walking speed 
General health 
0.95 
0.96 
0.37 
0.44 
Mental health 0.94 0.16 
Bodily pain 0.96 0.50 
Physical functioning 0.97 0.74 
Social functioning 0.88 <0.01* 
Vitality 0.97 0.70 
Role limitation due to 
physical functioning 
0.93 0.14 
Role limitation due to 
emotional functioning 
0.67 <0.01 * 
Table 7.2: Tests for normal distribution of data (n = 25, df = 25) 
Four domains gave significance levels less than 0.05 (*) therefore indicating 
deviation from a normal distribution and were thus analysed using non- 
parametric methods. 
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For those domains following a normal distribution, the following differences in 
scores were observed following cessation of therapy: 
Domain Mean 
difference 
in score 
95% 
confidence 
intervals 
Paired t-test 
statistic 
Level of 
significance 
Walking speed 1.2 -3.4 to 5.7 0.52 0.61 
General health -2.0 -7.5 to 3.4 -0.78 0.45 
Mental health -0.7 -7.1 to 5.6 -0.23 0.82 
Bodily pain -0.7 -10.5 to 1.9 0.13 0.90 
Physical functioning -4.0 -9.8 to 1.8 -1.43 0.17 
Vitality -3.2 -10.7 to 4.3 -0.88 0.39 
Role limitation due to 
physical functioning 
-1.0 -17.2 to 15.2 -0.13 0.90 
Table 7.3: Changes in health outcomes following cessation of peripheral 
vasodilators (n = 25, df = 24). 
As can be seen from the above results, stopping peripheral vasodilators had no 
significant effect on health outcomes. 
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This sample size was adequate to detect a difference in walking speed of 6.5% 
from a mean walking speed of 28.5% (standard deviation = 11.1), with a power of 
80% at a significance level of 5% (2-tailed test). 
For those domains deviating from a normal distribution, no significant 
differences in outcomes were observed. 
Domain Wilcoxon Matched Pairs Signed- 
Ranks test (z value) 
Level of 
significance 
Walking impairment -1.60 0.11 
Walking distance -0.28 0.78 
Social functioning -1.45 0.15 
Role limitation due to 
emotional functioning 
-0.94 0.35 
Table 7.4: Changes in health outcomes following cessation of peripheral 
vasodilators (n = 25, df = 24). 
The sample size was adequate to detect a difference in walking distance of 
16.6 
from a mean walking distance of 60.5% (standard deviation = 28.5), with a power 
of 80% at a significance level of 5% (2-tailed test). 
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Twenty patients (80%) were identified where factors such as shortness of breath. 
backache, caused the same or greater impairment to walking as pain or aching in 
calves. 
Of those 25 patients re-interviewed, 8 had either recommenced therapy or 
expressed a desire to do so. The remaining 17 patients (68%) had successfully 
stopped therapy resulting in annual cost savings amounting to £2768. 
There was no association between successfully stopping therapy and whether or 
2 not the patient smoked (x = 1.21, p=0.27). Similarly there was no association 
between successfully stopping therapy and whether or not the patient had 
previously been referred for vascular opinion (x2 = 0.00, p=1.00). 
On comparing those patients who had successfully stopped with those either 
restarting or expressing an interest to do so, a significant difference was observed 
in changes in walking distance with those in the latter group requesting therapy 
having a reduced walking distance (Mann-Whitney U test, z= -2.42, p=0.016). 
The mean walking distance decreased by a mean of 30% in those restarting 
therapy compared to a mean increase of 5.6% in those successfully stopping. 
Data were tested for correlation between the differences in scores from the 
Walking Impairment Questionnaire and the 8 domains of SF-36. Pearsons 
correlation coefficient was used for normally distributed data, Spearmans 
correlation coefficient for data not shown to be normally distributed. 
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Changes in walking distance were found to correlate with changes in walking 
speed (correlation coefficient 0.46, p=0.022). 
On comparing changes in walking distance with changes in SF-36 domains, the 
following results were obtained. 
Domain Correlation coefficient Level of significance 
General health 0.40 0.05* 
Mental health 0.061 0.77 
Bodily pain 0.11 0.61 
Physical functioning -0.11 0.63 
Social functioning 0.57 0.003* 
Vitality -0.15 0.47 
Role limitation due to 
emotional functioning 
0.22 0.30 
Role limitation due to 
physical functioning 
0.046 0.83 
Table 7.5: Correlation between differences in walking distance and SF-36 
domains (n = 25, * indicates significant correlation). 
Similarly, comparison was made between changes in walking speed and SF-36 
domains. 
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Domain Correlation coefficient Level of significance 
General health 0.42 0.037* 
Mental health 0.047 0.82 
Bodily pain 0.30 0.14 
Physical functioning 0.16 0.44 
Social functioning 0.49 0.013* 
Vitality -0.13 0.56 
Role limitation due to 
emotional functioning 
0.070 0.74 
Role limitation due to 
physical functioning 
0.093 0.66 
Table 7.6: Correlation between differences in walking speed and SF-36 
domains (n = 25, * indicates significant correlation). 
Changes in both walking distance and walking speed correlated with changes in 
general health and social functioning. 
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7.2 Discussion 
7.2.1 Interpretation of Findings 
No previous work in the UK provided data relating to the use of peripheral 
vasodilators in primary care. This study identified that 0.4% of listed patients 
were receiving these agents on repeat prescriptions and, in the majority of cases, 
treatment had been initiated in primary care. Previous work showed intermittent 
claudication to be most prevalent in elderly males (Kannel, McGee 1985). 
Although the present study identified that patients were generally elderly (median 
74 years), many more females were prescribed these agents than males. This 
comparison to previous work should be interpreted with caution since the present 
study did not aim to identify all patients with intermittent claudication, rather 
focusing on those prescribed peripheral vasodilators, who may not have been 
representative of the population of patients with intermittent claudication. 
Naftidrofuryl was the most commonly prescribed peripheral vasodilator, being 
used to treat the symptoms of intermittent claudication in the majority of patients. 
Further indications identified such as varicose veins, chilblains and leg cramps 
are outwith data sheet recommendations. The use of peripheral vasodilators for 
these indications is not based on the results of any published work. Although 
peripheral vasodilators are not recommended in the Grampian Joint Drug 
Formulary, several sources (Ruckley 1986, Lowe 1990, Waller, Chant 1995) have 
acknowledged a limited role in those with severe, disabling symptoms. 
It is, 
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however, recommended that in these patients, treatment should be for an initial 
period of 2 to 3 months followed by cessation of therapy in order to ascertain 
continued need for treatment. This study identified that these agents had been 
prescribed for considerable periods of time (median 3.5 years) without further 
review. Indeed cessation of therapy had only been documented in the medical 
notes of 1 patient. 
The main aims in treating intermittent claudication have been defined as being 
relief of symptoms and improvement of health related quality of life (Hiatt et al 
1995). Health outcomes measures used in this study were chosen in an attempt to 
reflect these aims with the Walking Impairment Questionnaire representing a 
disease specific measure and SF-36 a generic measure of health status. 
Patients were interviewed on 2 occasions with the first interview providing drug 
utilization information and baseline measurements of health status. The second 
interview which took place 2 months later determined the effect of cessation of 
therapy. A period of 2 months was considered sufficient to determine such effects 
since this represents an appropriate period during which a beneficial response to 
treatment would be evident (Ruckley 1986, Lowe 1990, Waller, Chant 1995). 
Withdrawal of peripheral vasodilators, as recommended in the Grampian Joint 
Drug Formulary, appeared to have no significant effect on any of the domains 
measured. Of particular importance was the lack of effect on walking 
distance 
and speed as measured by the Walking Impairment Questionnaire. 
Prospective 
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calculation of sample size was not possible since no data was available to allow 
determination of mean values prior to intervention, nor standard deviation of any 
differences. Similarly the clinically important difference had not been defined. 
Analysis of results identified that the sample studied was sufficient to detect 
differences of 6.5 and 16.6% in walking speed and walking distances 
respectively. These differences are less than those obtained by Regensteiner et al 
(1996) in a study of treadmill testing and strength testing, who identified that a 
difference of 31 % in walking distance was of importance. This would appear to 
confirm that the sample size used in the present study was sufficient. Although 
the Shapiro-Wilk W statistic for walking distance identified a significant 
deviation from a normal distribution, further exploration of the data showed 
values grouped around a mean and thus sample size calculations were performed 
based on parametric principles. 
Eight patients had either restarted therapy during the course of the study or had 
expressed an interest to do so. On comparing differences in scores for walking 
distances between this group and those who had successfully stopped therapy, a 
statistically significant and apparently clinical difference was observed. This may 
indeed indicate that some patients obtain some benefit from the continued use of 
these agents. The present study did not intend to be a clinical trial and 
included 
no placebo control group. These agents have been shown to produce a 
high 
placebo response (Anon 1996), which may be the basis 
for worsening walking 
distance on cessation of therapy. The differences in scores 
between those patients 
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successfully stopping therapy and those not may provide evidence for the 
responsiveness of the Walking Impairment Questionnaire. 
Results of changes in health outcomes must be interpreted with caution since 
those patients completing the study may not be representative of the total 
population of patients. In particular, 6 patients (17%) had not stopped therapy as 
instructed and a further 3 patients (9%) refused to take part in the second 
interview. Results of these patients could not be included in any final analysis but 
are likely to have differed from those patients completing the study. 
Patient reluctance to alter long term therapy was previously identified as a major 
reason for the continued prescribing of inappropriate drugs in primary care. 
Britten et al (1995) reported a study of 7 GPs who used various methods to 
identify patients in their practices whose drug therapy was regarded as being 
inappropriate. Peripheral vasodilators were amongst those drugs identified that 
patients were reluctant to stop. 
Many patients continued to smoke despite repeated advice to stop. Although 
more patients successfully stopping were non-smokers, this association did not 
reach statistical significance. In patients with intermittent claudication, the most 
appropriate treatment has been defined as cessation of smoking accompanied 
by 
an increase in daily walking (Housley 1988). Indeed, it has 
been recommended 
that if peripheral vasodilators are to be prescribed, this should only 
be after the 
effects of stopping smoking have been determined 
(Ruckley 1986). Given the 
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increased risk of cardiac arteriosclerotic complications in these patients, this area 
requires further attention as part of overall patient management. 
Patients referred for vascular investigations may be those with more severe 
symptoms but again no association was observed between successfully stopping 
therapy and previous vascular referral. 
Changes in walking speed were found to correlate with changes in walking 
distance, providing further evidence of the usefulness of the instrument. Several 
correlations were observed between both of these domains and SF-36. Changes in 
both walking distance and speed were found to correlate most highly with both 
general health and social functioning. These results are unexpected since the 
domains of physical functioning, role limitation due to physical functioning and 
vitality had previously been shown to be most affected by medical conditions 
(Ware et al 1993). In addition, bodily pain was significantly affected by an 
exercise programme; surgery produced changes in the domains of physical 
functioning, role limitation due to physical functioning, bodily pain and vitality 
(Currie et al 1995); treadmill training produced most effect on physical 
functioning (Regensteiner et al 1996). Data from this study showed changes in 
walking distance to be poorly correlated with bodily pain and physical 
functioning. These findings may question the validity of the SF-36 results. 
Although no information was identified from the patients' medical notes to 
indicate other changes likely to influence health outcomes, such unidentified 
factors may have been present. 
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7.2.2 Critical Appraisal of Method 
As outlined in chapter 6, cluster sampling was used as a method of obtaining a 
group of patients assumed to be representative of all patients in Grampian. No 
data was provided to establish the validity of this assumption. 
For health outcome measures to be appropriate, they must be shown to be valid, 
reliable and responsive in the population of patients under study. The Walking 
Impairment Questionnaire has previously been used in studies measuring the 
effects of surgery and structured exercise programmes, with results providing 
evidence of validity, reliability and responsiveness (Regensteiner et al 1996). 
However, no work using this measure has been published relating to studies of 
peripheral vasodilators. Similarly, there is a lack of data relating to SF-36 in this 
area. 
The walking impairment domain of this questionnaire rates the extent to which 
calf pain limits the ability to walk over the previous month. Data from this study 
identified that in 80% of patients, further problems such as shortness of breath, 
leg weakness caused greater impairment to walking than claudication pain. This 
may have complicated the measurement of health outcomes on cessation of 
therapy and may have masked differences in walking distance or walking speed 
attributable solely to changes in claudication. Several patients were identified 
where peripheral vasodilators were prescribed for indications other than 
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intermittent claudication. In such situations, perhaps alternative disease specific 
measures should have been sought. 
7.2.3 Conclusion 
Despite the limitations described above, this study attempted to measure health 
outcomes resulting from the implementation of formulary recommendations. Data 
obtained identified that, in this group of patients, peripheral vasodilators were 
successfully withdrawn in the majority of patients with no effects on health 
outcomes such as walking distance and speed and appeared to have no effect on 
health related quality of life while generating considerable cost savings. These 
findings require to be replicated in larger numbers of patients. 
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Chapter 8 
General Discussion 
8.1 Drug Formularies 
Previous work in the field of drug formularies in primary care focused on the 
effect on of implementing recommendations on prescribing patterns and drug 
costs (Grant et al 1985, Green 1985, Beardon et al 1987, Van Zwanenberg et al 
1987), with little reference made to the effect on health outcomes. The present 
study aimed to address this deficiency by measuring changes in health outcomes 
arising from implementation of selected recommendations of the Grampian Joint 
Drug Formulary in areas of both acute and repeat prescribing. 
Drugs for inclusion in a formulary are selected on the basis of efficacy, safety, 
cost-effectiveness and patient acceptability, in accordance with previous 
definitions of rational prescribing (Parish 1973, Barber 1995). More recently, 
Janknegt and Steenhoek (1997) described further factors of dosage frequency, 
likelihood of drug interactions, documentation of clinical experience, 
pharmacokinetic profile and pharmaceutical aspects. They acknowledged that 
trade-offs may require to be made between these criteria and proposed a more 
objective method to enable drug selection. This method, termed the System of 
Objectified Judgement Analysis (SOJA), involves prospectively defining 
Iý-, 
selection criteria, with each criterion being weighted for importance by an expert 
panel. The extent to which individual drugs fulfil each criterion is studied and a 
rating determined by the same expert panel. The final scores for each drug within 
a class are compared and that with the highest score selected for inclusion in the 
formulary. 
One of the most important steps in this selection process is critical appraisal of 
the available evidence. The emphasis placed on this evidence may, however, be 
influenced by emotional criteria arising from either positive or negative past 
experiences with either certain drugs or drug companies (Janknegt and Steenhoek 
1997). In the present study, the GPs were reluctant to prescribe misoprostol for 
NSAID prophylaxis due to their experience of adverse effects from this agent. 
This was despite the evidence that misoprostol will afford superior protection 
against NSAID induced duodenal and particularly gastric ulceration compared to 
H2RAs (Raskin et al 1996). Use of a more objective system for drug selection 
may reduce the influence of these highly emotional past experiences. 
Limitations of the SOJA method include the lack of data for many individual 
drugs and drug classes and that a subjective assessment of relative weightings and 
ratings for each drug are still required. In addition, the only 
health outcomes 
considered appear to be clinical efficacy and occurrence of adverse 
drug 
reactions. 
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Implementation of recommendations in this study generated considerable savings 
in relatively small numbers of patients. It must, however, be appreciated that the 
aim of developing and implementing a drug formulary is to rationalise 
prescribing, not solely to reduce costs and indeed, in certain therapeutic areas 
drug costs may actually increase. In addition, drug costs may differ substantially 
from overall treatment costs which will include costs associated with 
consultation, investigation, subsequent treatment and monitoring. There is a 
general lack of comparative pharmacoeconomic data which can be used to aid 
this drug selection process. 
This study involved both acute (antibiotics for the treatment of uncomplicated 
lower UTIs) and established long term prescribing (ulcer healing agents, 
peripheral vasodilators). Changing established therapy has been associated with 
many difficulties. Several workers have identified patient reluctance as being one 
of the main reasons for continuing to prescribe drugs with either little evidence of 
efficacy or which have been surpassed by superior therapies (Schwartz et al 1989, 
Britten et al 1995). In the present work, several of the patients prescribed 
peripheral vasodilators were reluctant to stop therapy for even a short period. Of 
those patients prescribed ulcer healing agents, several patients previously 
identified as candidates for H. pylori eradication did not wish this treatment 
despite explanation of the possible benefits. Excluding those receiving H. pylori 
eradication therapy, most other changes to repeat prescriptions were either 
associated with cessation of therapy, dose reduction or therapeutic substitution. 
These changes may not provide any additional benefit to the patient in terms of 
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health outcomes, other than possibly reducing the number of medicines to take 
each day and reduced likelihood of adverse drug reactions. As a consequence, 
patients may be less willing to have their treatment altered. 
This research did not aim to evaluate the role of the pharmacist in implementing 
and monitoring a drug formulary in primary care. Little research relating to 
pharmacist involvement with drug formularies in primary care has been 
described. Green (1985) and Beardon et al (1987) provided details of 
involvement mainly relating to the process of formulary development. Wider 
roles in this area have been recommended (Greenfield 1982, Audit Commission 
1994). Hughes and McFerran (1996) provided data describing views of 
community pharmacists towards formulary involvement. A structured 
questionnaire was sent to 100 randomly selected pharmacists in Northern Ireland. 
From a response rate of 66%, they identified that 52 (79%) agreed or strongly 
agreed that pharmacist involvement in formulary development was important, 
with two thirds stating that they would be prepared to approach GPs in relation to 
work in this area, but only 27% had previously collaborated. No data was, 
however, collected relating to further roles of monitoring formulary use, nor 
measuring the impact on health outcomes. This current research provides some 
information relating to pharmacist involvement in this area. Those GPs involved 
were extremely willing to have pharmacist input in this area, although 
improved 
mechanisms for implementing change in established therapy require to 
be 
evaluated. Kozma et al (1993) proposed a model for measuring the outcomes of 
pharmaceutical care incorporating economical, clinical 
(morbidity and mortality) 
15 5 
and humanistic outcomes (health related quality of life, satisfaction which could 
be used to measure pharmacist activities. 
8.2 Measurement of Health Outcomes 
The measurement of health outcomes provides an objective means of monitoring 
the patient's progress over time. Different outcome measures were used in the 
present research. For acute prescribing, the extent and speed of symptom relief 
was the main measure whereas in areas of repeat prescribing, measures of disease 
specific and generic health related quality of life were included. Disease specific 
measures were included to detect small changes in health status whereas generic 
measures provided much broader measures of health related quality of life. In 
relation to the effect of formulary implementation, the disease specific measure 
should provide the most valuable information. 
Several difficulties were associated with the interpretation of the scores of SF-36, 
the generic measure for both the ulcer healing agent and peripheral vasodilator 
studies. Estimating adequate sample size based on these scores was not 
performed due primarily to separate scores being determined 
for each of the 8 
domains, thus requiring separate sample size calculations. Brazier (1995) outlined 
methods for deriving a single index score for SF-36, aiming to reflect 
the strength 
of patient preference for the different aspects of health. 
Methods included 
combining domain scores into a single index using an assumed set of weights 
or 
alternatively valuing all possible health states 
defined by SF-36. Brazier 
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identified many limitations and concluded that further work in this area was 
required. 
Despite the absence of a valid method for calculating a single index of SF-36, 
sample sizes could be calculated for each domain using parametric principles as 
recommended (Ware et al 1993). The present work, however, identified that not 
all domains of SF-36 followed a normal distribution. Julious et al (1995) 
similarly described the inappropriateness of parametric evaluation of SF-36 data 
since the scores obtained represent categorical rather than continuous data. 
In the areas of repeat prescribing, health outcome measures were administered 
before and at a period following the change in treatment. Attempts were made to 
collect information relating to factors which may have influenced any health 
outcomes during this period but little information was documented in the 
patients' medical notes. Many patients were, however, elderly with multiple 
medical problems receiving multiple drugs, thus increasing the likelihood of 
further changes occurring which may have influenced health outcome 
measurement. This would be particularly important for the generic measure 
which is by definition a broad measure of health. A similar problem with 
SF-36 
was described by Hill and Harries (1993) who used this measure 
before and 3 
months after referral for visual difficulties, continence services or mental 
health 
services. They acknowledged that patients had multiple 
health problems and that 
effective intervention for one problem may not 
improve health status scores if 
other problems worsened or were considered more 
important. They identified 
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further problems associated with SF-36 including the difficulty that many patients 
experienced in comprehending many of the questions and the failure of SF-36 to 
identify improvements in health related quality of life experienced by the 
patients. Although several workers have identified SF-36 to be responsive to 
ulcer healing agents in gastro-oesophageal reflux disease (Stacey et al 1996) and 
surgery or exercise in peripheral vascular disease (Currie et al 1995, Regensteiner 
et al 1996), responsiveness may be highly dependent on the nature of the 
intervention. 
SF-36 may not be a practical measure in the clinical setting with most interviews 
in the present research lasting approximately 45 minutes. 
As explained above, this research identified several problems associated with the 
use of this generic measure, as summarised below: 
" inability to easily estimate sample sizes. 
" data strictly categorical thus limiting statistical manipulations. 
" lack of responsiveness to small but important changes. 
" some questions difficult for patients to comprehend. 
" lack of practicality in the clinical setting. 
A further criticism previously levelled at all generic measures 
is that they impose 
the choice of domains and attached values on the patient and 
that these may not 
be the domains which the patient considers most important 
(Ruta et al 1994). 
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They described a truly valid measure of health outcome as being one which fulfils 
the following: describes the effect of conditions on those aspects of lives that the 
patients consider most important; allows patients to rate the extent to which those 
aspects of life are affected; responds to change over time; reliable; suitable for a 
variety of patients in different settings; brief and simple. They produced the 
patient generated index (PGI) which involves the patients listing the 5 most 
important areas of their lives affected and a sixth for rating all other areas of their 
lives. Patients are then asked to rate how badly affected they are in each area on a 
scale of 0 (worse than they can imagine) to 100 (exactly as they would like to be). 
Patients then choose to spend a total of 60 points on those areas which they could 
improve. An index is generated by multiplying the 6 ratings by the proportion of 
the 60 points allocated to each and summing the results to produce a patient 
generated index. This measure was tested in 359 patients with low back pain. 
Scores were compared with SF-36 and a back pain questionnaire showing 
correlation with SF-36 domains of bodily pain, social functioning, role limitation 
due to physical functioning and with the back pain questionnaire. PGI scores 
were significantly lower in those patients referred to secondary care and reflected 
the GPs perception of pain severity. The authors concluded that the PGI had 
considerable potential for routine use in clinical settings. 
A similar measure, the "measure yourself medical outcome profile" 
(MYMOP) 
was described by Paterson (1996) who identified little work 
focusing on 
responsiveness of most health outcome measures and the 
lack of practicality of 
measures such as SF-36 in clinical settings. MYMOP consists of 
4 items scored 
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on a7 point scale (1, as good as it could be to 7, as bad as it could be). The first 2 
scales represent symptoms the patient considers most important. The third scale 
represents an activity of daily living disrupted and the fourth asks patients to rate 
general well-being in the previous week. The profile score is calculated as a mean 
of the 4 scores. MYMOP was compared to SF-36 in a sample of 265 patients 
presenting in primary care. Patients completed MYMOP initially and then 2 and 
4 weeks later with SF-36 completed initially and 4 weeks later. Patients also rated 
overall change in symptoms on a5 point scale from much better to much worse. 
Of the 265 patients, 193 completed all questionnaires. Changes in MYMOP 
scores at 2 and 4 weeks were consistent with ratings on the 5 point scale. The 
instrument was also able to detect more change in acute rather than chronic 
conditions. MYMOP was more responsive than SF-36 when comparing changes 
in scores in those rating overall symptoms "a little better" to those "about the 
same". Although MYMOP relates to symptoms over the preceding 7 days, 
measures such as this and PGI may be more appropriate than earlier measures of 
health outcome and require further evaluation. 
8.3 Primary Care Research Methods 
The present research involved the use of different methods of patient recruitment. 
data collection and measurement of health outcomes in the 3 therapeutic areas, 
each of which was associated with practical difficulties and limitations. The main 
problem associated with the urinary tract infection study was the 
lack of response 
from GPs who initially agreed to fully participate. Different methods of collecting 
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data relating to acutely prescribed drugs require to be developed. With repeat 
prescribing in the areas of ulcer healing agents and peripheral vasodilators, 
several deficiencies of the computer prescribing systems were highlighted. Many, 
patients were identified who had not requested prescriptions for considerable 
periods of time but these items had not been deleted from the patients' 
prescription files. Several further patients were taking regimes different from 
those recorded. These findings reduce the value of such systems which would 
otherwise be useful tools for both drug utilization research and audit. A higher 
proportion of patients agreed to be involved in the study of peripheral 
vasodilators than ulcer healing agents. Although the methods of patient 
recruitment used in these 2 areas were similar, letters informing patients of the 
study were signed by the GPs for peripheral vasodilators but by the researcher 
who was not known to the patients for ulcer healing agents. This simple change 
may have encouraged more patients to participate and should be borne in mind 
for further research in primary care. 
8.4 Conclusions 
Overall, this research highlighted the lack of work surrounding drug formularies 
in primary care. Further methods require to be developed for researching the use 
of acutely prescribed drugs based on formulary recommendations, measuring 
appropriate health outcomes. Such outcomes may need to be 
further refined but 
are generally less complex than those for repeat prescribing. 
In this latter area, 
further work is needed to determine the most appropriate method of 
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implementing change in patients established on long term therapy. including 
measures of patient satisfaction with any change. Appropriate health outcome 
measures require to be developed. Very few disease specific measures are 
available and patient generated measures require more attention. 
Health outcomes data provided by this research are limited and must therefore be 
interpreted with great caution. In each of the 3 areas less patients completed the 
studies than had been anticipated. This was a particular problem with data 
collection relating to uncomplicated lower UTIs and ulcer healing agents. As a 
result the data obtained cannot be extrapolated to the general population of 
patients in Grampian. This work should be replicated in greater numbers of 
representative patients. 
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Appendix 1 
Urinary Tract Infection Study 
To be completed by the doctor 
Was a urine specimen sent for culture 
Q 
yes 
Q 
no 
Did any factor affect drug choice ? 
e. g. drug interaction, contra-indication 
Q 
yes 
Q 
no 
If yes, please state factor 
Please state 
drug prescribed 
dose 
duration 
7o:. be completed by. 1he patient 
please tick the appropriate box 
confidential 
I have had the above study explained to me by my doctor and have had the opportunity to ask any 
questions. I understand that this is a study to look at cure rates and re-infection rates of urine infections 
and has been approved by the Joint Ethical Committee. I also understand that my doctor has agreed that 
I can take part and that I am completely free to withdraw from the study at any time I wish. I hereby 
fully and freely consent to take part. 
Name 
............................................................................ 
Date............................... 
Address .............................................................. 
Telephone number .......................... 
Once this has been signed, please tear this page off and hand to the receptionist. 
Patient numv 
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Appendix 2 
confidential 
Dear patient, 
I would like to thank you for agreeing to take part in this survey. 
Your doctor has diagnosed that you have a urine infection. This is a common condition in females. 
This survey is going to look at both cure rates and re-infection rates of urine infections. To do this. I would like 
you to fill in this questionnaire. 
Once you have completed the questionnaire, please send it back to me in the self addressed envelope. 
Please don't worry 
All information collected will be treated in the strictest confidence. There is no need to take part in the stud\ 
and you can pull out at any time. But it would be great if you could help me. 
I would like to thank you for taking the time to fill in the questionnaire. 
Yours faithfully, 
Lecturer. School of Pharmacy 
The questionnaire comes in 2 parts. 
198 
confidential 
Part 1: complete before you start taking the medicine prescribed by your doctor for your urine infection 
Which of the following symptoms were you suffering from when you visited your doctor ' 
Q 
passing urine more often 
Q 
pain when passing urine 
Q 
urine had a different smell 
Q 
other - please describe ............................................................ 
........................................................................................................................... . 
tick more than one box if appropriate 
2. How would you describe these symptoms ? 
Q 
mild 
Q 
moderate 
Q severe 
3. How long after first noticing these symptoms did you go to your doctor ? 
Ql to 2 days 
Q 3to4days 
Q more than 4 days 
4. Did you give a urine sample to your doctor 
? 
Q yes 
Q no 
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confidential 
Part 2.: complete after you stop taking the medicine prescribed by your doctor for your urine infection 
5. Did you take all of the medicine prescribed by your doctor for your urine infection 
Q 
yes 
Q 
no 
If no, please explain why not ................................................................................................ 
................................................................................................................................................ 
6. Once you stopped taking this medicine, how would you describe your symptoms 9 
Q 
gone away 
Q 
mild 
Q 
moderate 
Q 
severe 
7. If your symptoms went away, how long after you started taking this medicine did they go away ? 
Q1 to 2 days 
Q3 to 4 days 
Q 
more than 4 days 
8. Did you get any side effects which you think may have been caused by this medicine 
Q 
ves 
Q 
no 
If yes, please describe these side effects .................................................................................... 
......................................................................................................................... 
........................................................................................................... 
Please describe what you did when you got these side effects ...... ". """"".. "" ............. """..... .... 
................................................................................................... 
............................................................................................ 
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confidential 
9. Apart from the medicine prescribed by your doctor did you take any other medicine for . ox 
urine infection ? 
Q 
yes 
Q 
no 
If yes, what did you take ? ........................................................................................................... 
........................................................................................................................................................... 
10. Have you had to go back to your doctor because of your urine infection ? 
Q 
yes 
Q 
no 
If yes, why? .......................................................................................................... 
.............................................................................................................................................. 
11. Did you take time off work because of your urine infection ? 
Q 
yes 
Q 
no 
Sometimes urine infections can come back. To check that this has not happened, I would like to contact you in 
about 4 weeks time. This will only involve asking one or two questions. I could either write or phone you. 
Q 
contact me by letter 
Q 
contact me by phone phone no ..................... 
best time to phone............... 
Q 
please do not contact me 
Thank you very- much for helping me with this study. 
Please put the. questionnaire in the self addressed envelope and return 
it to me. 
Patient number .. 
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Appendix 3 
Dear Patient 
I am a lecturer at the School of Pharmacy, The Robert Gordon 
University, Aberdeen. I am carrying out a study looking at 
cure rates and re-infection rates for urine infections. 
A few weeks ago your doctor gave you a questionnaire to fill 
in and send back to myself. As yet I have not received this. I 
wonder if I could ask you to fill this in and return to me. I have 
included another questionnaire and envelope just in case you 
have misplaced it. Thank you very much for helping me. 
Yours sincerely 
Derek C Stewart 
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Appendix 4 
Urine Infection Study 
confidential 
Dear patient, 
A few weeks ago your doctor asked you to complete a questionnaire about a urine infection. Thank you very 
much for completing that questionnaire and returning it. I would be very grateful if you could now complete this 
small questionnaire and return it to me in the self addressed envelope. 
Since completing the last questionnaire about your urine infection 
1. Have the symptoms of your urine infection come back ? 
Q 
yes 
Q 
no tick the appropriate box 
2. If yes, how would you describe these symptoms" 
Q 
mild 
Q 
moderate 
Q 
severe 
3. If yes, what action did you take ? 
Q 
nothing 
Q 
returned to doctor 
Q 
other 
If other, please describe what you did .................................................................... 
.................................................................................................................................. 
4. If you returned to your doctor. were you given more medicine 
? 
Q 
yes 
Q 
no 
Thank you very much far helping. me with thisstuav. 
Please put the questionnaire in the self addressed envelope and return 
it to 
me. 
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Appendix 5 
', ter numrcr 
URLV, -IR Y TRACT INFECTION STUD Y 
FOLLOW UP TELEPHONE QUESTIONNAIRE 
Since completing the last questionnaire about your urine infection 
1. Have your symptoms come back ? 
Q 
yes 
Q 
no 
?. If yes, how would you describe these symptoms ? 
Q 
mild 
Q 
moderate 
Q 
severe 
3. If yes, what action did you take ? 
Q 
nothing 
Q returned to doctor 
Q 
other - please describe 
ý. If you returned to your doctor, were you given more medicine ? 
Q 
yes 
Q 
no 
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UTI Data Collection Form: Patients Returned 
Name 
Address 
Practice 
Date of UTI Prescription 
Date returned to GP 
Reason returned 
Consequences 
Prescription given QyQn 
Drug 
Dose 
Duration 
Sample sent QyQn 
Other 
Comments 
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Name 
Address 
Practice 
Date of UTI prescription 
Drug Prescribed 
UTI Data Collection Form: Sensitivity Reports 
Sample Results 
Isolate 2 
Resistant 
Was drug appropriate ? Cl y 
Was new prescription sent ?Qy 
Drug 
Dose 
Duration 
n Cl 
n Cl 
Was new drug most appropriate ?0y n Cl 
Sensitive 
Other Comments 
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Dr D. C. Gould 
Keith Medical Group 
Turner Street 
Keith 
AB55 3DJ 
Urinary Tract Infection Study 
Dear Dr Gould 
I am writing to give you a progress report on the above study which forms part of my PhD. the . ie% eiopment of drug utilisation evaluation studies in primary care. 
Twenty four general practitioners in Grampian agreed to help with the study which involves diving out .0 
questionnaires to females presenting with an uncomplicated urinary tract infection. This study has rnow 'ern 
running for approximately 12 months. The tables helow show the number of questionnaires -,,, % en 
participant, with your particular rate of distribution highlighted. 
GP 1 2 34 5 6 7 8 9 10 11 1_ i 
Number of 1 0 2 20 2 1 1 0 0 0 3 20 
questionnaires 
distributed 
GP 13 14 15 16 17 18 19 20 21 22 23 24 
Number of 18 3 3 0 0 0 0 0 4 0 0 6 
questionnaires 
distributed 
Of those questionnaires distributed, a high return rate of 76/84 (90%) has been achieved. It was initially 
estimated that 250 patients were required to provide meaningful results, but it now seem unlikely that this figure 
will be reached. I would, however, like to continue to collect data until September 1996, after which I will bnng 
the study to a close. 
I would be extremely grateful if you could continue to give out as many questionnaires as possible (the 
inclusion, exclusion criteria are shown on the front of the desk top organiser). The top sheet of the questionnaire 
should be completed during the consultation, removed and passed to reception. to be sent on to myself. 
If this study is causing any problems or if I can help in any way, please do not hesitate to contact me. 
Kind regards. 
Yours sincerely 
Derek C Stewart 
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28 August 1996 
Dr DC Gould 
Keith Medical Group 
Turner Street 
Keith 
AB55 3DJ 
Dear Dr Gould 
Previously you indicated your willingness to assist with part of my PhD, regarding drug utilisation studies, b 
distributing questionnaires to females presenting with symptoms of lower urinary tract infection. I am now 
writing to inform you that this study is being brought to a close. I would be very grateful if you could pass any 
remaining questionnaires and envelopes to the practice manager for collection. Please keep the desk top 
organiser -I am sure that you will be able to find a use for it. 
Overall a disappointing number of questionnaires were distributed, which may reduce the value of any findings. 
I would, however, like to thank you for your support in this project. 
Yours sincerely 
Derek C Stewart 
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\Iav 199Q' 
p1 
piifl 
Q 
rJnTl 
'Lý 
0 
ý0.; 
Communicable Disease & 
Environmental Medicine 
Information Sheet for 
General Practitioners 
Urinary Tract Infections in 
Primary Care 
We have been asked by our colleagues at RGU to convey to you the results of a 
recent project, co-ordinated by the School of Pharmacy, The Robert Gordon 
University, which looked at the treatment of uncomplicated urinary tract infections 
in primary care. 
The objectives of the project were to: 
  identify the treatment of young females presenting with uncomplicated 
urinary tract infections, in terms of drug, dose, duration of treatment. 
  
identify any factors affecting drip selection. 
  
compare treatment with that recommended in the Grampian Joint Drug 
Formulary antibiotic policy. 
  
investigate the use of microbiological testing. 
  
measure patient outcomes. 
Twenty four randomly selected general practitioners throughout Grampian cac; 1 
agreed to distribute 20 questionnaires to young females presenting with symptoms 
of an uncomplicated UTI. Patients excluded from the study included those 
pregnant; breast feeding; recently prescribed antibiotics; recurrent UTIs. 
Results 
Of the planned 480 questionnaires, only 89 (18.5x) were given out, which iimºts 
the value of any findings. Patient response was, however. verv high with 
30 90°x0 
questionnaires returned. 
The antibiotic policy recommends trimethoprim as first line treatment. 
_ ltibiotics used 
in this stud, are shown in the following graph: 
Published by the Communicable Disease Team 
Grampian Health Board 
Foresterhill, Westburn Road. 
Aberdeen AB25 2XH - Tel 01224 404008 
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This represents 61% adherence to the recommendations of the policy. 
Factors affecting selection of antibiotic were identified in 222 patients. Several of these would contraindicate 
trimethoprim including past adverse drug reaction to co-tnmoxazole, trying to conceive and hence the eve l 
of adherence is potentially much higher. 
The most common duration of therapy was 5 days (44%), with a range of 3 to 7 days. More than 90% of 
patient prescribed trimethoprim reported no or mild symptoms following treatment and only 2 patients 
returned to the GP. 
At a cost of 20p for 3 days and 34p for 5 days of trimethoprim, this appears to be very cost-effective. 
Microbiological Sampling 
Urine samples were cultured for 37 (42%) patients. Of these 37,8 patients had moved practices and the 
report had not been filed in the notes of one further patient. Of the remaining patients, sensitivity reports 
indicated the following: 
no growth for 11 patients. 
E. Coli was the most common infecting organism, being the sole infecting organism in 9 patients and 
along with E. faecalis in I patient. 
other infecting organism were S. Saproplryticus (2 patients) and Coliform (5 patients). 
5 instances of trimethoprim resistance were identified yet only 1 patient returned with symptoms. 
Sensitivity reports rarely resulted in a change in therapy. 
Derek C Stewart 
Lecturer in Clinical Pharmacy 
The Robert Gordon University 
School of Pharmacy -Faculty of Health and Food 
Schoolh ill.. Aberdeen Tel: 01224 262000 
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Patient's name 
Address/ 
Tel no. 
Date of birth 
GP responsible 
Current drug therapy 
(include details of 
date initiated, dose, 
likely duration) 
Data collection form - Ulcer healing agents 
Peterculter Health Centre 
Unit number 
Disease states 
Allergies/ADR 
Relevant biochemistry/haematology 
211 
History of ulcer healing agent 
Current ulcer healing agent prescribed 
Commenced by 
Date commended 
Reason commenced 
Investigations performed 
Results 
Complications of peptic disease eg bleed, stricture 
Comments on review 
Previous ulcer healing agents prescribed (include details of why commenced. 
investigations and results, when and why therapy stopped or altered. ) 
Other relevant data 
? 12 
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Dear 
I am a lecturer at the School of Pharmacy, The Robert Gordon University, Aberdeen. 
I am carrying out a study with the doctors at the Peterculter practice. 'Many patients 
are prescribed medicines such as and we are interested 
to find out how well these medicines work. 
From the computer at the practice, we have found that you get prescriptions for 
. As part of the study, I would like to come and interview you at home. This interview will last for about 45 minutes and %,. -ill ask 
about how well this medicine works, any side effects that you think you might get 
from it, and whether you think that you still need to take it. 
Please do not worry 
All information collected will be treated in the strictest confidence. There is no need 
for you to take part in the study if you do not want to and you can pull out at any 
time but I will very grateful if you agree to take part. I will telephone you in the next 
few days to find out if you agree to be interviewed and if you do, we will arrange a 
suitable time for the interview. 
Thank you very much for your help. I look forward to meeting you, if you decide to 
take part. 
Yours sincerely 
Derek C Stewart 
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CONSENT FORM 
Consent by patients to participate in the study on the effect of various types of 
stomach medicines. 
Name of patient .................................................................................... 
Principal Investigator: Derek Stewart 
I have read the information leaflet, which was previously sent to me, and have had 
the opportunity to discuss the details with Derek Stewart and to ask questions. 
I understand that this is part of a research project to study the use of various types of 
stomach medicines and has been approved by the Joint Ethical Committee of the 
University of Aberdeen and Grampian Health Board. 
I also understand that the doctors at Peterculter Health Centre have agreed that I can 
participate in the study. 
I have agreed to take part in the study as it has been described to me, but I understand 
that I am completely free to withdraw from the study at any time I wish. 
I hereby fully and freely consent to participate in the study which has been fully 
explained to me. 
Signature of patient ..................................................................... 
Date....................... 
I confirm that I have explained to the patient named above the nature and purpose of 
the study. 
Signature of investigator ............................................................. 
Date...................... 
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Interview Schedule for review of ulcer healing a en 
Patient name ...................................................... 
Ulcer healing agent being taken 
How much of the above medicine do you take? 
How long have you taken this for'? 
Why are you taking this? 
Do you think you get any side effects from it? 
Do you take any indigestion remedies'? 
Do tou take any pain killers? 
Do you smoke? 
How much alcohol do you drink per week? 
Have you changed your diet? 
Date of birth ............................. 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
......................................................... 
Symptom Severity 
a. Frequency of dyspeptic symptoms 
Over the past 6 months, have you experienced dyspeptic symptoms ? 
never 0 
on only 1 or 2 days 1 
on approximately I day per month 2 
on approximately I day per week 3 
on approximately 50% of days 4 
on most days 5 
b. Effect on normal activities 
Does the dyspepsia interfere with normal activities such as eating, sleeping or socialising? 
never 0 
sometimes 1 
regularly 2 
c. Time off work 
How many days have you lost off work due to your dyspepsia in the past six months `' 
none 0 
1-7 days 1 
more than 7 days 2 
I Consultation with medical profession 
How often have you attended a doctor due to dyspepsia in the past six months ? 
none 0 
once 1 
twice or more 2 
e GP visits to patient's home 
How often have you called your GP to visit you at home because of your 
dyspepsia in the last six months 
none 0 
once 1 
twice or more 
215 
, ests for dyspepsia 
How many tests have you had for your dyspepsia in the past six months'? 
none 0 
one 
two or more 
a. Treatment for dyspepsia 
t. Over the last six months, how frequently have you used medicines for your dyspepsia which you have 
yourself ? 
never p 
less than once per week 
more than once per week 2 
I. Over the last six months, for how long have you used medicines for your dyspepsia which were prescribed by a doctor ? 
never 0 
for 1 month or less 1 
for 1-3 months 2 
for more than .3 months 3 
SF36 
In general, would you say your health is : 
excellent 1 
very good 2 
good 
fair 4 
poor 5 
?. Compared to one year ago, how would you rate your health in general now ? 
much better now than one year ago I 
somewhat better now than one year ago 2 
about the same as one year ago 3 
somewhat worse than one year ago 4 
much worse now than one year ago 5 
3. The following items are about activities you might do during a typical day. Does your health now limit you 
in these activities? If so, how much'? 
ACTIVITIES Yes, Yes, No, not 
limited a limited limited at 
lot a little all 
a. Vigorous activities, such as running, lifting heavy 1 23 
objects, participating in strenuous sports 
b. Moderate activities, such as moving a table, pushing a 1 2! 3 
vacuum cleaner, bowling, or playing golf 
c. Lifting or carrying groceries 1 ? 
3 
d. Climbing several flights of stairs 1 2 
3 
e. Climbing one flight of stairs 1 
2 
C. Bending, kneeling or stooping 1 '- 
,. Walking more than a mile 1 --' 3 
h. Walking half a mile 1 
I. Walking one hundred yards 123 
Rý*tic..,, nr 
Arpccina ., nimcpif .12 13 J ..,. 
? 16 
ý. During the past -1 weeks. have you had an of the rollowing problems with your . pork x ether 
activities as a result of your physical health 
A YES NO 
a. Cut down on the amount of time you spent on work or 
other activities 
1 
b. Accomplished less than you would like 12 
c. Were limited in the kind of work or other activities 1 
d. Had difficulty performing the work or other activities 
(for example. it took extra effort) 
12 
5. During the past 4 weeks. have you had any of the following problems with your work or other regular saiiv 
activities as a result of any emotional problems (such as feeling depressed or anxious) `. ' 
YES NO 
a. Cut down on the amount of time you spent on work 
or other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Didn't do work or other activities as carefully as 
usual 
1 2 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your 
normal social activities with family, friends, neighbours, or groups ? 
Not at all 
Slightly 
Moderately 3 
Quite a bit 4 
Extremely 5 
7. How much bodily pain have you had during the past 4 weeks ? 
None 
Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both '. pork outside 
the home and housework) ? 
Not at all 1 
A little bit 
Moderately 
Quite a bit 4 
Extremely 5 
'17 
9. These questions are about how you feel and how things save been during : he -, as-, 4 . gee s. =ýr sac 
question. please give the one answer that comes closest to the way you ^a' e been eeiin_. 
How much of the time during the past 4 weeks 
All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
. -A little 
of the 
time 
None 
of the 
arne 
a. Did you feel full of life 1 2 3 4 
b. Have you been a very nervous person 1 2 3 4 5 h 
c. Have you felt so down in the dumps 1 
that nothing could cheer you up 
2 3 4 5 6 
d. Have you felt calm and peaceful 1 2 3 4 5 6 
e. Did you have a lot of energy 1 2 3 4 15 6 
f. Have you felt downhearted and low 1 2 3 4 5 6 
g. Did you feel worn out 1 2 3 4 5 
h. Have you been a happy person 1 3 4 5 
1. Did you feel tired 1 2 3 4 5 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting with friends, relatives etc. ) ? 
All of the time 1 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
11. How TRUE or FALSE is each of the following statements for you ? 
Definitely Mostly 
true true 
Don*t 
know 
Mostly 
false 
Definitely 
false 
a. I seem to get ill more easily than other 
12 3 `I 
people 
b. I am as healthy as anybody I know 
12 3 4 5 
c. I expect my health to get worse 
12 3 4 5 
d. My health is excellent 12 
3 4 J 
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PETERC 'I. T R HEALTH NTRF 
EVALUATION OF ULCER HF ar LN , ENTS 
Name 
Date of Interview 
Symptom score (range 0 to 20.0 indicates best control of symptoms) 
1. 
2. 
Sianature D-= 
Action taken 
Signature 
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Helicobacter pylori Eradication Information 
Your doctor has prescribed medication which may reduce your need to take 
medicines such as Zantac, ranitidine or cimetidine. 
Please read the following before you start to take this medication. 
What is Helicobacter pylori ? This is a bacterium that is found in the 
stomach and has been shown to cause 
ulcers to form. 
How can I get rid of it ?A combination of antibiotics and a medicine 
to heal ulcers taken for a short period of 
time can kill these bacteria in most people. 
You must make sure that you take the 
medicine as prescribed for the full course or 
it may not be effective. 
If you miss even a few doses or stop the 
medicine too soon the bacteria may not be 
completely killed and your ulcer may come 
back. 
Once you have killed the Helicobacter 
pylori, you will no longer need to take your 
ulcer healing medicine and your ulcer is 
less likely to come back. 
Will I have any side effects ?A few people will suffer from headache, 
nausea, sickness or diarrhoea. You may 
also notice a metallic taste. These are 
usually mild and last only a few days. 
Try very hard to put up with these side 
effects for the full course. 
If you are worried about any of these side 
effects, speak to your doctor or pharmacist. 
.0 
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INTERIM FOLLOW UP FOR ULCER HEALING AGENTS 
Name 
Address 
Date of Birth 
Changes to drug therapy since 1.96 
GP/Hospital Consultations since 1.96 
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Interview Schedule for re1'iew 1' rýlcý r Ilealit; g, agents 
Patient name ...................................................... Date ,, t birth.......................... 
Previous ulcer healing therapy ...................................................................................... Change in therapy ........................... .............................................................................. Date of change .............................................................................................................. 
How much of the above medicine do you take " .......................................................... Have you noticed any side-effects'? .............................................................................. Do you take any indigestion remedies '? ....................................................................... 
Symptom Severity 
a. Frequency of dyspe tv toms 
Over the past 6 months, have you experienced dyspeptic symptoms :' 
never 0 
on only l or 2 days 1 
on approximately I day per month 
on approximately 1 day per week 3 
on approximately 50% of days 4 
on most days 5 
b. Effect on normal activities 
Does the dyspepsia interfere with normal activities such as eating, sleeping or socialising ? 
never 0 
sometimes I 
regularly 2 
c. Time off work 
How many days have you lost off work due to your dyspepsia in the past six months ? 
none 0 
1-7 days 1 
more than 7 days 2 
d. Consultation with medical profession 
How often have you attended a doctor due to dyspepsia in the past six months ? 
none 0 
once 1 
twice or more 
e. GP visits to patient's home 
How often have you called your GP to visit you at home 
because of your dyspepsia in the last six months 
none 0 
once 1 
twice or more 2 
ý» 
i Fests "or dyspepsia 
How mann tests have you had for Your dv-spepsia in the past six months 
none 0 
one I 
two or more 2 
a. Treatment for dyspepsia 
1. Over the last six months, how frequently have you used medicines for your dyspepsia which you have ortained bý yourself ? 
never 0 
less than once per week 1 
more than once per week 2 
2. Over the last six months, for how long have you used medicines for your dyspepsia which were prescribed by a doctor? 
never 0 
for 1 month or less 1 
for 1-3 months 2 
for more than 3 months 3 
1 
.i 
SF-36 
In general, would you say your health is : 
excellent 
very good 2 
good 3 
fair 4 
poor 5 
Compared to one year ago, how would you rate your health in general now ? 
much better now than one year ago 1 
somewhat better now than one year ago 2 
about the same as one year ago 3 
somewhat worse than one year ago 4 
much worse now than one year ago 5 
The following items are about activities you might do during a typical day. Does your health now limit you 
in these activities? If so, how much ? 
f Bending, kneeling or stooping 1 
g. Walking more than a mile 
h. Walking half a mile 1- 
I. Walking one hundred yards 
12 
I. Bathing or dressing yourself ý13 
ACTIVITIES Yes, Yes, No, 
limited limited not 
a lot a little limited 
at all 
a. Vigorous activities, such as running, lifting heavy 1 !? 3 
objects, participating in strenuous sports 
b. Moderate activities, such as moving a table, pushing a 1 3 
vacuum cleaner, bowling, or playing golf 
c. Lifting or carrying groceries 1 -' 
3 
d. Climbing several flights of stairs 123 
Climbing one flight of stairs 123 _ý 
/ 
a. During the past 4 weeks, have you had any of the following problems % ith ; our .ý cri: r At er -etui :r ýsýiv 
activities as a result of your physical health ? 
YES NO 
a. Cut down on the amount of time you spent on work or 
other activities 
12 
b. Accomplished less than you would like l2 
c. Were limited in the kind of work or other activities 
d. Had difficulty performing the work or other activities 
(for example, it took extra effort) 
12 
ý. During the past 4 weeks, have you had any of the following problems with your work or other regular dal I\ 
activities as a result of any emotional problems (such as feeling depressed or anxious) 
YES NO 
a. Cut down on the amount of time you spent on work 
or other activities 
1 2 
b. Accomplished less than you would like 1 
c. Didn't do work or other activities as carefully as 
usual 
1 2 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your 
normal social activities with family, friends, neighbours, or groups ? 
Not at all 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
7. How much bodily pain have you had during the past 4 weeks 
? 
None 
Very mild 2 
Mild 
Moderate 4 
Severe 5 
Very severe 6 
8. During the past 4 weeks, how much did pain 
interfere with your normal work (including both work outside 
the home and housework) ? 
Not at all 1 
A little bit 2 1 
Moderately 
Quite a bit 
4 
Extremely 5 
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These questions are about how you feel and how things have peen Iunng n-, 
. 7a-st 
4 . gee a ýr _ýc 
_tuestion. please give the one answer that comes closest :o he . %aN" . -ou na%e Heen How much of the time during the past 4 weeks 
All of 
the 
time 
Most A good 
of the bit of 
time the 
time 
Some A little one 
of the of the of 't e 
time time time 
a. Did you feel full of life 1 2 3 456 
b. Have you been a very nervous person 3 456 
c. Have you felt so down in the dumps 
that nothing could cheer you up 
1 2 3 4 15 6 
d. Have you felt calm and peaceful 1 2 13 4 6 
C. Did you have a lot of energy 1 2 3 -t 5! 6 
t. Have you felt downhearted and low 12 3 -ý 6 
g. Did you feel worn out 12 3 11 5Ib 
h. Have you been a happy person 12 34 56 
1. Did you feel tired I t 5 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with 
your social activities (like visiting with friends, relatives etc. ) ? 
All of the time 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
11. How TRUE or FALSE is each of the following statements for you? 
Definitely Mostly Don't Mostly Definitely 
true true know false false 
a. [ seem to get ill more easily than other 1 -' 
3 45 
people 
b. I am as healthy as anybody I know 12 
3 45 
c. I expect my health to get worse 12 
345 
d. My health is excellent 12 
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DATA COLLECTION FORM - PERIPHERAL VASODILATORS 
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Duration of Continuous Vasodilator Therapy 
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Appendix 20 
Dear 
We are carrying out a review of all patients prescribed medicines 
such as ....................................... 
Derek Stewart, who is a pharmacist, is helping us with this. He would 
like to come and speak to you about this medicine and how well it 
works. This will take place in your own home and will only last for 
about 30 minutes. 
We would be very grateful if you could make time to see him and he 
will telephone you in the next few days to arrange a suitable time. 
Yours sincerely 
Dr 
X28 
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PATIENT CONSENT FORM 
Name of patient .................................................................................... 
Principal Investigator: Derek Stewart 
I have read the information leaflet on the above study and have had the 
opportunity to discuss the details with Derek Stewart and to ask questions. 
I understand that this is part of a research project to study the use of medicines 
such as ........................................... and has been approved by the Joint Ethical 
Committee of the University of Aberdeen and Grampian Health Board. 
I also understand that my doctor has agreed that I can participate in the study. 
I have agreed to take part in the study as it has been described to me. but I 
understand that I am completely free to withdraw from the study at any time I 
wish. 
I hereby fully and freely consent to participate in the study which has been fully 
explained to me. 
Signature of patient 
Date 
I confirm that I have explained to the patient named above the nature and purpose 
of the study. 
Signature of investigator ............................................................. 
Date ...................... 
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PA TIENT INFORMATION LEAFLET 
Many patients are prescribed medicines such as ............................ 
This review will look at the patients prescribed these medicines. To 
do this, I need to talk to these patients. This will involve one or 
perhaps two interviews, lasting about 30 minutes. During this 
interview, I will ask questions about: 
" What you take this medicine for 
" If you get any side effects from it 
" How well this medicine works 
9 Your health in general 
After the interview, if it seems that you are not getting the best from 
this medicine or that you no longer need to take it, your doctor may 
alter things. I would then like to come back to find out how the 
change has affected you. 
Please do not worry. Everything that you tell me will 
be treated in the 
strictest confidence. 
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Name 
Address 
Peripheral Vasodilator Prescribed 
How many of the above do you take per day ? 
What are you taking this medicine for ? 
How long have you been taking this medicine ? 
Do you think that you get any side-effects ? 
Do you smoke ? If yes, how much per day 
Sate) Birth 
WALKING IMPAIRMENT 
QUESTIONNAIRE 
a. WALKING DISTANCE 
For each of the following distances, tell me the degree of difficulty that best describes how hard it was for 
you to walk without stopping to rest. 
During the past month, how much physical difficulty did you have 
None Some Much Did not do 
1. Walking indoors, such as 
around your home 
3 2 1 0 
2. Walking 50 ft 3 2 1 0 
3. Walking 150 ft 3 2 1 0 
4. Walking 300 ft 1 3 ?1 1 0 
5. Walking 600 ft 3 1 0 
6. Walking 900 ft 3 2 1 0 
7. Walking 1500 ft 3 2 1 0 
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B. WALKING SPEED 
These questions refer to how fast you were able to walk 300 rt. ?! ease tell me . he 
required for you to walk at each of these speeds without stopping to rest. 
During the past month how much physical difficulty did you have 
None Some Much Did not do 
1. Walking 300 ft slowly ; 2 1 0 
2. Walking 300 ft at average g 
speed 
3 0 
3. Walking 300 ft quickly 1 0 
4. Running or jogging 300 ft 1 0 
C. WALKING IMPAIRMENT 
These questions ask about the reasons why you had difficulty walking. I would like to know how much 
difficulty you had walking because of each of these problems. By difficulty, we mean how hard it was or 
how much physical effort it took to walk because of each of these problems. For each reason tell me which 
best describes your degree of difficulty. 
During the past month how much difficulty walking did you have because of 
None Slight Some Much Very 
1. Pain or aching in your calves 4 3 1 0 
2. Pain or aching in your thighs 4 3 2 1 0 
3. Pain, stiffness, or aching in you 
joints (knees or hips) 
4 3 2 1 0 
4. Pain or discomfort in your chest 4 32 1 0 
5. Weakness in one or both of your 
legs 
4 3 1 0 
6. Shortness of breath 4 3 '- 1 
%. Heart palpitations 42 i1 
S. Other problems 43 
If there are other problems. please describe these to me. 
_32 
ý SF-36 
In `general, would you say your health is : 
excellent 
very good 2 
good 3 
fair 4 
poor 5 
2. Compared to one year ago, how would you rate your health in general now ? 
much better now than one year ago 
somewhat better now than one year ago 
about the same as one year ago 3 
somewhat worse than one year ago 4 
much worse now than one year ago 5 
The following items are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much ? 
ACTIVITIES Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, 
not 
limited 
at all 
a. Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
1 2 3 
b. Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling, or playing golf 
1 2 3 
c. Lifting or carrying groceries 1 2 
d. Climbing several flights of stairs 1 2 3 
e. Climbing one flight of stairs 1 2 3 
f. Bending, kneeling or stooping 1 '? 3 
g. Walking more than a mile 1 2 3 
h. Walking half a mile 1 2 3 
i. Walking one hundred yards 1 2 3 
J. Bathing or dressing yourself 1 2 3 
4. During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of your physical health ? 
YES NO 
a. Cut down on the amount of time you spent on work or 
other activities 
12 
b. Accomplished less than you would like 1 
c. Were limited in the kind of work or other activities 1 
d. Had difficulty performing the work or other activities 
(for example. it took extra effort) 
1 
During the past 4 weeks, have you had any of the following problems with your work or other regular daii\ 
activities as a result of any emotional problems (such as feeling depressed or anxious)'. 
YES NO 
1. Cut down on the amount of time you spent on work I2 
1 or other activities 
b. Accomplished less than you would like 1I 
Didn't do work or other activities as caretuilý as 1 
usual 
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6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with 
your normal social activities with family, friends. neighbours, or groups "I 
Not at all 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
7. How much bodily pain have you had during the past 4 weeks ? 
None 1 
Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside 
the home and housework) ? 
Not at all 
A little bit 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
234 
These questions are about how you : eei and how things have ^een Dunne . hc past eei; s. For ýc question. please dive the one answer that comes closest to : ne '. tiav '-ou have Deer 
How much of the time during the past -4 'weeks 
All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
)t : `ze 
rC 
None 
of : he 
time 
a. Did you feel full of life 1I 3 1 
b. Have you been a very nervous person 1 2 3 j4 
c. Have you felt so down in the dumps 1 
that nothing could cheer you up 
2 3 -: 5 o 
d. Have you felt calm and peaceful 1 2 3 i 7 
e. Did you have a lot of energy 1 2 3 -1 5 6 
f. Have you felt downhearted and low 1 2 3 -1 5 6 
]. Did you feel worn out 1 2 3 4 5 6 
h. Have you been a happy person 1 2 3 4 5 6 
1. Did you feel tired 1 3 14 5 1h 
10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting with friends, relatives etc. ) ? 
All of the time 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
11. How TRUE or FALSE is each of the following statements for you ? 
Definitely Mostly Don't `Iostly Definitely 
true true know false false 
a. I seem to get ill more easily than other 12 
t 
people 
b. I am as healthy as anybody [ know 1 
2 3 4 
c. I expect my health to get worse 
1 2 3 = 
d. My health is excellent 1 I= 
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Which doctor do you usually see ? 
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Appendix 24 
Address: 
Date o 
Periph 
f Interv 
eral vas 
iew: 
odila tor the rapy 
Indica tion. ac cordi ng to p atient 
\Valki g impairment score (due to pain or aching in calves): 
(range 0-100%. 0 indicates total impairment) 
ýwýc ý, 3;.. ý. 
Walking distance score: 
(range 0-100%. 100% indicates no problems in walking distances up to 500 yards) 
Walking speed score: 
(range 0-100%. 100% indicates no problems in walking 100 yards at any speed, including jogging) 
Quality of Life 
SF-36 measures health from the patient's point of view by scoring standardised responses to standardised questions 
in 9 separate areas. 
In each area, a higher score indicates a better health state. 
Physical Functioning: 
(extent to which health limits physical activities) 
Role Functioning - Physical: 
(extent to which physical health interferes with work or other daily activities) 
Bodily Pain: 
(Intensity and effect of pain on normal activities) 
Vital' v: 
Social Functionine: 
(extent to which physical health or emotional problems interfere with normal social activities ) 
Role Functioning - Emotional: 
(extent to which emotional problems interfere with work or other 
daily activities) 
Mental Health: 
Reported Health Transition: 
ý evaiuation of current health compared to one year ago) 
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Appendix 25 
Dear 
You will recently remember meeting a pharmacist who had a few 
questions to ask about your ........................ tablets. 
To allow us to see how much benefit you are still getting from your 
............................ tablets, we would now 
like you to stop these for a 
couple of months. The pharmacist will then arrange to see you again. 
We would therefore be grateful if you could stop taking your 
............................. tablets and you will 
be reveiwed in due course. 
If you have any queries, contact me at the surgery. 
Yours sincerely 
Dr 
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Appendix 26 
INTERIM FOLLOW UP FOR PERIPHERAL VASODILATORS 
Name 
Address 
Date of Birth 
Changes to drug therapy since commencement of study 
GP/Hospital Consultations since commencement of study 
